<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY b006-009-9780702070280 SYSTEM "b006-009-9780702070280" NDATA IMAGE><!ENTITY b006-023-9780702070280 SYSTEM "b006-023-9780702070280" NDATA IMAGE><!ENTITY b006-024-9780702070280 SYSTEM "b006-024-9780702070280" NDATA IMAGE><!ENTITY b006-025-9780702070280 SYSTEM "b006-025-9780702070280" NDATA IMAGE><!ENTITY f006-001-9780702070280 SYSTEM "f006-001-9780702070280" NDATA IMAGE><!ENTITY f006-002-9780702070280 SYSTEM "f006-002-9780702070280" NDATA IMAGE><!ENTITY f006-003-9780702070280 SYSTEM "f006-003-9780702070280" NDATA IMAGE><!ENTITY f006-004-9780702070280 SYSTEM "f006-004-9780702070280" NDATA IMAGE><!ENTITY f006-005-9780702070280 SYSTEM "f006-005-9780702070280" NDATA IMAGE><!ENTITY f006-006-9780702070280 SYSTEM "f006-006-9780702070280" NDATA IMAGE><!ENTITY f006-007-9780702070280 SYSTEM "f006-007-9780702070280" NDATA IMAGE><!ENTITY f006-008-9780702070280 SYSTEM "f006-008-9780702070280" NDATA IMAGE><!ENTITY f006-009-9780702070280 SYSTEM "f006-009-9780702070280" NDATA IMAGE><!ENTITY f006-010-9780702070280 SYSTEM "f006-010-9780702070280" NDATA IMAGE><!ENTITY f006-011-9780702070280 SYSTEM "f006-011-9780702070280" NDATA IMAGE><!ENTITY f006-012-9780702070280 SYSTEM "f006-012-9780702070280" NDATA IMAGE><!ENTITY f006-013-9780702070280 SYSTEM "f006-013-9780702070280" NDATA IMAGE><!ENTITY f006-014-9780702070280 SYSTEM "f006-014-9780702070280" NDATA IMAGE><!ENTITY f006-015-9780702070280 SYSTEM "f006-015-9780702070280" NDATA IMAGE><!ENTITY f006-016-9780702070280 SYSTEM "f006-016-9780702070280" NDATA IMAGE><!ENTITY f006-017-9780702070280 SYSTEM "f006-017-9780702070280" NDATA IMAGE><!ENTITY f006-018-9780702070280 SYSTEM "f006-018-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY if006-001-9780702070280 SYSTEM "if006-001-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00006" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00006-8</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00006-8</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0010"><ce:label>Fig. 6.1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Chain of infection.</ce:simple-para><ce:simple-para id="sp0015" role="caption">The infectious agent is the organism that causes the disease. The reservoir is the place where the population of an infectious agent is maintained. The portal of exit is the point from which the infectious agent leaves the reservoir. Transmission is the process by which the infectious agent is transferred from the reservoir to the human host, either directly or via a vector or fomite. The portal of entry is the body site that is first accessed by the infectious agent. Finally, in order for disease to ensue, the person to whom the infectious agent is transmitted must be a susceptible host.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 6.1</ce:alt-text><ce:link id="ln0010" locator="f006-001-9780702070280" xlink:href="pii:B9780702070280000068/f006-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0015"><ce:label>Fig. 6.2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" role="title">A generic virus life cycle.</ce:simple-para><ce:simple-para id="sp0025" role="caption">Life cycle components common to most viruses are host cell attachment and penetration, virus uncoating, nucleic acid and protein synthesis, virus assembly and release. Virus release is achieved either by budding, as illustrated, or by lysis of the cell membrane. Life cycles vary between viruses.</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 6.2</ce:alt-text><ce:link id="ln0020" locator="f006-002-9780702070280" xlink:href="pii:B9780702070280000068/f006-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 6.3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0030" role="title">Flow chart for bacterial identification, including Gram film appearances on light microscopy (×100).</ce:simple-para><ce:simple-para id="sp9000" role="caption">(MALDI-TOF-MS = matrix-assisted laser desorption/ionisation time-of-flight mass spectroscopy)</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 6.3</ce:alt-text><ce:link id="ln0030" locator="f006-003-9780702070280" xlink:href="pii:B9780702070280000068/f006-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 6.4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" role="title">Beta-haemolytic streptococci (A) and alpha-haemolytic streptococci (B) spread on each half of a blood agar plate (backlit).</ce:simple-para><ce:simple-para id="sp0040" role="caption">This image is half life size. ×0.5. Beta-haemolysis renders the agar transparent around the colonies (A) and alpha-haemolysis imparts a green tinge to the agar (B).</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 6.4</ce:alt-text><ce:link id="ln0035" locator="f006-004-9780702070280" xlink:href="pii:B9780702070280000068/f006-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 6.5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">Human non-sterile sites and normal flora in health.</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 6.5</ce:alt-text><ce:link id="ln0040" locator="f006-005-9780702070280" xlink:href="pii:B9780702070280000068/f006-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 6.6</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0050" role="title">An overview of the processing of blood cultures.</ce:simple-para><ce:simple-para id="sp0055" role="caption">*In laboratories equipped with MALDI-TOF-MS (<ce:cross-ref id="crf9000" refid="s0200">p. 106</ce:cross-ref>), rapid definitive organism identification may be achieved at stage 6 and/or stage 8.</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 6.6</ce:alt-text><ce:link id="ln0060" locator="f006-006-9780702070280" xlink:href="pii:B9780702070280000068/f006-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 6.7</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0060" role="title">The workings of matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS).</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 6.7</ce:alt-text><ce:source>Adapted from Sobin K, Hameer D, Ruparel T. Digital genotyping using molecular affinity and mass spectrometry. Nature Rev Genet 2003; 4:1001–1008.</ce:source><ce:link id="ln0065" locator="f006-007-9780702070280" xlink:href="pii:B9780702070280000068/f006-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 6.8</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0065" role="title">Detection of antigen, nucleic acid and antibody in infectious disease.</ce:simple-para><ce:simple-para id="sp0070" role="caption">The acute sample is usually taken during the first week of illness, and the convalescent sample 2–4 weeks later. Detection limits and duration of detectability vary between tests and diseases, although in most diseases immunoglobulin M (IgM) is detectable within the first 1–2 weeks.</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 6.8</ce:alt-text><ce:link id="ln0070" locator="f006-008-9780702070280" xlink:href="pii:B9780702070280000068/f006-008-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 6.9</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0075" role="title">Antibody (Ab) and antigen (Ag) detection by enzyme-linked immunosorbent assay (ELISA).</ce:simple-para><ce:simple-para id="sp0080" role="caption">This can be configured in various ways. <ce:bold>A</ce:bold> Patient Ab binds to immobilised specific Ag and is detected by addition of anti-immunoglobulin–enzyme conjugate and chromogenic substrate. <ce:bold>B</ce:bold> Patient Ab binds to immobilised Ig subclass-specific Ab and is detected by addition of specific Ag, followed by antibody–enzyme conjugate and chromogenic substrate. <ce:bold>C</ce:bold> Patient Ab and antibody–enzyme conjugate bind to immobilised specific Ag. Magnitude of colour change reaction is inversely proportional to concentration of patient Ab. <ce:bold>D</ce:bold> Patient Ag binds to immobilised Ab and is detected by addition of antibody–enzyme conjugate and chromogenic substrate. In A, the conjugate Ab is specific for human immunoglobulin. In B–D, it is specific for Ag from the disease-causing organism.</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 6.9</ce:alt-text><ce:link id="ln0075" locator="f006-009-9780702070280" xlink:href="pii:B9780702070280000068/f006-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 6.10</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0085" role="title">Antimicrobial susceptibility testing by disc diffusion (panels 1-4) and minimum inhibitory concentration (MIC, panel 5).</ce:simple-para><ce:simple-para id="sp0090" role="caption">1. The test organism is spread over the surface of an agar plate. 2. Antimicrobial-impregnated discs (A–F) are placed on the surface and the plate is incubated (e.g. overnight). 3–4. After incubation, zones of growth inhibition may be seen. The organism is considered susceptible if the diameter of the zone of inhibition exceeds a pre-determined threshold. 5. In a ‘diffusion strip’ test, the strip is impregnated with antimicrobialat a concentration gradient that decreases steadily from top to bottom.The system is designed so that the MIC value is the point at whichthe ellipse cuts a scale on the strip (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 6.10</ce:alt-text><ce:source>4, Kindly supplied byCharlotte Symes.</ce:source><ce:link id="ln0080" locator="f006-010-9780702070280" xlink:href="pii:B9780702070280000068/f006-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 6.11</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0095" role="title">Geographical locations of some infectious disease outbreaks, with examples of emerging and re-emerging diseases.</ce:simple-para><ce:simple-para id="sp0100" role="caption">(CPE = carbapenemase-producing Enterobacteriaceae; MDR-TB = multidrug-resistant tuberculosis; MERS-Co-V = Middle East respiratory syndrome coronavirus; XDR-TB = extensively drug-resistant tuberculosis)</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 6.11</ce:alt-text><ce:link id="ln0085" locator="f006-011-9780702070280" xlink:href="pii:B9780702070280000068/f006-011-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 6.12</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0120" role="title">Commonly encountered health care-associated infections (HCAIs) and the factors that predispose to them.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 6.12</ce:alt-text><ce:link id="ln0100" locator="f006-012-9780702070280" xlink:href="pii:B9780702070280000068/f006-012-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 6.13</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0125" role="title">Hand-washing.</ce:simple-para><ce:simple-para id="sp0130" role="caption">Good hand hygiene, whether with soap/water or alcohol handrub, includes areas that are often missed, such as fingertips, web spaces, palmar creases and the backs of hands.</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 6.13</ce:alt-text><ce:source>Adapted from the ‘How to Handwash’ URL: <ce:inter-ref id="iw0015" xlink:href="http://who.int/gpsc/5may/How_To_Handwash_Poster.pdf">who.int/gpsc/5may/How_To_Handwash_Poster.pdf</ce:inter-ref> © World Health Organization 2009. All rights reserved.</ce:source><ce:copyright type="other" year="2009"/><ce:link id="ln0110" locator="f006-013-9780702070280" xlink:href="pii:B9780702070280000068/f006-013-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0080"><ce:label>Fig. 6.14</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0140" role="title">The relationship between infection prevention and control (IPC) and antimicrobial stewardship (AMS).</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 6.14</ce:alt-text><ce:link id="ln0150" locator="f006-014-9780702070280" xlink:href="pii:B9780702070280000068/f006-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0085"><ce:label>Fig. 6.15</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0145" role="title">Stages in the selection and refinement of antimicrobial therapy: ‘Start Smart – Then Focus’.</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 6.15</ce:alt-text><ce:link id="ln0165" locator="f006-015-9780702070280" xlink:href="pii:B9780702070280000068/f006-015-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 6.16</ce:label><ce:caption id="ca0085"><ce:simple-para id="sp0150" role="title">Examples of mechanisms of antimicrobial resistance.</ce:simple-para><ce:simple-para id="sp0155" role="caption">(CAT = chloramphenicol acetyltransferase; ESBLs = extended-spectrum β-lactamases; MRSA = meticillin-resistant <ce:italic>Staph. aureus</ce:italic>; NDM-1 = New Delhi metallo-β-lactamase 1).</ce:simple-para></ce:caption><ce:alt-text id="atte0085" role="short">Fig. 6.16</ce:alt-text><ce:link id="ln0170" locator="f006-016-9780702070280" xlink:href="pii:B9780702070280000068/f006-016-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 6.17</ce:label><ce:caption id="ca0090"><ce:simple-para id="sp0160" role="title">Antimicrobial pharmacodynamics.</ce:simple-para><ce:simple-para id="sp0165" role="caption">The curve represents drug concentrations after a single dose of an antimicrobial agent. Factors that determine microbial killing are C<ce:inf loc="post">max</ce:inf> : MIC ratio (concentration-dependent killing), time above MIC (time-dependent killing) and AUC : MIC ratio.</ce:simple-para></ce:caption><ce:alt-text id="atte0090" role="short">Fig. 6.17</ce:alt-text><ce:link id="ln0180" locator="f006-017-9780702070280" xlink:href="pii:B9780702070280000068/f006-017-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0100"><ce:label>Fig. 6.18</ce:label><ce:caption id="ca0095"><ce:simple-para id="sp0170" role="title">Dosing of aminoglycosides using the Hartford nomogram.</ce:simple-para><ce:simple-para id="sp0175" role="caption">The nomogram is used to determine the dose interval for 7 mg doses of gentamicin or tobramycin, using measurements of drug levels in plasma 6–14 hours after a single dose.</ce:simple-para></ce:caption><ce:alt-text id="atte0095" role="short">Fig. 6.18</ce:alt-text><ce:link id="ln0210" locator="f006-018-9780702070280" xlink:href="pii:B9780702070280000068/f006-018-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0010" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0015" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0100" role="short">Image 1</ce:alt-text></ce:inline-figure>6.1</ce:label><ce:alt-text id="atte0105" role="short">6.1</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Definition of an infectious agent – Koch's postulates</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0140"><ce:list id="olist0030"><ce:list-item id="o0120"><ce:label>1</ce:label><ce:para id="p0145">The same organism must be present in every case of the disease</ce:para></ce:list-item><ce:list-item id="o0125"><ce:label>2</ce:label><ce:para id="p0150">The organism must be isolated from the diseased host and grown in pure culture</ce:para></ce:list-item><ce:list-item id="o0130"><ce:label>3</ce:label><ce:para id="p0155">The isolate must cause the disease, when inoculated into a healthy, susceptible animal</ce:para></ce:list-item><ce:list-item id="o0135"><ce:label>4</ce:label><ce:para id="p0160">The organism must be re-isolated from the inoculated, diseased animal</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0015" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0025" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0110" role="short">Image 2</ce:alt-text></ce:inline-figure>6.2</ce:label><ce:alt-text id="atte0115" role="short">6.2</ce:alt-text><ce:textbox-head><ce:title id="tit0020">How bacteria are identified</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0030"><ce:section-title id="st0025">Gram stain reaction (see <ce:cross-ref id="crf0135" refid="f0020">Fig. 6.3</ce:cross-ref>)</ce:section-title><ce:para id="p0175"><ce:list id="ulist0035"><ce:list-item id="u0140"><ce:label>•</ce:label><ce:para id="p0180">Gram-positive (thick peptidoglycan layer), Gram-negative (thin peptidoglycan) or unstainable</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0035"><ce:section-title id="st0030">Microscopic morphology</ce:section-title><ce:para id="p0185"><ce:list id="ulist0040"><ce:list-item id="u0145"><ce:label>•</ce:label><ce:para id="p0190">Cocci (round cells) or bacilli (elongated cells)</ce:para></ce:list-item><ce:list-item id="u0150"><ce:label>•</ce:label><ce:para id="p0195">Presence or absence of capsule</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0040"><ce:section-title id="st0035">Cell association</ce:section-title><ce:para id="p0200"><ce:list id="ulist0045"><ce:list-item id="u0155"><ce:label>•</ce:label><ce:para id="p0205">Association in clusters, chains or pairs</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0045"><ce:section-title id="st0040">Colonial characteristics</ce:section-title><ce:para id="p0210"><ce:list id="ulist0050"><ce:list-item id="u0160"><ce:label>•</ce:label><ce:para id="p0215">Colony size, shape or colour</ce:para></ce:list-item><ce:list-item id="u0165"><ce:label>•</ce:label><ce:para id="p0220">Effect on culture media (e.g. β-haemolysis of blood agar in haemolytic streptococci; see <ce:cross-ref id="crf0140" refid="f0025">Fig. 6.4</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0050"><ce:section-title id="st0045">Atmospheric requirements</ce:section-title><ce:para id="p0225"><ce:list id="ulist0055"><ce:list-item id="u0170"><ce:label>•</ce:label><ce:para id="p0230">Strictly aerobic (requires O<ce:inf loc="post">2</ce:inf>), strictly anaerobic (requires absence of O<ce:inf loc="post">2</ce:inf>), facultatively aerobic (grows with or without O<ce:inf loc="post">2</ce:inf>) or micro-aerophilic (requires reduced O<ce:inf loc="post">2</ce:inf>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0050">Biochemical reactions</ce:section-title><ce:para id="p0235"><ce:list id="ulist0060"><ce:list-item id="u0175"><ce:label>•</ce:label><ce:para id="p0240">Expression of enzymes (oxidase, catalase, coagulase)</ce:para></ce:list-item><ce:list-item id="u0180"><ce:label>•</ce:label><ce:para id="p0245">Ability to ferment or hydrolyse various biochemical substrates</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0060"><ce:section-title id="st0055">Motility</ce:section-title><ce:para id="p0250"><ce:list id="ulist0065"><ce:list-item id="u0185"><ce:label>•</ce:label><ce:para id="p0255">Motile or non-motile</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0060">Antibiotic susceptibility</ce:section-title><ce:para id="p0260"><ce:list id="ulist0070"><ce:list-item id="u0190"><ce:label>•</ce:label><ce:para id="p0265">Identifies organisms with invariable susceptibility (e.g. to optochin in <ce:italic>Streptococcus pneumoniae</ce:italic> or metronidazole in obligate anaerobes)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0065">Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS)</ce:section-title><ce:para id="p0270"><ce:list id="ulist0075"><ce:list-item id="u0195"><ce:label>•</ce:label><ce:para id="p0275">A rapid technique that identifies bacteria and some fungi from their specific molecular composition</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0075"><ce:section-title id="st0070">Sequencing bacterial 16s ribosomal RNA gene</ce:section-title><ce:para id="p0280"><ce:list id="ulist0080"><ce:list-item id="u0200"><ce:label>•</ce:label><ce:para id="p0285">A highly specific test for identification of organisms in pure culture and in samples from normally sterile sites</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0080"><ce:section-title id="st0075">Whole-genome sequencing</ce:section-title><ce:para id="p0290"><ce:list id="ulist0085"><ce:list-item id="u0205"><ce:label>•</ce:label><ce:para id="p0295">Although not yet in routine use, whole-genome sequencing (WGS) offers the potential to provide rapid and simultaneous identification, sensitivity testing and typing of organisms from pure culture and/or directly from clinical samples. As such, WGS is likely to replace many of the technologies described above over the next few years (<ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0300">p. 58</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0020" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0045" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0120" role="short">Image 3</ce:alt-text></ce:inline-figure>6.3</ce:label><ce:alt-text id="atte0125" role="short">6.3</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Exotoxin-mediated bacterial diseases</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0370"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0130" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Organism</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Antibiotic-associated diarrhoea/pseudomembranous colitis</ce:bold></entry><entry align="left"><ce:italic>Clostridium difficile</ce:italic> (<ce:intra-ref id="ii0040" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0445">p. 230</ce:intra-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Botulism</ce:bold></entry><entry align="left"><ce:italic>Clostridium botulinum</ce:italic> (<ce:intra-ref id="ii0045" xlink:href="pii:B978-0-7020-7028-0.00025-1#p7895">p. 1126</ce:intra-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cholera</ce:bold></entry><entry align="left"><ce:italic>Vibrio cholerae</ce:italic> (<ce:intra-ref id="ii0050" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1565">p. 264</ce:intra-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Diphtheria</ce:bold></entry><entry align="left"><ce:italic>Corynebacterium diphtheriae</ce:italic> (<ce:intra-ref id="ii0055" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1595">p. 265</ce:intra-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Haemolytic uraemic syndrome</ce:bold></entry><entry align="left">Enterohaemorrhagic <ce:italic>Escherichia coli</ce:italic> (<ce:italic>E. coli</ce:italic> O157 and other strains) (<ce:intra-ref id="ii0060" xlink:href="pii:B978-0-7020-7028-0.00011-1#p5450">p. 263</ce:intra-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Necrotising pneumonia</ce:bold></entry><entry align="left"><ce:italic>Staphylococcus aureus</ce:italic> (<ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00011-1#p4245">p. 250</ce:intra-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tetanus</ce:bold></entry><entry align="left"><ce:italic>Clostridium tetani</ce:italic> (<ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00025-1#s1565">p. 1125</ce:intra-ref>)</entry></row><row><entry align="left"><ce:bold>Toxic shock syndrome</ce:bold></entry><entry align="left"><ce:italic>Staphylococcus aureus</ce:italic> (<ce:intra-ref id="ii0075" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1145">p. 252</ce:intra-ref>)<ce:br/><ce:italic>Streptococcus pyogenes</ce:italic> (<ce:intra-ref id="ii9000" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1170">p. 253</ce:intra-ref>)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0025" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0050" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0135" role="short">Image 4</ce:alt-text></ce:inline-figure>6.4</ce:label><ce:alt-text id="atte0140" role="short">6.4</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Tests used to diagnose infection</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0135"><ce:section-title id="st0125">Non-specific markers of inflammation/infection</ce:section-title><ce:para id="p0415"><ce:list id="ulist0095"><ce:list-item id="u0220"><ce:label>•</ce:label><ce:para id="p0420">e.g. White cell count in blood sample (WCC), plasma C-reactive protein (CRP), procalcitonin, serum lactate, cell counts in urine or cerebrospinal fluid (CSF), CSF protein and glucose</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0140"><ce:section-title id="st0130">Direct detection of organisms or organism components</ce:section-title><ce:para id="p0425"><ce:list id="ulist0100"><ce:list-item id="u0225"><ce:label>•</ce:label><ce:para id="p0430">Microscopy</ce:para></ce:list-item><ce:list-item id="u0230"><ce:label>•</ce:label><ce:para id="p0435">Detection of organism components (e.g. antigen, toxin)</ce:para></ce:list-item><ce:list-item id="u0235"><ce:label>•</ce:label><ce:para id="p0440">Nucleic acid amplification (e.g. polymerase chain reaction)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0145"><ce:section-title id="st0135">Culture of organisms</ce:section-title><ce:para id="p0445"><ce:list id="ulist0105"><ce:list-item id="u0240"><ce:label>•</ce:label><ce:para id="p0450">± Antimicrobial susceptibility testing</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0150"><ce:section-title id="st0140">Tests of the host's specific immune response</ce:section-title><ce:para id="p0455"><ce:list id="ulist0110"><ce:list-item id="u0245"><ce:label>•</ce:label><ce:para id="p0460">Antibody detection</ce:para></ce:list-item><ce:list-item id="u0250"><ce:label>•</ce:label><ce:para id="p0465">Interferon-gamma release assays (IGRA)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0055" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000068/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0145" role="short">Image 5</ce:alt-text></ce:inline-figure>6.5</ce:label><ce:alt-text id="atte0150" role="short">6.5</ce:alt-text><ce:textbox-head><ce:title id="tit0035">How to provide samples for microbiological sampling</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0155"><ce:section-title id="st0145">Communicate with the laboratory</ce:section-title><ce:para id="p0470"><ce:list id="ulist0115"><ce:list-item id="u0255"><ce:label>•</ce:label><ce:para id="p0475">Discuss samples that require processing urgently or that may contain hazardous or unusual pathogens with laboratory staff <ce:italic>before</ce:italic> collection</ce:para></ce:list-item><ce:list-item id="u0260"><ce:label>•</ce:label><ce:para id="p0480">Communication is key to optimising microbiological diagnosis. If there is doubt about any aspect of sampling, it is far better to discuss it with laboratory staff beforehand than to risk diagnostic delay by inappropriate sampling or sample handling</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0150">Take samples based on a clinical diagnosis</ce:section-title><ce:para id="p0485"><ce:list id="ulist0120"><ce:list-item id="u0265"><ce:label>•</ce:label><ce:para id="p0490">Sampling in the absence of clinical evidence of infection is rarely appropriate (e.g. collecting urine, or sputum for culture)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0165"><ce:section-title id="st0155">Use the correct container</ce:section-title><ce:para id="p0495"><ce:list id="ulist0125"><ce:list-item id="u0270"><ce:label>•</ce:label><ce:para id="p0500">Certain tests (e.g. nucleic acid and antigen detection tests) require proprietary sample collection equipment</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0170"><ce:section-title id="st0160">Follow sample collection procedures</ce:section-title><ce:para id="p0505"><ce:list id="ulist0130"><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0510">Failure to follow sample collection instructions precisely can result in false-positive (e.g. contamination of blood culture samples) or false-negative (e.g. collection of insufficient blood for culture) results</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0165">Label sample and request form correctly</ce:section-title><ce:para id="p0515"><ce:list id="ulist0135"><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0520">Label sample containers and request forms according to local policies, with demographic identifiers, specimen type and time/date collected</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0525">Include clinical details on request forms</ce:para></ce:list-item><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0530">Identify samples carrying a high risk of infection (e.g. blood liable to contain a blood-borne virus) with a hazard label</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0180"><ce:section-title id="st0170">Use appropriate packaging</ce:section-title><ce:para id="p0535"><ce:list id="ulist0140"><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0540">Close sample containers tightly and package securely (usually in sealed plastic bags)</ce:para></ce:list-item><ce:list-item id="u0300"><ce:label>•</ce:label><ce:para id="p0545">Attach request forms to samples but not in the same compartment (to avoid contamination, should leakage occur)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0175">Manage storage and transport</ce:section-title><ce:para id="p0550"><ce:list id="ulist0145"><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0555">Transport samples to the microbiology laboratory quickly</ce:para></ce:list-item><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0560">If pre-transport storage is required, conditions (e.g. refrigeration, incubation, storage at room temperature) vary with sample type</ce:para></ce:list-item><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0565">Notify the receiving laboratory prior to arrival of unusual or urgent samples, to ensure timely processing</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0155" role="short">Image 6</ce:alt-text></ce:inline-figure>6.6</ce:label><ce:alt-text id="atte0160" role="short">6.6</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Incubation periods of important infections<ce:cross-ref id="crf0295" refid="tn0025"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0840"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0165" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Infection</entry><entry align="left">Incubation period</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Short incubation periods</ce:bold></entry></row><row rowsep="0"><entry align="left">Anthrax, cutaneous<ce:cross-ref id="crf0300" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">9 hrs to 2 weeks</entry></row><row rowsep="0"><entry align="left">Anthrax, inhalational<ce:cross-ref id="crf0305" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">2 days<ce:cross-ref id="crf0310" refid="tn0030"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row rowsep="0"><entry align="left">Bacillary dysentery<ce:cross-ref id="crf0315" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">1–6 days</entry></row><row rowsep="0"><entry align="left">Cholera<ce:cross-ref id="crf0320" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">2 hrs to 5 days</entry></row><row rowsep="0"><entry align="left">Dengue haemorrhagic fever<ce:cross-ref id="crf0325" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">3–14 days</entry></row><row rowsep="0"><entry align="left">Diphtheria<ce:cross-ref id="crf0330" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">1–10 days</entry></row><row rowsep="0"><entry align="left">Gonorrhoea<ce:cross-ref id="crf0335" refid="tn0040"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">2–10 days</entry></row><row rowsep="0"><entry align="left">Influenza<ce:cross-ref id="crf0340" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">1–3 days</entry></row><row rowsep="0"><entry align="left">Meningococcaemia<ce:cross-ref id="crf0345" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">2–10 days</entry></row><row rowsep="0"><entry align="left">Norovirus<ce:cross-ref id="crf0350" refid="tn0025"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">1–3 days</entry></row><row rowsep="0"><entry align="left">SARS coronavirus<ce:cross-ref id="crf0355" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">2–7 days<ce:cross-ref id="crf0360" refid="tn0030"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row rowsep="1"><entry align="left">Scarlet fever<ce:cross-ref id="crf0365" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">2–4 days</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Intermediate incubation periods</ce:bold></entry></row><row rowsep="0"><entry align="left">Amoebiasis<ce:cross-ref id="crf0370" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">1–4 weeks</entry></row><row rowsep="0"><entry align="left">Brucellosis<ce:cross-ref id="crf0375" refid="tn0040"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">5–30 days</entry></row><row rowsep="0"><entry align="left">Chickenpox<ce:cross-ref id="crf0380" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">11–20 days</entry></row><row rowsep="0"><entry align="left">Lassa fever<ce:cross-ref id="crf0385" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">3–21 days</entry></row><row rowsep="0"><entry align="left">Malaria<ce:cross-ref id="crf0390" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">10–15 days</entry></row><row rowsep="0"><entry align="left">Measles<ce:cross-ref id="crf0395" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">6–19 days</entry></row><row rowsep="0"><entry align="left">Mumps<ce:cross-ref id="crf0400" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">15–24 days</entry></row><row rowsep="0"><entry align="left">Poliomyelitis<ce:cross-ref id="crf0405" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">3–35 days</entry></row><row rowsep="0"><entry align="left">Psittacosis<ce:cross-ref id="crf0410" refid="tn0040"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">1–4 weeks</entry></row><row rowsep="0"><entry align="left">Rubella<ce:cross-ref id="crf0415" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">15–20 days</entry></row><row rowsep="0"><entry align="left">Typhoid<ce:cross-ref id="crf0420" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">5–31 days</entry></row><row rowsep="1"><entry align="left">Whooping cough<ce:cross-ref id="crf0425" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">5–21 days</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Long incubation periods</ce:bold></entry></row><row rowsep="0"><entry align="left">Hepatitis A<ce:cross-ref id="crf0430" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">3–7 weeks</entry></row><row rowsep="0"><entry align="left">Hepatitis B<ce:cross-ref id="crf0435" refid="tn0040"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">6 weeks to 6 months</entry></row><row rowsep="0"><entry align="left">Leishmaniasis, cutaneous<ce:cross-ref id="crf0440" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">Weeks to months</entry></row><row rowsep="0"><entry align="left">Leishmaniasis, visceral<ce:cross-ref id="crf0445" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">Months to years</entry></row><row rowsep="0"><entry align="left">Leprosy (Hansen's disease)<ce:cross-ref id="crf0450" refid="tn0035"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">5–20 years</entry></row><row rowsep="0"><entry align="left">Rabies<ce:cross-ref id="crf0455" refid="tn0040"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">2–8 weeks<ce:cross-ref id="crf0460" refid="tn0030"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row rowsep="0"><entry align="left"><ce:italic>Trypanosoma brucei gambiense</ce:italic> infection<ce:cross-ref id="crf0465" refid="tn0050"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry><entry align="left">Months to years</entry></row><row><entry align="left">Tuberculosis<ce:cross-ref id="crf0470" refid="tn0045"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">1–12 months</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0115">(SARS = severe acute respiratory syndrome)</ce:simple-para></ce:legend><ce:table-footnote id="tn0025"><ce:label>1</ce:label><ce:note-para id="np0025">Incubation periods are approximate and may differ from local or national guidance.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0030"><ce:label>2</ce:label><ce:note-para id="np0030">Longer incubation periods have been reported.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0035"><ce:label>3</ce:label><ce:note-para id="np0035">WHO.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0040"><ce:label>4</ce:label><ce:note-para id="np0040">Health Protection Agency (now Health Protection England).</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0045"><ce:label>5</ce:label><ce:note-para id="np0045">Richardson M, Elliman D, Maguire H, et al. Pediatr Infect Dis J 2001; 20:380–388.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0050"><ce:label>6</ce:label><ce:note-para id="np0050">Centers for Disease Control, USA.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0090" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0170" role="short">Image 7</ce:alt-text></ce:inline-figure>6.7</ce:label><ce:alt-text id="atte0175" role="short">6.7</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Periods of infectivity in common childhood infectious diseases</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0835"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0180" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Infectious period</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Chickenpox</ce:bold><ce:cross-ref id="crf0230" refid="tn0010"><ce:bold><ce:sup loc="post">1</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">From 4 days before until 5 days after appearance of the rash (transmission before 48 hrs prior to the onset of rash is rare)<ce:cross-ref id="crf0235" refid="pg0010"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Measles</ce:bold><ce:cross-ref id="crf0240" refid="tn0015"><ce:bold><ce:sup loc="post">2</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">From 4 days before onset to 4 days after onset of the rash</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mumps</ce:bold><ce:cross-ref id="crf0245" refid="tn0020"><ce:bold><ce:sup loc="post">3</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">From 2–3 days before to 5 days after disease onset<ce:cross-ref id="crf0250" refid="pg0015"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Rubella</ce:bold><ce:cross-ref id="crf0255" refid="tn0020"><ce:bold><ce:sup loc="post">3</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">From 10 days before until 15 days after the onset of the rash, but most infectious during prodromal illness<ce:cross-ref id="crf0260" refid="pg0010"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Scarlet fever</ce:bold><ce:cross-ref id="crf0265" refid="tn0010"><ce:bold><ce:sup loc="post">1</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">Unknown<ce:cross-ref id="crf0270" refid="pg0020"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry></row><row><entry align="left"><ce:bold>Whooping cough</ce:bold><ce:cross-ref id="crf0275" refid="tn0010"><ce:bold><ce:sup loc="post">1</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">Unknown<ce:cross-ref id="crf0280" refid="pg0020"><ce:sup loc="post">6</ce:sup></ce:cross-ref><ce:sup loc="post">,</ce:sup><ce:cross-ref id="crf0285" refid="pg0025"><ce:sup loc="post">7</ce:sup></ce:cross-ref></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0105"><ce:sup loc="post">4–6</ce:sup>Exclude from contact with non-immune and immunocompromised people for 5 days from <ce:anchor id="pg0010"><ce:sup loc="post">4</ce:sup></ce:anchor>onset of rash, <ce:anchor id="pg0015"><ce:sup loc="post">5</ce:sup></ce:anchor>onset of parotitis, or <ce:anchor id="pg0020"><ce:sup loc="post">6</ce:sup></ce:anchor>start of antibiotic treatment. <ce:anchor id="pg0025"><ce:sup loc="post">7</ce:sup></ce:anchor>Exclude for 3 weeks if untreated.</ce:simple-para><ce:simple-para id="sp0110">Durations are approximate and vary between information sources, and these recommendations may differ from local or national guidance.</ce:simple-para></ce:legend><ce:table-footnote id="tn0010"><ce:label>1</ce:label><ce:note-para id="np0010">From Richardson M, Elliman D, Maguire H, et al. Pediatr Infect Dis J 2001; 20:380–388.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0015"><ce:label>2</ce:label><ce:note-para id="np0015">Centers for Disease Control, USA; <ce:inter-ref id="iw0010" xlink:href="http://cdc.gov/measles/hcp/">cdc.gov/measles/hcp/</ce:inter-ref>.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0020"><ce:label>3</ce:label><ce:note-para id="np0020">Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas and Bennett's Principles and practice of infectious diseases, 8th edn. Philadelphia: Elsevier; 2015.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0105" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0185" role="short">Image 8</ce:alt-text></ce:inline-figure>6.8</ce:label><ce:alt-text id="atte0190" role="short">6.8</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Measures used in infection prevention and control (IPC)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0335"><ce:section-title id="st0320">Institutions</ce:section-title><ce:para id="p0865"><ce:list id="ulist0175"><ce:list-item id="u0425"><ce:label>•</ce:label><ce:para id="p0870">Handling, storage and disposal of clinical waste</ce:para></ce:list-item><ce:list-item id="u0430"><ce:label>•</ce:label><ce:para id="p0875">Containment and safe removal of spilled blood and body fluids</ce:para></ce:list-item><ce:list-item id="u0435"><ce:label>•</ce:label><ce:para id="p0880">Cleanliness of environment and medical equipment</ce:para></ce:list-item><ce:list-item id="u0440"><ce:label>•</ce:label><ce:para id="p0885">Specialised ventilation (e.g. laminar flow, air filtration, controlled pressure gradients)</ce:para></ce:list-item><ce:list-item id="u0445"><ce:label>•</ce:label><ce:para id="p0890">Sterilisation and disinfection of instruments and equipment</ce:para></ce:list-item><ce:list-item id="u0450"><ce:label>•</ce:label><ce:para id="p0895">Food hygiene</ce:para></ce:list-item><ce:list-item id="u0455"><ce:label>•</ce:label><ce:para id="p0900">Laundry management</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0340"><ce:section-title id="st0325">Health-care staff</ce:section-title><ce:para id="p0905"><ce:list id="ulist0180"><ce:list-item id="u0460"><ce:label>•</ce:label><ce:para id="p0910">Education</ce:para></ce:list-item><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0915">Hand hygiene, including hand-washing (see <ce:cross-ref id="crf0490" refid="f0070">Fig. 6.13</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0920">Sharps management and disposal</ce:para></ce:list-item><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0925">Use of personal protective equipment (masks, sterile and non-sterile gloves, gowns and aprons)</ce:para></ce:list-item><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0930">Screening health workers for disease (e.g. tuberculosis, hepatitis B virus, MRSA)</ce:para></ce:list-item><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0935">Immunisation and post-exposure prophylaxis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0345"><ce:section-title id="st0330">Clinical practice</ce:section-title><ce:para id="p0940"><ce:list id="ulist0185"><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0945">Antibiotic stewardship (<ce:cross-ref id="crf9005" refid="s0400">p. 115</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0950">Aseptic technique</ce:para></ce:list-item><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0955">Perioperative antimicrobial prophylaxis</ce:para></ce:list-item><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0960">Screening patients for colonisation or infection (e.g. MRSA, GRE, CPE)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0335">Response to infections</ce:section-title><ce:para id="p0965"><ce:list id="ulist0190"><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0970">Surveillance to detect alert organism (see text) outbreaks and antimicrobial resistance</ce:para></ce:list-item><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0975">Antibiotic chemoprophylaxis in infectious disease contacts, if indicated (see <ce:cross-ref id="crf0495" refid="b0095">Box 6.18</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0980">Isolation (see <ce:cross-ref id="crf0500" refid="b0050">Box 6.9</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0985">Reservoir control</ce:para></ce:list-item><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0990">Vector control</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0995">(CPE = carbapenemase-producing Enterobacteriaceae; GRE = glycopeptide-resistant enterococci; MRSA = meticillin-resistant <ce:italic>Staphylococcus aureus</ce:italic>)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0115" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0195" role="short">Image 9</ce:alt-text></ce:inline-figure>6.9</ce:label><ce:alt-text id="atte0200" role="short">6.9</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Types of isolation precaution<ce:cross-ref id="crf0515" refid="tn0055"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1005"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0205" role="short">Unlabelled table</ce:alt-text><tgroup cols="1"><colspec colname="col1" colnum="1"/><tbody><row><entry align="left"><ce:display><ce:figure id="f0075"><ce:alt-text id="atte0210" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0120" locator="b006-009-9780702070280" xlink:href="pii:B9780702070280000068/b006-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp9010"><ce:sup loc="post">2</ce:sup>Not a CDC recommendation.</ce:simple-para><ce:simple-para id="sp9015"><ce:sup loc="post">3</ce:sup>Subject to local risk assessment.</ce:simple-para><ce:simple-para id="sp9020"><ce:sup loc="post">4</ce:sup>Or in any immunocompromised patient until possibility of disseminated infection excluded.(ESBL = extended-spectrum β-lactamase; GRE = glycopeptide-resistant enterococci; MRSA = meticillin-resistant <ce:italic>Staph. aureus</ce:italic>; RSV = respiratory syncytial virus; SARS = severe acute respiratory syndrome; VRSA = vancomycin-resistant <ce:italic>Staph. aureus</ce:italic>; VZV = varicella zoster virus)</ce:simple-para></ce:legend><ce:table-footnote id="tn0055"><ce:label>1</ce:label><ce:note-para id="np9000">Recommendations based on 2007 CDC guideline for isolation precautions. May differ from local or national recommendations.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0125" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0215" role="short">Image 10</ce:alt-text></ce:inline-figure>6.10</ce:label><ce:alt-text id="atte0220" role="short">6.10</ce:alt-text><ce:textbox-head><ce:title id="tit0060">Terminology in outbreaks of infection</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1015"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0225" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Term</entry><entry align="left">Definition</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Classification of related cases of infectious disease</ce:bold><ce:cross-ref id="crf0540" refid="tn0075"><ce:bold>*</ce:bold></ce:cross-ref></entry></row><row rowsep="0"><entry align="left">Cluster</entry><entry align="left">An aggregation of cases of a disease that are closely grouped in time and place, and may or may not exceed the expected number</entry></row><row rowsep="0"><entry align="left">Epidemic</entry><entry align="left">The occurrence of more cases of disease than expected in a given area or among a specific group of people over a particular period of time</entry></row><row rowsep="0"><entry align="left">Outbreak</entry><entry align="left">Synonymous with epidemic. Alternatively, a localised, as opposed to generalised, epidemic</entry></row><row rowsep="1"><entry align="left">Pandemic</entry><entry align="left">An epidemic occurring over a very wide area (several countries or continents) and usually affecting a large proportion of the population</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Classification of affected patients (cases)</ce:bold></entry></row><row rowsep="0"><entry align="left">Index case</entry><entry align="left">The first case identified in an outbreak</entry></row><row rowsep="0"><entry align="left">Primary cases</entry><entry align="left">Cases acquired from a specific source of infection</entry></row><row rowsep="1"><entry align="left">Secondary cases</entry><entry align="left">Cases acquired from primary cases</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Types of outbreak</ce:bold></entry></row><row rowsep="0"><entry align="left">Common source outbreak</entry><entry align="left">Exposure to a common source of infection (e.g. water-cooling tower, medical staff member shedding MRSA). New primary cases will arise until the source is no longer present</entry></row><row rowsep="0"><entry align="left">Point source outbreak</entry><entry align="left">Exposure to a single source of infection at a specific point in time (e.g. contaminated food at a party). Primary cases will develop disease synchronously</entry></row><row><entry align="left">Person-to-person spread</entry><entry align="left">Outbreak with both primary and secondary cases. May complicate point source or common source outbreak</entry></row></tbody></tgroup><ce:table-footnote id="tn0075"><ce:label>*</ce:label><ce:note-para id="np0075">Adapted from <ce:inter-ref id="iw0020" xlink:href="http://cdc.gov">cdc.gov</ce:inter-ref>. (MRSA = meticillin-resistant <ce:italic>Staphylococcus aureus</ce:italic>)</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0130" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0230" role="short">Image 11</ce:alt-text></ce:inline-figure>6.11</ce:label><ce:alt-text id="atte0235" role="short">6.11</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Reasons for including an infectious disease on a regional/national list of reportable diseases<ce:cross-ref id="crf0550" refid="tn0080">*</ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1025"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0240" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Reason for inclusion</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Endemic/local disease with the potential to spread and/or cause outbreaks</ce:bold></entry><entry align="left">Influenza, <ce:italic>Salmonella</ce:italic>, tuberculosis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Imported disease with the propensity to spread and/or cause outbreaks</ce:bold></entry><entry align="left">Typhoid, cholera (depending on local epidemiology)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Evidence of a possible breakdown in health protection/public health functions</ce:bold></entry><entry align="left"><ce:italic>Legionella</ce:italic>, <ce:italic>Cryptosporidium</ce:italic></entry></row><row rowsep="1"><entry align="left"><ce:bold>Evidence of a possible breakdown in food safety practices</ce:bold></entry><entry align="left">Botulism, verotoxigenic <ce:italic>E. coli</ce:italic></entry></row><row rowsep="1"><entry align="left"><ce:bold>Evidence of a possible failure of a vaccination programme</ce:bold></entry><entry align="left">Measles, poliomyelitis, pertussis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Disease with the potential to be a novel or increasing threat to human health</ce:bold></entry><entry align="left">SARS, MERS-CoV, multi-resistant bacteria</entry></row><row rowsep="1"><entry align="left"><ce:bold>Evidence of expansion of the range of a reservoir/vector</ce:bold></entry><entry align="left">Lyme disease, rabies, West Nile encephalitis</entry></row><row><entry align="left"><ce:bold>Evidence of possible deliberate release</ce:bold></entry><entry align="left">Anthrax, tularaemia, plague, smallpox, botulism</entry></row></tbody></tgroup><ce:table-footnote id="tn0080"><ce:label>*</ce:label><ce:note-para id="np0080">Given the different geographical ranges of individual diseases and wide national variations in public health services, vaccination programmes and availability of resources, reporting regulations vary between regions, states and countries. Many diseases are reportable for more than one reason. (MERS-CoV = Middle East respiratory syndrome coronavirus; SARS = severe acute respiratory syndrome)</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0135" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0245" role="short">Image 12</ce:alt-text></ce:inline-figure>6.12</ce:label><ce:alt-text id="atte0250" role="short">6.12</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Indications for post-exposure prophylaxis with immunoglobulins</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0365"><ce:section-title id="st0350">Human normal immunoglobulin (pooled immunoglobulin)</ce:section-title><ce:para id="p1035"><ce:list id="ulist0195"><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p1040">Hepatitis A (unvaccinated contacts<ce:cross-ref id="crf0560" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0085">Active immunisation is preferred if contact is with a patient who is within 1 week of onset of jaundice.</ce:note-para></ce:footnote>)</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p1045">Measles (exposed child with heart or lung disease)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0370"><ce:section-title id="st0355">Human specific immunoglobulin</ce:section-title><ce:para id="p1050"><ce:list id="ulist0200"><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p1055">Hepatitis B (sexual partners, inoculation injuries, infants born to infected mothers)</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p1060">Tetanus (high-risk wounds or incomplete or unknown immunisation status)</ce:para></ce:list-item><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p1065">Rabies</ce:para></ce:list-item><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p1070">Chickenpox (immunosuppressed children and adults, pregnant women)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0140" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0255" role="short">Image 13</ce:alt-text></ce:inline-figure>6.13</ce:label><ce:alt-text id="atte0260" role="short">6.13</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Vaccines in current clinical use</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0380"><ce:section-title id="st0365">Live attenuated vaccines</ce:section-title><ce:para id="p1080"><ce:list id="ulist0205"><ce:list-item id="u0565"><ce:label>•</ce:label><ce:para id="p1085">Measles, mumps, rubella (MMR)</ce:para></ce:list-item><ce:list-item id="u0570"><ce:label>•</ce:label><ce:para id="p1090">Oral poliomyelitis (OPV, not used in UK)</ce:para></ce:list-item><ce:list-item id="u0575"><ce:label>•</ce:label><ce:para id="p1095">Rotavirus</ce:para></ce:list-item><ce:list-item id="u0580"><ce:label>•</ce:label><ce:para id="p1100">Tuberculosis (bacille Calmette–Guérin, BCG)</ce:para></ce:list-item><ce:list-item id="u0585"><ce:label>•</ce:label><ce:para id="p1105">Typhoid (oral typhoid vaccine)</ce:para></ce:list-item><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p1110">Varicella zoster virus</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0385"><ce:section-title id="st0370">Inactivated (killed) whole-cell vaccines</ce:section-title><ce:para id="p1115"><ce:list id="ulist0210"><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p1120">Cholera</ce:para></ce:list-item><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p1125">Hepatitis A</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p1130">Influenza</ce:para></ce:list-item><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p1135">Poliomyelitis (inactivated polio virus, IPV)</ce:para></ce:list-item><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p1140">Rabies</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0390"><ce:section-title id="st0375">Component vaccines</ce:section-title><ce:para id="p1145"><ce:list id="ulist0215"><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p1150">Anthrax (adsorbed extracted antigens)</ce:para></ce:list-item><ce:list-item id="u0625"><ce:label>•</ce:label><ce:para id="p1155">Diphtheria (adsorbed toxoid)</ce:para></ce:list-item><ce:list-item id="u0630"><ce:label>•</ce:label><ce:para id="p1160">Hepatitis B (adsorbed recombinant hepatitis B surface antigen, HBsAg)</ce:para></ce:list-item><ce:list-item id="u0635"><ce:label>•</ce:label><ce:para id="p1165"><ce:italic>Haemophilus influenzae</ce:italic> type B (conjugated capsular polysaccharide)</ce:para></ce:list-item><ce:list-item id="u0640"><ce:label>•</ce:label><ce:para id="p1170">Human papillomavirus (recombinant capsid proteins)</ce:para></ce:list-item><ce:list-item id="u0645"><ce:label>•</ce:label><ce:para id="p1175">Meningococcal, quadrivalent A, C, Y, W135 (conjugated capsular polysaccharide)</ce:para></ce:list-item><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p1180">Meningococcal, serogroup C (conjugated capsular polysaccharide)</ce:para></ce:list-item><ce:list-item id="u0655"><ce:label>•</ce:label><ce:para id="p1185">Pertussis (adsorbed extracted antigens)</ce:para></ce:list-item><ce:list-item id="u0660"><ce:label>•</ce:label><ce:para id="p1190">Pneumococcal conjugate (PCV; conjugated capsular polysaccharide, 13 serotypes)</ce:para></ce:list-item><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p1195">Pneumococcal polysaccharide (PPV; purified capsular polysaccharide, 23 serotypes)</ce:para></ce:list-item><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p1200">Tetanus (adsorbed toxoid)</ce:para></ce:list-item><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p1205">Typhoid (purified Vi capsular polysaccharide)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0145" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0265" role="short">Image 14</ce:alt-text></ce:inline-figure>6.14</ce:label><ce:alt-text id="atte0270" role="short">6.14</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Guidelines for vaccination against infectious disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1225"><ce:list id="ulist0220"><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p1230">The principal contraindication to inactivated vaccines is an anaphylactic reaction to a previous dose or a vaccine component</ce:para></ce:list-item><ce:list-item id="u0685"><ce:label>•</ce:label><ce:para id="p1235">Live vaccines should not be given during an acute infection, to pregnant women or to the immunosuppressed, unless the immunosuppression is mild and the benefits outweigh the risks</ce:para></ce:list-item><ce:list-item id="u0690"><ce:label>•</ce:label><ce:para id="p1240">If two live vaccines are required, they should be given either simultaneously in opposite arms or 4 weeks apart</ce:para></ce:list-item><ce:list-item id="u0695"><ce:label>•</ce:label><ce:para id="p1245">Live vaccines should not be given for 3 months after an injection of human normal immunoglobulin (HNI)</ce:para></ce:list-item><ce:list-item id="u0700"><ce:label>•</ce:label><ce:para id="p1250">HNI should not be given for 2 weeks after a live vaccine</ce:para></ce:list-item><ce:list-item id="u0705"><ce:label>•</ce:label><ce:para id="p1255">Hay fever, asthma, eczema, sickle-cell disease, topical glucocorticoid therapy, antibiotic therapy, prematurity and chronic heart and lung diseases, including tuberculosis, are not contraindications to vaccination</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0155" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0275" role="short">Image 15</ce:alt-text></ce:inline-figure>6.15</ce:label><ce:alt-text id="atte0280" role="short">6.15</ce:alt-text><ce:textbox-head><ce:title id="tit0085">Target and mechanism of action of common antibacterial agents</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0425"><ce:section-title id="st0410">Aminoglycosides, chloramphenicol, macrolides, lincosamides, oxazolidinones</ce:section-title><ce:para id="p1310"><ce:list id="ulist0230"><ce:list-item id="u0730"><ce:label>•</ce:label><ce:para id="p1315">Inhibition of bacterial protein synthesis by binding to subunits of bacterial ribosomes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0430"><ce:section-title id="st0415">Tetracyclines</ce:section-title><ce:para id="p1320"><ce:list id="ulist0235"><ce:list-item id="u0735"><ce:label>•</ce:label><ce:para id="p1325">Inhibition of protein synthesis by preventing transfer RNA binding to ribosomes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0435"><ce:section-title id="st0420">Beta-lactams</ce:section-title><ce:para id="p1330"><ce:list id="ulist0240"><ce:list-item id="u0740"><ce:label>•</ce:label><ce:para id="p1335">Inhibition of cell wall peptidoglycan synthesis by competitive inhibition of transpeptidases (‘penicillin-binding proteins’)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0440"><ce:section-title id="st0425">Cyclic lipopeptide (daptomycin)</ce:section-title><ce:para id="p1340"><ce:list id="ulist0245"><ce:list-item id="u0745"><ce:label>•</ce:label><ce:para id="p1345">Insertion of lipophilic tail into plasma membrane causing depolarisation and cell death</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0445"><ce:section-title id="st0430">Glycopeptides</ce:section-title><ce:para id="p1350"><ce:list id="ulist0250"><ce:list-item id="u0750"><ce:label>•</ce:label><ce:para id="p1355">Inhibition of cell wall peptidoglycan synthesis by forming complexes with D-alanine residues on peptidoglycan precursors</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0450"><ce:section-title id="st0435">Nitroimidazoles</ce:section-title><ce:para id="p1360"><ce:list id="ulist0255"><ce:list-item id="u0755"><ce:label>•</ce:label><ce:para id="p1365">The reduced form of the drug causes strand breaks in DNA</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0455"><ce:section-title id="st0440">Quinolones</ce:section-title><ce:para id="p1370"><ce:list id="ulist0260"><ce:list-item id="u0760"><ce:label>•</ce:label><ce:para id="p1375">Inhibition of DNA replication by binding to DNA topoisomerases (DNA gyrase and topoisomerase IV), preventing supercoiling and uncoiling of DNA</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0460"><ce:section-title id="st0445">Rifamycins</ce:section-title><ce:para id="p1380"><ce:list id="ulist0265"><ce:list-item id="u0765"><ce:label>•</ce:label><ce:para id="p1385">Inhibition of DNA synthesis by inhibiting DNA-dependent RNA polymerase</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0465"><ce:section-title id="st0450">Sulphonamides and trimethoprim</ce:section-title><ce:para id="p1390"><ce:list id="ulist0270"><ce:list-item id="u0770"><ce:label>•</ce:label><ce:para id="p1395">Inhibition of folate synthesis by dihydropteroate synthase (sulphonamides) and dihydrofolate reductase (trimethoprim) inhibition</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0160" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0285" role="short">Image 16</ce:alt-text></ce:inline-figure>6.16</ce:label><ce:alt-text id="atte0290" role="short">6.16</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Antimicrobial options for common infecting bacteria</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1400"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0295" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Organism</entry><entry align="left">Antimicrobial options<ce:cross-ref id="crf0595" refid="tn0085">*</ce:cross-ref></entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gram-positive organisms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:italic>Enterococcus faecalis</ce:italic></entry><entry align="left">Ampicillin, vancomycin/teicoplanin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Enterococcus faecium</ce:italic></entry><entry align="left">Vancomycin/teicoplanin, linezolid</entry></row><row rowsep="0"><entry align="left">Glycopeptide-resistant enterococci</entry><entry align="left">Linezolid, tigecycline, daptomycin</entry></row><row rowsep="0"><entry align="left">MRSA</entry><entry align="left">Clindamycin, vancomycin, rifampicin (never used as monotherapy), linezolid, daptomycin, tetracyclines, tigecycline, co-trimoxazole</entry></row><row rowsep="0"><entry align="left"><ce:italic>Staphylococcus aureus</ce:italic></entry><entry align="left">Flucloxacillin, clindamycin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Streptococcus pyogenes</ce:italic></entry><entry align="left">Penicillin, clindamycin, vancomycin</entry></row><row rowsep="1"><entry align="left"><ce:italic>Streptococcus pneumoniae</ce:italic></entry><entry align="left">Penicillin, cephalosporins, levofloxacin, vancomycin</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gram-negative organisms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:italic>Escherichia coli</ce:italic>, ‘coliforms’ (enteric Gram-negative bacilli)</entry><entry align="left">Amoxicillin, trimethoprim, cefuroxime, ciprofloxacin, co-amoxiclav</entry></row><row rowsep="0"><entry align="left"><ce:italic>Enterobacter</ce:italic> spp., <ce:italic>Citrobacter</ce:italic> spp.</entry><entry align="left">Ciprofloxacin, meropenem, ertapenem, aminoglycosides</entry></row><row rowsep="0"><entry align="left">ESBL-producing Enterobacteriaceae</entry><entry align="left">Ciprofloxacin, meropenem, ertapenem (if sensitive), temocillin, aminoglycosides</entry></row><row rowsep="0"><entry align="left">Carbapenemase-producing Enterobacteriaceae</entry><entry align="left">Ciprofloxacin, aminoglycosides, tigecycline, colistin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Haemophilus influenzae</ce:italic></entry><entry align="left">Amoxicillin, co-amoxiclav, macrolides, cefuroxime, cefotaxime, ciprofloxacin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Legionella pneumophila</ce:italic></entry><entry align="left">Azithromycin, levofloxacin, doxycycline</entry></row><row rowsep="0"><entry align="left"><ce:italic>Neisseria gonorrhoeae</ce:italic></entry><entry align="left">Ceftriaxone/cefixime, spectinomycin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Neisseria meningitidis</ce:italic></entry><entry align="left">Penicillin, cefotaxime/ceftriaxone, chloramphenicol</entry></row><row rowsep="0"><entry align="left"><ce:italic>Pseudomonas aeruginosa</ce:italic></entry><entry align="left">Ciprofloxacin, piperacillin–tazobactam, aztreonam, meropenem, aminoglycosides, ceftazidime/cefepime</entry></row><row rowsep="1"><entry align="left"><ce:italic>Salmonella typhi</ce:italic></entry><entry align="left">Ceftriaxone, azithromycin (uncomplicated typhoid), chloramphenicol (resistance common)</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Strict anaerobes</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:italic>Bacteroides</ce:italic> spp.</entry><entry align="left">Metronidazole, clindamycin, co-amoxiclav, piperacillin–tazobactam, meropenem</entry></row><row rowsep="0"><entry align="left"><ce:italic>Clostridium difficile</ce:italic></entry><entry align="left">Metronidazole, vancomycin (oral), fidaxomicin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Clostridium</ce:italic> spp.</entry><entry align="left">Penicillin, metronidazole, clindamycin</entry></row><row rowsep="1"><entry align="left"><ce:italic>Fusobacterium</ce:italic> spp.</entry><entry align="left">Penicillin, metronidazole, clindamycin</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other organisms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:italic>Chlamydia trachomatis</ce:italic></entry><entry align="left">Azithromycin, doxycycline</entry></row><row><entry align="left"><ce:italic>Treponema pallidum</ce:italic></entry><entry align="left">Penicillin, doxycycline</entry></row></tbody></tgroup><ce:table-footnote id="tn0085"><ce:label>*</ce:label><ce:note-para id="np0090">Antibiotic selection depends on multiple factors, including local susceptibility patterns, which vary enormously between geographical areas. There are many appropriate alternatives to those listed. (ESBL = extended-spectrum β-lactamase; MRSA = meticillin-resistant <ce:italic>Staphylococcus aureus</ce:italic>)</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0175" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0300" role="short">Image 17</ce:alt-text></ce:inline-figure>6.17</ce:label><ce:alt-text id="atte0305" role="short">6.17</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Duration of antimicrobial therapy for some common infections<ce:cross-ref id="crf0615" refid="tn0090">*</ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1455"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0310" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Infection</entry><entry align="left">Duration of therapy</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral infections</ce:bold></entry></row><row rowsep="1"><entry align="left">Herpes simplex encephalitis</entry><entry align="left">2–3 weeks</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial infections</ce:bold></entry></row><row rowsep="0"><entry align="left">Gonorrhoea</entry><entry align="left">Single dose</entry></row><row rowsep="0"><entry align="left">Infective endocarditis (streptococcal, native valve)</entry><entry align="left">4 weeks ± gentamicin for first 2 weeks</entry></row><row rowsep="0"><entry align="left">Infective endocarditis (prosthetic valve)</entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry align="left">Osteomyelitis</entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry align="left">Pneumonia (community-acquired, severe)</entry><entry align="left">7–10 days (no organism identified), 14–21 days (<ce:italic>Staph. aureus</ce:italic> or <ce:italic>Legionella</ce:italic> spp.)</entry></row><row rowsep="0"><entry align="left">Septic arthritis</entry><entry align="left">2–4 weeks</entry></row><row rowsep="0"><entry align="left">Urinary tract infection (male)</entry><entry align="left">2 weeks</entry></row><row rowsep="0"><entry align="left">Urinary tract infection, upper tract, uncomplicated (female)</entry><entry align="left">7 days</entry></row><row rowsep="1"><entry align="left">Urinary tract infection, lower (female)</entry><entry align="left">3 days</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Mycobacterial infections</ce:bold></entry></row><row rowsep="0"><entry align="left">Tuberculosis (meningeal)</entry><entry align="left">12 months</entry></row><row rowsep="1"><entry align="left">Tuberculosis (pulmonary)</entry><entry align="left">6 months</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fungal infections</ce:bold></entry></row><row rowsep="0"><entry align="left">Invasive pulmonary aspergillosis</entry><entry align="left">Until clinical/radiological resolution and reversal of predisposition</entry></row><row><entry align="left">Candidaemia (acute disseminated)</entry><entry align="left">2 weeks after last positive blood culture and resolution of signs and symptoms</entry></row></tbody></tgroup><ce:table-footnote id="tn0090"><ce:label>*</ce:label><ce:note-para id="np0095">All recommendations are indicative. Actual duration takes into account predisposing factors, specific organisms and antimicrobial susceptibility, adjuvant therapies, current guidelines and clinical response.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0185" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0315" role="short">Image 18</ce:alt-text></ce:inline-figure>6.18</ce:label><ce:alt-text id="atte0320" role="short">6.18</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Recommendations for antimicrobial prophylaxis in adults<ce:cross-ref id="crf0630" refid="tn0095">*</ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1480"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0325" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Infection risk</entry><entry align="left">Recommended antimicrobial</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial</ce:bold></entry></row><row rowsep="0"><entry align="left">Diphtheria (prevention of secondary cases)</entry><entry align="left">Erythromycin</entry></row><row rowsep="0"><entry align="left">Gas gangrene (after high amputation or major trauma)</entry><entry align="left">Penicillin or metronidazole</entry></row><row rowsep="0"><entry align="left">Lower gastrointestinal tract surgery</entry><entry align="left">Cefuroxime + metronidazole, gentamicin + metronidazole, or co-amoxiclav (single dose only)</entry></row><row rowsep="0"><entry align="left">Meningococcal disease (prevention of secondary cases)</entry><entry align="left">Rifampicin or ciprofloxacin</entry></row><row rowsep="0"><entry align="left">Rheumatic fever (prevention of recurrence)</entry><entry align="left">Phenoxymethylpenicillin or sulfadiazine</entry></row><row rowsep="0"><entry align="left">Tuberculosis (prevention of secondary cases)</entry><entry align="left">Isoniazid ± rifampicin</entry></row><row rowsep="1"><entry align="left">Whooping cough (prevention of secondary cases)</entry><entry align="left">Erythromycin</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral</ce:bold></entry></row><row rowsep="0"><entry align="left">HIV, occupational exposure (sharps injury)</entry><entry align="left">Combination tenofovir/emtricitabine and raltegravir. Modified if index case's virus known to be resistant</entry></row><row rowsep="1"><entry align="left">Influenza A (prevention of secondary cases in adults with chronic respiratory, cardiovascular or renal disease, immunosuppression or diabetes mellitus)</entry><entry align="left">Oseltamivir</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fungal</ce:bold></entry></row><row rowsep="0"><entry align="left">Aspergillosis (in high-risk haematology patients)</entry><entry align="left">Posaconazole (voriconazole or itraconazole alternatives if intolerant)</entry></row><row rowsep="1"><entry align="left"><ce:italic>Pneumocystis</ce:italic> pneumonia (prevention in HIV and other immunosuppressed states)</entry><entry align="left">Co-trimoxazole, pentamidine or dapsone</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoal</ce:bold></entry></row><row><entry align="left">Malaria (prevention of travel-associated disease)</entry><entry align="left">Specific antimalarials depend on travel itinerary (<ce:intra-ref id="ii0250" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2090">p. 278</ce:intra-ref>)</entry></row></tbody></tgroup><ce:table-footnote id="tn0095"><ce:label>*</ce:label><ce:note-para id="np0100">These are based on current UK practice. Recommendations may vary locally or nationally. Antimicrobial prophylaxis for infective endocarditis during dental procedures is not currently recommended in the UK.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0190" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000068/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0330" role="short">Image 19</ce:alt-text></ce:inline-figure>6.19</ce:label><ce:alt-text id="atte0335" role="short">6.19</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Antimicrobial agents in pregnancy<ce:cross-ref id="crf0645" refid="fn0015"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:footnote id="fn0015"><ce:label>1</ce:label><ce:note-para id="np0105">Data extracted from Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press; (<ce:inter-ref id="iw0025" xlink:href="http://medicinescomplete.com">medicinescomplete.com</ce:inter-ref>) [accessed on 16 March 2013].</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0510"><ce:section-title id="st0495">Contraindicated</ce:section-title><ce:para id="p1490"><ce:list id="ulist0280"><ce:list-item id="u0790"><ce:label>•</ce:label><ce:para id="p1495">Chloramphenicol: neonatal ‘grey baby’ syndrome – collapse, hypotension and cyanosis</ce:para></ce:list-item><ce:list-item id="u0795"><ce:label>•</ce:label><ce:para id="p1500">Fluconazole: teratogenic in high doses</ce:para></ce:list-item><ce:list-item id="u0800"><ce:label>•</ce:label><ce:para id="p1505">Quinolones: arthropathy in animal studies</ce:para></ce:list-item><ce:list-item id="u0805"><ce:label>•</ce:label><ce:para id="p1510">Sulphonamides: neonatal haemolysis and methaemoglobinaemia</ce:para></ce:list-item><ce:list-item id="u0810"><ce:label>•</ce:label><ce:para id="p1515">Tetracyclines, glycylcyclines: skeletal abnormalities in animals in first trimester; fetal dental discoloration and maternal hepatotoxicity with large parenteral doses in second or third trimesters</ce:para></ce:list-item><ce:list-item id="u0815"><ce:label>•</ce:label><ce:para id="p1520">Trimethoprim: teratogenic in first trimester</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0515"><ce:section-title id="st0500">Relatively contraindicated</ce:section-title><ce:para id="p1525"><ce:list id="ulist0285"><ce:list-item id="u0820"><ce:label>•</ce:label><ce:para id="p1530">Aminoglycosides: potential damage to fetal auditory and vestibular nerves in second and third trimesters</ce:para></ce:list-item><ce:list-item id="u0825"><ce:label>•</ce:label><ce:para id="p1535">Metronidazole: avoidance of high dosages is recommended<ce:cross-ref id="crf0650" refid="fn0020"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:footnote id="fn0020"><ce:label>2</ce:label><ce:note-para id="np0110">Theoretical risk of teratogenicity, not supported by available clinical evidence.</ce:note-para></ce:footnote></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0505">Not known to be harmful; use only when necessary</ce:section-title><ce:para id="p1540"><ce:list id="ulist0290"><ce:list-item id="u0830"><ce:label>•</ce:label><ce:para id="p1545">Aciclovir</ce:para></ce:list-item><ce:list-item id="u0835"><ce:label>•</ce:label><ce:para id="p1550">Cephalosporins</ce:para></ce:list-item><ce:list-item id="u0840"><ce:label>•</ce:label><ce:para id="p1555">Clarithromycin</ce:para></ce:list-item><ce:list-item id="u0845"><ce:label>•</ce:label><ce:para id="p1560">Clindamycin</ce:para></ce:list-item><ce:list-item id="u0850"><ce:label>•</ce:label><ce:para id="p1565">Erythromycin</ce:para></ce:list-item><ce:list-item id="u0855"><ce:label>•</ce:label><ce:para id="p1570">Glycopeptides</ce:para></ce:list-item><ce:list-item id="u0860"><ce:label>•</ce:label><ce:para id="p1575">Linezolid</ce:para></ce:list-item><ce:list-item id="u0865"><ce:label>•</ce:label><ce:para id="p1580">Meropenem</ce:para></ce:list-item><ce:list-item id="u0870"><ce:label>•</ce:label><ce:para id="p1585">Penicillins</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0195" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000068/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0340" role="short">Image 20</ce:alt-text></ce:inline-figure>6.20</ce:label><ce:alt-text id="atte0345" role="short">6.20</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Problems with antimicrobial therapy in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1590"><ce:list id="ulist0295"><ce:list-item id="u0875"><ce:label>•</ce:label><ce:para id="p1595"><ce:bold><ce:italic>Clostridium difficile</ce:italic> infection</ce:bold>: all antibiotics predispose to some extent, but second- and third-generation cephalosporins, co-amoxiclav and fluoroquinolones (e.g. ciprofloxacin) especially so.</ce:para></ce:list-item><ce:list-item id="u0880"><ce:label>•</ce:label><ce:para id="p1600"><ce:bold>Hypersensitivity reactions</ce:bold>: rise in incidence due to increased previous exposure.</ce:para></ce:list-item><ce:list-item id="u0885"><ce:label>•</ce:label><ce:para id="p1605"><ce:bold>Renal impairment</ce:bold>: may be significant in old age, despite ‘normal’ creatinine levels (<ce:intra-ref id="ii0255" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0045">p. 386</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u0890"><ce:label>•</ce:label><ce:para id="p1610"><ce:bold>Nephrotoxicity</ce:bold>: more likely, e.g. first-generation cephalosporins, aminoglycosides.</ce:para></ce:list-item><ce:list-item id="u0895"><ce:label>•</ce:label><ce:para id="p1615"><ce:bold>Accumulation of β-lactam antibiotics</ce:bold>: may result in myoclonus, seizures or coma.</ce:para></ce:list-item><ce:list-item id="u0900"><ce:label>•</ce:label><ce:para id="p1620"><ce:bold>Reduced gastric acid production</ce:bold>: gastric pH is higher, which causes increased penicillin absorption.</ce:para></ce:list-item><ce:list-item id="u0905"><ce:label>•</ce:label><ce:para id="p1625"><ce:bold>Reduced hepatic metabolism</ce:bold>: results in a higher risk of isoniazid-related hepatotoxicity.</ce:para></ce:list-item><ce:list-item id="u0910"><ce:label>•</ce:label><ce:para id="p1630"><ce:bold>Quinolones</ce:bold>: associated with delirium and may increase the risk of seizures.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0200" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0350" role="short">Image 21</ce:alt-text></ce:inline-figure>6.21</ce:label><ce:alt-text id="atte0355" role="short">6.21</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Beta-lactam antibiotics</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0530"><ce:section-title id="st0515">Penicillins</ce:section-title><ce:para id="p1640"><ce:list id="ulist0300"><ce:list-item id="u0915"><ce:label>•</ce:label><ce:para id="p1645">Natural penicillins: benzylpenicillin, phenoxymethylpenicillin</ce:para></ce:list-item><ce:list-item id="u0920"><ce:label>•</ce:label><ce:para id="p1650">Penicillinase-resistant penicillins: meticillin, flucloxacillin, nafcillin, oxacillin</ce:para></ce:list-item><ce:list-item id="u0925"><ce:label>•</ce:label><ce:para id="p1655">Aminopenicillins: ampicillin, amoxicillin</ce:para></ce:list-item><ce:list-item id="u0930"><ce:label>•</ce:label><ce:para id="p1660">Carboxy- and ureido-penicillins: ticarcillin, piperacillin, temocillin</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0535"><ce:section-title id="st0520">Cephalosporins</ce:section-title><ce:para id="p1665"><ce:list id="ulist0305"><ce:list-item id="u0935"><ce:label>•</ce:label><ce:para id="p1670">See <ce:cross-ref id="crf0665" refid="b0115">Box 6.22</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0540"><ce:section-title id="st0525">Monobactams</ce:section-title><ce:para id="p1675"><ce:list id="ulist0310"><ce:list-item id="u0940"><ce:label>•</ce:label><ce:para id="p1680">Aztreonam</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0545"><ce:section-title id="st0530">Carbapenems</ce:section-title><ce:para id="p1685"><ce:list id="ulist0315"><ce:list-item id="u0945"><ce:label>•</ce:label><ce:para id="p1690">Imipenem, meropenem, ertapenem, doripenem</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0205" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0360" role="short">Image 22</ce:alt-text></ce:inline-figure>6.22</ce:label><ce:alt-text id="atte0365" role="short">6.22</ce:alt-text><ce:textbox-head><ce:title id="tit0120">Cephalosporins</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1765"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0370" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>First generation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0325"><ce:list-item id="u0975"><ce:label>•</ce:label><ce:para id="p1770">Cefalexin, cefradine (oral)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0330"><ce:list-item id="u0980"><ce:label>•</ce:label><ce:para id="p1775">Cefazolin (IV)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Second generation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0335"><ce:list-item id="u0985"><ce:label>•</ce:label><ce:para id="p1780">Cefuroxime (oral/IV)</ce:para></ce:list-item><ce:list-item id="u0990"><ce:label>•</ce:label><ce:para id="p1785">Cefaclor (oral)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0340"><ce:list-item id="u0995"><ce:label>•</ce:label><ce:para id="p1790">Cefoxitin (IV)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Third generation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0345"><ce:list-item id="u1000"><ce:label>•</ce:label><ce:para id="p1795">Cefixime (oral)</ce:para></ce:list-item><ce:list-item id="u1005"><ce:label>•</ce:label><ce:para id="p1800">Cefotaxime (IV)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0350"><ce:list-item id="u1010"><ce:label>•</ce:label><ce:para id="p1805">Ceftriaxone (IV)</ce:para></ce:list-item><ce:list-item id="u1015"><ce:label>•</ce:label><ce:para id="p1810">Ceftazidime (IV)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fourth generation</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0355"><ce:list-item id="u1020"><ce:label>•</ce:label><ce:para id="p1815">Cefepime (IV)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fifth generation (also referred to as ‘next generation’)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0360"><ce:list-item id="u1025"><ce:label>•</ce:label><ce:para id="p1820">Ceftobiprole (IV)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0365"><ce:list-item id="u1030"><ce:label>•</ce:label><ce:para id="p1825">Ceftaroline (IV)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0215" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0375" role="short">Image 23</ce:alt-text></ce:inline-figure>6.23</ce:label><ce:alt-text id="atte0380" role="short">6.23</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Quinolones and fluoroquinolones</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2040"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte0385" role="short">Unlabelled table</ce:alt-text><tgroup cols="1"><colspec colname="col1" colnum="1"/><tbody><row><entry align="left"><ce:display><ce:figure id="f0105"><ce:alt-text id="atte0390" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0220" locator="b006-023-9780702070280" xlink:href="pii:B9780702070280000068/b006-023-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp9025">*‘Atypical’ pathogens include <ce:italic>Mycoplasma pneumoniae</ce:italic> and <ce:italic>Legionella</ce:italic> spp. Fluoroquinolones have variable activity against <ce:italic>M. tuberculosis and</ce:italic> other mycobacteria.</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0125" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0225" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0395" role="short">Image 24</ce:alt-text></ce:inline-figure>6.24</ce:label><ce:alt-text id="atte0400" role="short">6.24</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Antifungal agents</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2385"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0405" role="short">Unlabelled table</ce:alt-text><ce:link id="ln0230" locator="b006-024-9780702070280" xlink:href="pii:B9780702070280000068/b006-024-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0235" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000068/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0410" role="short">Image 25</ce:alt-text></ce:inline-figure>6.25</ce:label><ce:alt-text id="atte0415" role="short">6.25</ce:alt-text><ce:textbox-head><ce:title id="tit0135">Antiviral agents</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2450"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0420" role="short">Unlabelled table</ce:alt-text><tgroup cols="1"><colspec colname="col1" colnum="1"/><tbody><row><entry align="left"><ce:display><ce:figure id="f0110"><ce:alt-text id="atte0425" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0240" locator="b006-025-9780702070280" xlink:href="pii:B9780702070280000068/b006-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp9030">*Antiviral agents used in viral hepatitis are discussed on <ce:intra-ref id="ii0345" xlink:href="pii:B978-0-7020-7028-0.00022-6#p2860">pages 875</ce:intra-ref> and <ce:intra-ref id="ii9005" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0745">878</ce:intra-ref>. (AIDS = acquired immunodeficiency syndrome; CMV = cytomegalovirus; CNS = central nervous system; HIV = human immunodeficiency virus; HSV = herpes simplex virus; IM = intramuscular; IV = intravenous; RSV = respiratory syncytial virus; VZV = varicella zoster virus)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>6</ce:label><ce:title id="tit0010">Principles of infectious disease</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000068-f592ef8da2706697d106e543798cebb4" id="au0010"><ce:given-name>JAT</ce:given-name><ce:surname>Sandoe</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B9780702070280000068-f379761fbdbc82d17dd476f3e28b3c17" id="au0015"><ce:given-name>DH</ce:given-name><ce:surname>Dockrell</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Infectious agents</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>100</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Normal microbial flora</ce:bold> <ce:cross-ref id="crf0015" refid="s0095"><ce:bold>102</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0020"><ce:para id="p0020"><ce:bold>Host–pathogen interactions</ce:bold> <ce:cross-ref id="crf0020" refid="s0100"><ce:bold>104</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025"><ce:bold>Investigation of infection</ce:bold> <ce:cross-ref id="crf0025" refid="s0130"><ce:bold>105</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0030"><ce:para id="p0030">Direct detection of pathogens <ce:cross-ref id="crf0030" refid="s0190">105</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035">Culture <ce:cross-ref id="crf0035" refid="s0210">106</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0040"><ce:para id="p0040">Indirect detection of pathogens <ce:cross-ref id="crf0040" refid="s0220">106</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050">Antimicrobial susceptibility testing <ce:cross-ref id="crf0045" refid="s0265">109</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055"><ce:bold>Epidemiology of infection</ce:bold> <ce:cross-ref id="crf0050" refid="s0270"><ce:bold>110</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060"><ce:bold>Infection prevention and control</ce:bold> <ce:cross-ref id="crf0055" refid="s0325"><ce:bold>111</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0065"><ce:para id="p0065">Health care-associated infection <ce:cross-ref id="crf0060" refid="s0330">111</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">Outbreaks of infection <ce:cross-ref id="crf0065" refid="s0355">114</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Immunisation <ce:cross-ref id="crf0070" refid="s0360">114</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080"><ce:bold>Antimicrobial stewardship</ce:bold> <ce:cross-ref id="crf0075" refid="s0405"><ce:bold>115</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0085"><ce:para id="p0085"><ce:bold>Treatment of infectious diseases</ce:bold> <ce:cross-ref id="crf0080" refid="s0410"><ce:bold>116</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0090"><ce:para id="p0090">Principles of antimicrobial therapy <ce:cross-ref id="crf0085" refid="s0415">116</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Antibacterial agents <ce:cross-ref id="crf0090" refid="s0505">120</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100">Antimycobacterial agents <ce:cross-ref id="crf0095" refid="s0810">125</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Antifungal agents <ce:cross-ref id="crf0100" refid="s0855">125</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Antiviral agents <ce:cross-ref id="crf0105" refid="s0915">126</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115">Antiparasitic agents <ce:cross-ref id="crf0110" refid="s0975">128</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:para id="p0120">‘Infection’ in its strict sense describes the situation where microorganisms or other infectious agents become established in the host organism's cells or tissues, replicate, cause harm and induce a host response. If a microorganism survives and replicates on a mucosal surface without causing harm or illness, the host is said to be ‘colonised’ by that organism. If a microorganism survives and lies dormant after invading host cells or tissues, infection is said to be ‘latent’. When the infectious agent, or the host response to it, is sufficient to cause illness or harm, then the process is termed an ‘infectious disease’. Most pathogens (infectious agents that can cause disease) are microorganisms but some are multicellular organisms. The manifestations of disease may aid pathogen dissemination (e.g. diarrhoea).</ce:para><ce:para id="p0125">The term ‘infection’ is often used interchangeably with ‘infectious disease’ but not all infections are ‘infectious’, i.e. transmissible from person to person. Infectious diseases transmitted between hosts are called communicable diseases, whereas those caused by organisms that are already colonising the host are described as endogenous. The distinction is blurred in some situations, including health care-associated infections such as meticillin-resistant <ce:italic>Staphylococcus aureus</ce:italic> (MRSA) or <ce:italic>Clostridium difficile</ce:italic> infection (CDI), in which colonisation precedes infection but the colonising bacteria may have been recently transmitted between patients. The chain of infection (<ce:cross-ref id="crf0115" refid="f0010">Fig. 6.1</ce:cross-ref><ce:float-anchor refid="f0010"/>) describes six essential elements for communicable disease transmission.</ce:para><ce:para id="p0130">Despite dramatic advances in hygiene, immunisation and antimicrobial therapy, infectious agents still cause a massive burden of disease worldwide. Key challenges remain in tackling infection in resource-poor countries. Microorganisms are continually mutating and evolving; the emergence of new infectious agents and antimicrobial-resistant microorganisms is therefore inevitable. This chapter describes the biological and epidemiological principles of infectious diseases and the general approach to their prevention, diagnosis and treatment. Specific infectious diseases are described in <ce:intra-refs id="iis0010" xlink:type="extended"><ce:intra-refs-text xlink:label="intra-refs-start" xlink:type="resource">Chapters 11–13</ce:intra-refs-text><ce:intra-ref-end xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011" xlink:label="intra-ref-end" xlink:type="locator"><ce:intra-ref-title xlink:type="title">Chapter 11</ce:intra-ref-title></ce:intra-ref-end><ce:intra-ref-end xlink:href="pii:B978-0-7020-7028-0.00012-3#c00012" xlink:label="intra-ref-end" xlink:type="locator"><ce:intra-ref-title xlink:type="title">Chapter 12</ce:intra-ref-title></ce:intra-ref-end><ce:intra-ref-end xlink:href="pii:B978-0-7020-7028-0.00013-5#c00013" xlink:label="intra-ref-end" xlink:type="locator"><ce:intra-ref-title xlink:type="title">Chapter 13</ce:intra-ref-title></ce:intra-ref-end><ce:intra-refs-link xlink:from="intra-refs-start" xlink:to="intra-ref-end" xlink:type="arc"/></ce:intra-refs> and many of the organ-based chapters.</ce:para><ce:section id="s0010"><ce:section-title id="st0010">Infectious agents</ce:section-title><ce:para id="p0135">The concept of an infectious agent was established by Robert Koch in the 19th century (<ce:cross-ref id="crf0120" refid="b0010">Box 6.1</ce:cross-ref><ce:float-anchor refid="b0010"/>). Although fulfilment of ‘Koch's postulates’ became the standard for the definition of an infectious agent, they do not apply to uncultivable organisms (e.g. <ce:italic>Mycobacterium leprae</ce:italic>, <ce:italic>Tropheryma whipplei</ce:italic>) or members of the normal human flora (e.g. <ce:italic>Escherichia coli</ce:italic>, <ce:italic>Candida</ce:italic> spp.). The following groups of infectious agents are now recognised.</ce:para><ce:section id="s0015"><ce:section id="s0020"><ce:section-title id="st0015">Viruses</ce:section-title><ce:para id="p0165">Viruses are incapable of independent replication. Instead, they subvert host cellular processes to ensure synthesis of their nucleic acids and proteins. Viruses' genetic material (the genome) consists of single- or double-stranded DNA or RNA. Retroviruses transcribe their RNA into DNA in the host cell by reverse transcription. An antigenically unique protein coat (capsid) encloses the genome, and together these form the nucleocapsid. In many viruses, the nucleocapsid is packaged within a lipid envelope. Enveloped viruses are less able to survive in the environment and are spread by respiratory, sexual or blood-borne routes, including arthropod-based transmission. Non-enveloped viruses survive better in the environment and are predominantly transmitted by faecal–oral or, less often, respiratory routes. A generic virus life cycle is shown in <ce:cross-ref id="crf0125" refid="f0015">Figure 6.2</ce:cross-ref><ce:float-anchor refid="f0015"/>. A virus that infects a bacterium is a bacteriophage (phage).</ce:para></ce:section><ce:section id="s0025"><ce:section-title id="st0020">Prokaryotes: bacteria (including mycobacteria and actinomycetes)</ce:section-title><ce:para id="p0170">Prokaryotic cells are capable of synthesising their own proteins and nucleic acids, and are able to reproduce autonomously, although they lack a nucleus. The bacterial cell membrane is bounded by a peptidoglycan cell wall, which is thick (20–80 nm) in Gram-positive organisms and thin (5–10 nm) in Gram-negative ones. The Gram-negative cell wall is surrounded by an outer membrane containing lipopolysaccharide. Genetic information is contained within a chromosome but bacteria may also contain rings of extra-chromosomal DNA, known as plasmids, which can be transferred between organisms, without cells having to divide. Bacteria may be embedded in a polysaccharide capsule, and motile bacteria are equipped with flagella. Although many prokaryotes are capable of independent existence, some (e.g. <ce:italic>Chlamydia trachomatis</ce:italic>, <ce:italic>Coxiella burnetii</ce:italic>) are obligate intracellular organisms. Bacteria that can grow in artificial culture media are classified and identified using a range of characteristics (<ce:cross-ref id="crf0130" refid="b0015">Box 6.2</ce:cross-ref><ce:float-anchor refid="b0015"/>); examples are shown in <ce:cross-ref id="crf0145" refid="f0020">Figures 6.3</ce:cross-ref><ce:float-anchor refid="f0020"/> and <ce:cross-ref id="crf0150" refid="f0025">6.4</ce:cross-ref><ce:float-anchor refid="f0025"/>.</ce:para></ce:section><ce:section id="s0085"><ce:section-title id="st0080">Eukaryotes: fungi, protozoa and helminths</ce:section-title><ce:para id="p0300">Eukaryotic cells contain membrane-bound organelles, including nuclei, mitochondria and Golgi apparatus. Pathogenic eukaryotes are unicellular (e.g. fungi, protozoa) or complex multicellular organisms (e.g. nematodes, trematodes and cestodes, <ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2385">p. 288</ce:intra-ref>).</ce:para><ce:para id="p0305">Fungi exist as either moulds (filamentous fungi) or yeasts. Dimorphic fungi exist in either form, depending on environmental conditions (see <ce:intra-ref id="ii0020" xlink:href="pii:B978-0-7020-7028-0.00011-1#f0330">Fig. 11.59</ce:intra-ref>, <ce:intra-ref id="ii0025" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2830">p. 300</ce:intra-ref>). The fungal plasma membrane differs from the human cell membrane in that it contains the sterol, ergosterol. Fungi have a cell wall made up of polysaccharides, chitin and mannoproteins. In most fungi, the main structural component of the cell wall is β-1,3-D-glucan, a glucose polymer. These differences from mammalian cells are important because they offer useful therapeutic targets.</ce:para><ce:para id="p0310">Protozoa and helminths are often referred to as parasites. Many parasites have complex multi-stage life cycles, which involve animal and/or plant hosts in addition to humans.</ce:para></ce:section><ce:section id="s0090"><ce:section-title id="st0085">Prions</ce:section-title><ce:para id="p0315">Although prions are transmissible and have some of the characteristics of infectious agents, they are not microorganisms and are not diagnosed in microbiology laboratories. Prions are covered on <ce:intra-ref id="ii0030" xlink:href="pii:B978-0-7020-7028-0.00011-1#p4245">page 250</ce:intra-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0095"><ce:section-title id="st0090">Normal microbial flora</ce:section-title><ce:para id="p0320">The human body is colonised by large numbers of microorganisms (collectively termed the human microbiota). These colonising bacteria, also referred to as the ‘normal flora’, are able to survive and replicate on skin and mucosal surfaces. The gastrointestinal tract and the mouth are the two most heavily colonised sites in the body and their microbiota are distinct, in both composition and function. Knowledge of non-sterile body sites and their normal flora is required to inform microbiological sampling strategies and interpret culture results (<ce:cross-ref id="crf0155" refid="f0030">Fig. 6.5</ce:cross-ref><ce:float-anchor refid="f0030"/>).</ce:para><ce:para id="p0325">The microbiome is the total burden of microorganisms, their genes and their environmental interactions, and is now recognised to have a profound influence over human health and disease. Maintenance of the normal flora is beneficial to health. For example, lower gastrointestinal tract bacteria synthesise and excrete vitamins (e.g. vitamins K and B<ce:inf loc="post">12</ce:inf>); colonisation with normal flora confers ‘colonisation resistance’ to infection with pathogenic organisms by altering the local environment (e.g. lowering pH), producing antibacterial agents (e.g. bacteriocins (small antimicrobial peptides/proteins), fatty acids and metabolic waste products), and inducing host antibodies that cross-react with pathogenic organisms.</ce:para><ce:para id="p0330">Conversely, normally sterile body sites must be kept sterile. The mucociliary escalator transports environmental material deposited in the respiratory tract to the nasopharynx. The urethral sphincter prevents flow from the non-sterile urethra to the sterile bladder. Physical barriers, including the skin, lining of the gastrointestinal tract and other mucous membranes, maintain sterility of the submucosal tissues, blood stream and peritoneal and pleural cavities, for example.</ce:para><ce:para id="p0335">The normal flora contribute to endogenous disease mainly by translocation to a sterile site but excessive growth at the ‘normal’ site (overgrowth) can also cause disease. Overgrowth is exemplified by dental caries, vaginal thrush and ‘blind loop’ syndrome (<ce:intra-ref id="ii0035" xlink:href="pii:B978-0-7020-7028-0.00021-4#p3960">p. 808</ce:intra-ref>). Translocation results from spread along a surface or penetration though a colonised surface, e.g. urinary tract infection caused by perineal/enteric flora, and surgical site infections, particularly of prosthetic materials, caused by skin flora such as staphylococci. Normal flora also contribute to disease by cross-infection, in which organisms that are colonising one individual cause disease when transferred to another, more susceptible, individual.</ce:para><ce:para id="p0340">The importance of limiting perturbations of the microbiota by antimicrobial therapy is increasingly recognised. Probiotics are microbes or mixtures of microbes that are given to a patient to prevent or treat infection and are intended to restore a beneficial profile of microbiota. Although probiotics have been used in a number of settings, whether they have demonstrable clinical benefits remains a subject of debate.</ce:para></ce:section><ce:section id="s0100"><ce:section-title id="st0095">Host–pathogen interactions</ce:section-title><ce:para id="p0345">‘Pathogenicity’ is the capability of an organism to cause disease and ‘virulence’ is the extent to which a pathogen is able to cause disease. Pathogens produce proteins and other factors, termed virulence factors, which contribute to disease.<ce:list id="ulist0090"><ce:list-item id="u0210"><ce:label>•</ce:label><ce:para id="p0350"><ce:italic>Primary pathogens</ce:italic> cause disease in a proportion of individuals to whom they are exposed, regardless of the host's immunological status.</ce:para></ce:list-item><ce:list-item id="u0215"><ce:label>•</ce:label><ce:para id="p0355"><ce:italic>Opportunistic pathogens</ce:italic> cause disease only in individuals whose host defences are compromised, e.g. by an intravascular catheter, or when the immune system is compromised, by genetic susceptibility or immunosuppressive therapy.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0105"><ce:section id="s0110"><ce:section-title id="st0100">Characteristics of successful pathogens</ce:section-title><ce:para id="p0360">Successful pathogens have a number of attributes. They compete with host cells and colonising flora by various methods, including sequestration of nutrients and production of bacteriocins. Motility enables pathogens to reach their site of infection, often sterile sites that colonising bacteria do not reach, such as the distal airway. Many microorganisms, including viruses, use ‘adhesins’ to attach to host cells initially. Some pathogens can invade through tissues. Many bacterial and fungal infections form ‘biofilms’. After initial adhesion to a host surface, bacteria multiply in biofilms to form complex three-dimensional structures surrounded by a matrix of host and bacterial products that afford protection to the colony and limit the effectiveness of antimicrobials. Biofilms forming on man-made medical devices such as vascular catheters or grafts can be particularly difficult to treat.</ce:para><ce:para id="p0365">Pathogens may produce toxins, microbial molecules that cause adverse effects on host cells, either at the site of infection, or remotely following carriage through the blood stream. Endotoxin is the lipid component of Gram-negative bacterial outer membrane lipopolysaccharide. It is released when bacterial cells are damaged and has generalised inflammatory effects. Exotoxins are proteins released by living bacteria, which often have specific effects on target organs (<ce:cross-ref id="crf0160" refid="b0020">Box 6.3</ce:cross-ref><ce:float-anchor refid="b0020"/>).</ce:para><ce:para id="p0375">Intracellular pathogens, including viruses, bacteria (e.g. <ce:italic>Salmonella</ce:italic> spp., <ce:italic>Listeria monocytogenes</ce:italic> and <ce:italic>Mycobacterium tuberculosis</ce:italic>), parasites (e.g. <ce:italic>Leishmania</ce:italic> spp.) and fungi (e.g. <ce:italic>Histoplasma capsulatum</ce:italic>), are able to survive in intracellular environments, including after phagocytosis by macrophages. Pathogenic bacteria express different genes, depending on environmental stress (pH, iron starvation, O<ce:inf loc="post">2</ce:inf> starvation etc.) and anatomical location.</ce:para><ce:para id="p0380">Genetic diversity enhances the pathogenic capacity of bacteria. Some virulence factor genes are found on plasmids or in phages and are exchanged between different strains or species. The ability to acquire genes from the gene pool of all strains of the species (the ‘bacterial supragenome’) increases diversity and the potential for pathogenicity. Viruses exploit their rapid reproduction and potential to exchange nucleic acid with host cells to enhance diversity. Once a strain acquires a particularly effective combination of virulence genes, it may become an epidemic strain, accounting for a large subset of infections in a particular region. This phenomenon accounts for influenza pandemics (see <ce:cross-ref id="crf0165" refid="b0055">Box 6.10</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0115"><ce:section-title id="st0105">The host response</ce:section-title><ce:para id="p0385">Innate and adaptive immune and inflammatory responses, which humans use to control the normal flora and respond to pathogens, are reviewed in <ce:intra-ref id="ii0085" xlink:href="pii:B978-0-7020-7028-0.00004-4#c00004">Chapter 4</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0120"><ce:section-title id="st0110">Pathogenesis of infectious disease</ce:section-title><ce:para id="p0390">The harmful manifestations of infection are determined by a combination of the virulence of the organism and the host response to infection. Despite the obvious benefits of an intact host response, an excessive response is undesirable. Cytokines and antimicrobial factors contribute to tissue injury at the site of infection, and an excessive inflammatory response may lead to hypotension and organ dysfunction (<ce:intra-ref id="ii0090" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0475">p. 196</ce:intra-ref>). The contribution of the immune response to disease manifestations is exemplified by the immune reconstitution inflammatory syndrome (IRIS). This is seen, for example, in human immunodeficiency virus (HIV) infection, post-transplantation neutropenia or tuberculosis (which causes suppression of T-cell function): there is a paradoxical worsening of the clinical condition as the immune dysfunction is corrected, caused by an exuberant but dysregulated inflammatory response.</ce:para><ce:section id="s0125"><ce:section-title id="st0115">The febrile response</ce:section-title><ce:para id="p9065">Thermoregulation is altered in infectious disease, which may cause both hyperthermia (fever) and hypothermia. Fever is mediated mainly by ‘pyrogenic cytokines’ (e.g. interleukins IL-1 and IL-6, and tumour necrosis factor alpha (TNF-α)), which are released in response to various immunological stimuli including activation of pattern recognition receptors (PRRs) by microbial pyrogens (e.g. lipopolysaccharide) and factors released by injured cells. Their ultimate effect is to induce the synthesis of prostaglandin E<ce:inf loc="post">2</ce:inf>, which binds to specific receptors in the preoptic nucleus of the hypothalamus (thermoregulatory centre), causing the core temperature to rise.</ce:para><ce:para id="p9070">Rigors are a clinical symptom (or sign if they are witnessed) characterised by feeling very cold (‘chills’) and uncontrollable shivering, usually followed by fever and sweating. Rigors occur when the thermoregulatory centre attempts to correct a core temperature to a higher level by stimulating skeletal muscle activity and shaking.</ce:para><ce:para id="p9075">There are data to support the hypothesis that raised body temperature interferes with the replication and/or virulence of pathogens. The mechanisms and possible protective role of infection-driven hypothermia, however, are poorly understood, and require further study.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0130"><ce:section-title id="st0120">Investigation of infection</ce:section-title><ce:para id="p0410">The aims of investigating a patient with suspected infection are to confirm the presence of infection, identify the specific pathogen(s) and identify its susceptibility to specific antimicrobial agents in order to optimise therapy. The presence of infection may be suggested by identifying proteins that are produced in response to pathogens as part of the innate immune and acute phase responses (<ce:intra-ref id="ii0100" xlink:href="pii:B978-0-7020-7028-0.00004-4#p0470">p. 70</ce:intra-ref>). Pathogens may be detected directly (e.g. by culturing a normally sterile body site) or their presence may be inferred by identifying the host response to the organism, (‘indirect detection’, <ce:cross-ref id="crf0170" refid="b0025">Box 6.4</ce:cross-ref><ce:float-anchor refid="b0025"/>). Careful sampling increases the likelihood of diagnosis (<ce:cross-ref id="crf0175" refid="b0030">Box 6.5</ce:cross-ref><ce:float-anchor refid="b0030"/>). Culture results must be interpreted in the context of the normal flora at the sampled site (see <ce:cross-ref id="crf0180" refid="f0030">Fig. 6.5</ce:cross-ref>). The extent to which a microbiological test result supports or excludes a particular diagnosis depends on its statistical performance (e.g. sensitivity, specificity, positive and negative predictive value, <ce:intra-ref id="ii0105" xlink:href="pii:B978-0-7020-7028-0.00001-9#s0040">p. 4</ce:intra-ref>). Sensitivity and specificity vary according to the time between infection and testing, and positive and negative predictive values depend on the prevalence of the condition in the test population. The complexity of test interpretation is illustrated in <ce:cross-ref id="crf0185" refid="f0045">Figure 6.8</ce:cross-ref> below, which shows the ‘windows of opportunity’ afforded by various testing methods. Given this complexity, effective communication between the clinician and the microbiologist is vital to ensure accurate test interpretation.</ce:para><ce:section id="s0190"><ce:section-title id="st0180">Direct detection of pathogens</ce:section-title><ce:para id="p0570">Some direct detection methods provide rapid results and enable detection of organisms that cannot be grown easily on artificial culture media, such as <ce:italic>Chlamydia</ce:italic> spp.; they can also provide information on antimicrobial sensitivity, e.g. <ce:italic>Mycobacterium tuberculosis</ce:italic>.</ce:para><ce:section id="s0195"><ce:section-title id="st0185">Detection of whole organisms</ce:section-title><ce:para id="p0575">Whole organisms are detected by examination of biological fluids or tissue using a microscope.<ce:list id="ulist0150"><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0580"><ce:italic>Bright field microscopy</ce:italic> (in which the test sample is interposed between the light source and the objective lens) uses stains to enhance visual contrast between the organism and its background. Examples include Gram staining of bacteria and Ziehl–Neelsen or auramine staining of acid- and alcohol-fast bacilli (AAFB) in tuberculosis (the latter requires an ultraviolet light source). In histopathological examination of tissue samples, multiple stains are used to demonstrate not only the presence of microorganisms but also features of disease pathology.</ce:para></ce:list-item><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0585"><ce:italic>Dark field microscopy</ce:italic> (in which light is scattered to make organisms appear bright on a dark background) is used, for example, to examine genital chancre fluid in suspected syphilis.</ce:para></ce:list-item><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0590"><ce:italic>Electron microscopy</ce:italic> may be used to examine stool and vesicle fluid to detect enteric and herpesviruses, respectively, but its use has largely been supplanted by nucleic acid detection (see below).</ce:para></ce:list-item><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0595"><ce:italic>Flow cytometry</ce:italic> can be used to analyse liquid samples (e.g. urine) for the presence of particles based on properties such as size, impedance and light scatter. This technique can detect bacteria but may misidentify other particles as bacteria too.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0200"><ce:section-title id="st0190">Detection of components of organisms</ce:section-title><ce:para id="p0600">Components of microorganisms detected for diagnostic purposes include nucleic acids, cell wall molecules, toxins and other antigens. Commonly used examples include <ce:italic>Legionella pneumophila</ce:italic> serogroup 1 antigen in urine and cryptococcal polysaccharide antigen in cerebrospinal fluid (CSF). Most antigen detection methods are based on in vitro binding of specific antigen/antibody and are described below. Other methods may be used, such as tissue culture cytotoxicity assay for <ce:italic>C. difficile</ce:italic> toxin. In toxin-mediated disease, detection of toxin may be of greater relevance than identification of the organism itself (e.g. stool <ce:italic>C. difficile</ce:italic> toxin).</ce:para><ce:section id="s0205"><ce:section-title id="st0195">Nucleic acid amplification tests</ce:section-title><ce:para id="p0605">In a nucleic acid amplification test (NAAT), specific sequences of microbial DNA and RNA are identified using a nucleic acid primer that is amplified exponentially by enzymes to generate multiple copies of a target nucleotide sequence. The most commonly used amplification method is the polymerase chain reaction (PCR; see <ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00003-2#f0065">Fig. 3.11</ce:intra-ref>, <ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0250">p. 53</ce:intra-ref>). Reverse transcription (RT) PCR is used to detect RNA from RNA viruses (e.g. hepatitis C virus and HIV-1). The use of fluorescent labels in the reaction enables ‘real-time’ detection of amplified DNA; quantification is based on the principle that the time taken to reach the detection threshold is proportional to the initial number of copies of the target nucleic acid sequence. In multiplex PCR, multiple primer pairs are used to enable detection of several different organisms at once.</ce:para><ce:para id="p0610">Determination of nucleotide sequences in a target gene(s) can be used to assign microorganisms to specific strains, which may be relevant to treatment and/or prognosis (e.g. in hepatitis C infection, <ce:intra-ref id="ii0125" xlink:href="pii:B978-0-7020-7028-0.00022-6#p2995">p. 877</ce:intra-ref>). Genes that are relevant to pathogenicity (such as toxin genes) or antimicrobial resistance can also be detected; for example, the <ce:italic>mecA</ce:italic> gene is used to screen for MRSA.</ce:para><ce:para id="p0615">NAATs are the most sensitive direct detection methods and are also relatively rapid. They are used widely in virology, where the possibility of false-positive results from colonising or contaminating organisms is remote, and are applied to blood, respiratory samples, stool and urine. In bacteriology, PCR is used to examine CSF, blood, tissue and genital samples, and multiplex PCR is being developed for use in faeces. PCR is particularly helpful for microorganisms that cannot be readily cultured, e.g. <ce:italic>Tropheryma whipplei</ce:italic>, and is being used increasingly in mycology and parasitology.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0210"><ce:section-title id="st0200">Culture</ce:section-title><ce:para id="p0620">Microorganisms may be both detected and further characterised by culture from clinical samples (e.g. tissue, swabs and body fluids).<ce:list id="ulist0155"><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0625"><ce:italic>Ex vivo culture</ce:italic> (tissue or cell culture) was widely used in the isolation of viruses but has been largely supplanted by NAAT.</ce:para></ce:list-item><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0630"><ce:italic>In vitro culture</ce:italic> (in artificial culture media) of bacteria and fungi is used to confirm the presence of pathogens, allow identification, test antimicrobial susceptibility and subtype the organism for epidemiological purposes.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0635">Culture has its limitations: results are not immediate, even for organisms that are easy to grow, and negative cultures rarely exclude infection. Organisms such as <ce:italic>Mycobacterium tuberculosis</ce:italic> are slow-growing, typically taking at least 2 weeks, even in rapid-culture systems. Certain organisms, such as <ce:italic>Mycobacterium leprae</ce:italic> and <ce:italic>Tropheryma whipplei</ce:italic>, cannot be cultivated on artificial media, and others (e.g. <ce:italic>Chlamydia</ce:italic> spp. and viruses) grow only in culture systems, which are slow and labour-intensive.</ce:para><ce:section id="s0215"><ce:section-title id="st0205">Blood culture</ce:section-title><ce:para id="p0640">The terms ‘bacteraemia’ and ‘fungaemia’ describe the presence of bacteria and fungi in the blood. ‘Blood-stream infection’ (<ce:intra-ref id="ii0130" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0355">p. 225</ce:intra-ref>) is the association of bacteraemia/fungaemia with clinical evidence of infection. The presence of bacteraemia/fungaemia can be determined by inoculating a liquid culture medium with freshly drawn blood, which is then incubated in a system that monitors it constantly for growth of microorganisms (e.g. by detecting products of microbial respiration using fluorescence; <ce:cross-ref id="crf0190" refid="f0035">Fig. 6.6</ce:cross-ref><ce:float-anchor refid="f0035"/>). If growth is detected, organisms are identified and sensitivity testing is performed. Traditionally, identification has been achieved by Gram stain appearance and biochemical reactions. However, matrix-assisted laser desorption/ionisation time-of-flight mass spectroscopy (MALDI-TOF-MS; see <ce:cross-ref id="crf0195" refid="b0015">Box 6.2</ce:cross-ref>) is being used increasingly to identify organisms. MALDI-TOF-MS produces a profile of proteins of different sizes from the target microorganism and uses databases of such profiles to identify the organism (<ce:cross-ref id="crf0200" refid="f0040">Fig. 6.7</ce:cross-ref><ce:float-anchor refid="f0040"/>). It is rapid and accurate. Taking multiple blood samples for culture at different times allows differentiation of transient (one or two positive samples) and persistent (majority are positive) bacteraemia. This can be clinically important in the identification of the source of infection (<ce:intra-ref id="ii0140" xlink:href="pii:B978-0-7020-7028-0.00016-0#p6795">p. 530</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0220"><ce:section-title id="st0210">Indirect detection of pathogens</ce:section-title><ce:para id="p0645">Tests may be used to detect the host's immune (antibody) response to a specific microorganism, and can enable the diagnosis of infection with organisms that are difficult to detect by other methods or are no longer present in the host. The term ‘serology’ describes tests carried out on serum and includes both antigen (direct) and antibody (indirect) detection.</ce:para><ce:section id="s0225"><ce:section-title id="st0215">Antibody detection</ce:section-title><ce:para id="p0650">Organism-specific antibody detection is applied mainly to blood (<ce:cross-ref id="crf0205" refid="f0045">Fig. 6.8</ce:cross-ref><ce:float-anchor refid="f0045"/>). Results are typically expressed as titres: that is, the reciprocal of the highest dilution of the serum at which antibody is detectable (for example, detection at serum dilution of 1 : 64 gives a titre of 64). ‘Seroconversion’ is defined as either a change from negative to positive detection or a fourfold rise in titre between acute and convalescent serum samples. An acute sample is usually taken during the first week of disease and the convalescent sample 2–4 weeks later. Earlier diagnosis can be achieved by detection of immunoglobulin M (IgM) antibodies, which are produced early in infection (<ce:intra-ref id="ii0145" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0125">p. 68</ce:intra-ref>). A limitation of these tests is that antibody production requires a fully functional host immune system, so there may be false-negative results in immunocompromised patients. Also, other than in chronic infections and with IgM detection, antibody tests usually provide a retrospective diagnosis.</ce:para><ce:para id="p0655">Antibody detection methods are described below (antigen detection methods are also described here as they share similar methodology).</ce:para><ce:section id="s0230"><ce:section-title id="st0220">Enzyme-linked immunosorbent assay</ce:section-title><ce:para id="p0660">The principles of the enzyme-linked immunosorbent assay (ELISA, EIA) are illustrated in <ce:cross-ref id="crf0210" refid="f0050">Figure 6.9</ce:cross-ref><ce:float-anchor refid="f0050"/>. These assays rely on linking an antibody with an enzyme that generates a colour change on exposure to a chromogenic substrate. Various configurations allow detection of antigens or specific subclasses of immunoglobulin (e.g. IgG, IgM, IgA). ELISA may also be adapted to detect PCR products, using immobilised oligonucleotide hybridisation probes and various detection systems.</ce:para></ce:section><ce:section id="s0235"><ce:section-title id="st0225">Immunoblot (Western blot)</ce:section-title><ce:para id="p0665">Microbial proteins are separated according to molecular weight by polyacrylamide gel electrophoresis (PAGE) and transferred (blotted) on to a nitrocellulose membrane, which is incubated with patient serum. Binding of specific antibody is detected with an enzyme–anti-immunoglobulin conjugate similar to that used in ELISA, and specificity is confirmed by its location on the membrane. Immunoblotting is a highly specific test, which may be used to confirm the results of less specific tests such as ELISA (e.g. in Lyme disease, <ce:intra-ref id="ii0150" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">p. 255</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0240"><ce:section-title id="st0230">Immunofluorescence assays</ce:section-title><ce:para id="p0670">Indirect immunofluorescence assays (IFAs) detect antibodies by incubating a serum sample with immobilised antigen (e.g. cells known to be infected with virus on a glass slide); any virus-specific antibody present in the serum binds to antigen and is then detected using a fluorescent-labelled anti-human immunoglobulin (‘secondary’ antibody). Fluorescence is visualised using a microscope. This method can also detect organisms in clinical samples (usually tissue or centrifuged cells) using a specific antibody in place of immobilised antigen to achieve capture.</ce:para></ce:section><ce:section id="s0245"><ce:section-title id="st0235">Complement fixation test</ce:section-title><ce:para id="p0675">In a complement fixation test (CFT), patient serum is heat-treated to inactivate complement and mixed with the test antigen. Any specific antibody in the serum will complex with the antigen. Complement is then added to the reaction. If antigen–antibody complexes are present, the complement will be ‘fixed’ (consumed). Sheep erythrocytes, coated with an anti-erythrocyte antibody, are added. The degree of erythrocyte lysis reflects the remaining complement and is inversely proportional to the quantity of the specific antigen–antibody complex present.</ce:para></ce:section><ce:section id="s0250"><ce:section-title id="st0240">Agglutination tests</ce:section-title><ce:para id="p0680">When antigens are present on the surface of particles (e.g. cells, latex particles or microorganisms) and cross-linked with antibodies, visible clumping (or ‘agglutination’) occurs.<ce:list id="ulist0160"><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0685">In <ce:italic>direct agglutination</ce:italic>, patient serum is added to a suspension of organisms that express the test antigen. For example, in the Weil–Felix test, if a patient's serum contains antibodies to rickettsial species they cause agglutination when <ce:italic>Proteus</ce:italic> spp. surface (O) antigens are added because the antibodies cross-react with the <ce:italic>Proteus</ce:italic> antigens. The test lacks sensitivity and specificity but is still used to diagnose rickettsial infection in resource-limited settings. The Widal test reaction uses a suspension of <ce:italic>Salmonella typhi</ce:italic> and <ce:italic>S. paratyphi</ce:italic> ‘A’ and ‘B’, treated to retain only ‘O’ and ‘H’ antigens. These antigens are kept to detect corresponding antibodies in serum from a patient suspected of having typhoid fever. The test is not specific but is still used in some parts of the world.</ce:para></ce:list-item><ce:list-item id="u0355"><ce:label>•</ce:label><ce:para id="p0690">In <ce:italic>indirect (passive) agglutination</ce:italic>, specific antigen is attached to the surface of carrier particles, which agglutinate when incubated with patient samples that contain specific antibodies.</ce:para></ce:list-item><ce:list-item id="u0360"><ce:label>•</ce:label><ce:para id="p0695">In <ce:italic>reverse passive agglutination</ce:italic> (an antigen detection test), the carrier particle is coated with antibody rather than antigen.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0255"><ce:section-title id="st0245">Other tests</ce:section-title><ce:para id="p0700">Immunodiffusion involves antibodies and antigen migrating through gels, with or without the assistance of electrophoresis, and forming insoluble complexes where they meet. The complexes are seen on staining as ‘precipitin bands’. Immunodiffusion is used in the diagnosis of dimorphic fungi (<ce:intra-ref id="ii0155" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2830">p. 300</ce:intra-ref>) and some forms of aspergillosis (<ce:intra-ref id="ii0160" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1195">p. 596</ce:intra-ref>).</ce:para><ce:para id="p0705">Immunochromatography is used to detect antigen. The system consists of a porous test strip (e.g. a nitrocellulose membrane), at one end of which there is target-specific antibody, complexed with coloured microparticles. Further specific antibody is immobilised in a transverse narrow line some distance along the strip. Test material (e.g. blood or urine) is added to the antibody–particle complexes, which then migrate along the strip by capillary action. If these are complexed with antigen, they will be immobilised by the specific antibody and visualised as a transverse line across the strip. If the test is negative, the antibody–particle complexes will bind to a line of immobilised anti-immunoglobulin antibody placed further along the strip, which acts as a negative control. Immunochromatographic tests are rapid and relatively cheap to perform, and are appropriate for point-of-care testing, e.g. in HIV 1 and malaria (<ce:intra-ref id="ii0165" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1990">p. 276</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0260"><ce:section-title id="st0250">Antibody-independent specific immunological tests</ce:section-title><ce:para id="p0710">The interferon-gamma release assay (IGRA) is being used increasingly to diagnose latent tuberculosis infection (LTBI). The principle behind IGRA is discussed on <ce:intra-ref id="ii0170" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1155">page 594</ce:intra-ref>. IGRA cannot distinguish between latent and active tuberculosis infection and is therefore appropriate for use only in countries where the background incidence of tuberculosis is low.</ce:para></ce:section></ce:section><ce:section id="s0265"><ce:section-title id="st0255">Antimicrobial susceptibility testing</ce:section-title><ce:para id="p0715">If growth of microorganisms in culture is inhibited by the addition of an antimicrobial agent, the organism is considered to be susceptible to that antimicrobial. Bacteriostatic agents cause reversible inhibition of growth and bactericidal agents cause cell death; the terms fungistatic/fungicidal are equivalent for antifungal agents, and virustatic/virucidal for antiviral agents. The lowest concentration of antimicrobial agent at which growth is inhibited is the minimum inhibitory concentration (MIC), and the lowest concentration that causes cell death is the minimum bactericidal concentration (MBC). If the MIC is less than or equal to a predetermined breakpoint threshold, the organism is considered susceptible, and if the MIC is greater than the breakpoint, it is resistant.</ce:para><ce:para id="p0720">Breakpoints are determined for each antimicrobial agent from a combination of pharmacokinetic (<ce:intra-ref id="ii0175" xlink:href="pii:B978-0-7020-7028-0.00002-0#s0040">p. 17</ce:intra-ref>) and clinical data. The relationship between in vitro antimicrobial susceptibility and clinical response is complex, as response also depends on immune status, pharmacokinetic variability (<ce:intra-ref id="ii0180" xlink:href="pii:B978-0-7020-7028-0.00002-0#s0040">p. 17</ce:intra-ref>), comorbidities that may influence pharmacokinetics or pharmacodynamics, and antibiotic dosing, as well as MIC/MBC. Thus, although treating a patient according to the results of susceptibility testing increases the likelihood of recovery, it does not guarantee therapeutic success.</ce:para><ce:para id="p0725">Susceptibility testing is often carried out by disc diffusion (<ce:cross-ref id="crf0215" refid="f0055">Fig. 6.10</ce:cross-ref><ce:float-anchor refid="f0055"/>). Antibiotic-impregnated filter paper discs are placed on agar plates containing bacteria; antibiotic diffuses into the agar, resulting in a concentration gradient centred on the disc. Bacteria are unable to grow where the antibiotic concentration exceeds the MIC, which may therefore be inferred from the size of the zone of inhibition. The MIC is commonly measured in diagnostic laboratories using ‘diffusion strips’.</ce:para></ce:section></ce:section><ce:section id="s0270"><ce:section-title id="st0260">Epidemiology of infection</ce:section-title><ce:para id="p0730">The communicability of infectious disease means that, once a clinician has diagnosed an infectious disease, potential exposure of other patients must also be considered. The patient may require separation from other patients (‘isolation’), or an outbreak of disease may need to be investigated in the community (<ce:intra-ref id="ii0185" xlink:href="pii:B978-0-7020-7028-0.00005-6#c00005">Ch. 5</ce:intra-ref>). The approach will be specific to the microorganism involved (<ce:intra-refs id="iis0015" xlink:type="extended"><ce:intra-refs-text xlink:label="intra-refs-start" xlink:type="resource">Chs 11–13</ce:intra-refs-text><ce:intra-ref-end xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011" xlink:label="intra-ref-end" xlink:type="locator"><ce:intra-ref-title xlink:type="title">Ch 11</ce:intra-ref-title></ce:intra-ref-end><ce:intra-ref-end xlink:href="pii:B978-0-7020-7028-0.00012-3#c00012" xlink:label="intra-ref-end" xlink:type="locator"><ce:intra-ref-title xlink:type="title">Ch 12</ce:intra-ref-title></ce:intra-ref-end><ce:intra-ref-end xlink:href="pii:B978-0-7020-7028-0.00013-5#c00013" xlink:label="intra-ref-end" xlink:type="locator"><ce:intra-ref-title xlink:type="title">Ch 13</ce:intra-ref-title></ce:intra-ref-end><ce:intra-refs-link xlink:from="intra-refs-start" xlink:to="intra-ref-end" xlink:type="arc"/></ce:intra-refs>) but the principles are outlined below.</ce:para><ce:section id="s0275"><ce:section id="s0280"><ce:section-title id="st0265">Geographical and temporal patterns of infection</ce:section-title><ce:section id="s0285"><ce:section-title id="st0270">Endemic disease</ce:section-title><ce:para id="p0735">Endemic disease has a constant presence within a given geographical area or population. The infectious agent may have a reservoir, vector or intermediate host that is geographically restricted, or may itself have restrictive environmental requirements (e.g. temperature range, humidity). The population affected may be geographically isolated or the disease may be limited to unvaccinated populations. Factors that alter geographical restriction include:<ce:list id="ulist0165"><ce:list-item id="u0365"><ce:label>•</ce:label><ce:para id="p0740">expansion of an animal reservoir (e.g. Lyme disease from reforestation)</ce:para></ce:list-item><ce:list-item id="u0370"><ce:label>•</ce:label><ce:para id="p0745">vector escape (e.g. airport malaria)</ce:para></ce:list-item><ce:list-item id="u0375"><ce:label>•</ce:label><ce:para id="p0750">extension of host range (e.g. schistosomiasis from dam construction)</ce:para></ce:list-item><ce:list-item id="u0380"><ce:label>•</ce:label><ce:para id="p0755">human migration (e.g. carbapenemase-producing <ce:italic>Klebsiella pneumoniae</ce:italic>)</ce:para></ce:list-item><ce:list-item id="u0385"><ce:label>•</ce:label><ce:para id="p0760">public health service breakdown (e.g. diphtheria in unvaccinated areas)</ce:para></ce:list-item><ce:list-item id="u0390"><ce:label>•</ce:label><ce:para id="p0765">climate change (e.g. dengue virus and Rift Valley fever).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0275">Emerging and re-emerging disease</ce:section-title><ce:para id="p0770">An emerging infectious disease is one that has newly appeared in a population, or has been known for some time but is increasing in incidence or geographical range. If the disease was previously known and thought to have been controlled or eradicated, it is considered to be re-emerging. Many emerging diseases are caused by organisms that infect animals and have undergone adaptations that enable them to infect humans. This is exemplified by HIV-1, which is believed to have originated in higher primates in Africa. The geographical pattern of some recent emerging and re-emerging infections is shown in <ce:cross-ref id="crf0220" refid="f0060">Figure 6.11</ce:cross-ref><ce:float-anchor refid="f0060"/>.</ce:para></ce:section></ce:section><ce:section id="s0295"><ce:section-title id="st0280">Reservoirs of infection</ce:section-title><ce:para id="p0775">The US Centers for Disease Control (CDC) define a reservoir of infection as any person, other living organism, environment or combination of these in which the infectious agent lives and replicates and on which the infectious agent is dependent for its survival. The infectious agent is transmitted from this reservoir to a susceptible host.</ce:para><ce:section id="s0300"><ce:section-title id="st0285">Human reservoirs</ce:section-title><ce:para id="p0780">Both colonised individuals and those with infection can act as reservoirs, e.g. with <ce:italic>Staph. aureus</ce:italic> (including MRSA), <ce:italic>Strep. pyogenes</ce:italic> and <ce:italic>C. difficile.</ce:italic> For infected humans to act as reservoirs, the infections caused must be long-lasting in at least a proportion of those affected, to enable onward transmission (e.g. tuberculosis, sexually transmitted infections). Humans are the only reservoir for some infections (e.g. measles).</ce:para></ce:section><ce:section id="s0305"><ce:section-title id="st0290">Animal reservoirs</ce:section-title><ce:para id="p0785">The World Health Organization (WHO) defines a zoonosis as ‘a disease or infection that is naturally transmissible from vertebrate animals to humans’. Infected animals may be asymptomatic. Zoonotic agents may be transmitted via any of the routes described below. Primary infection with zoonoses may be transmitted onward between humans, causing secondary disease (e.g. Q fever, brucellosis, Ebola).</ce:para></ce:section><ce:section id="s0310"><ce:section-title id="st0295">Environmental reservoirs</ce:section-title><ce:para id="p0790">Many infective pathogens are acquired from an environmental source. However, some of these are maintained in human or animal reservoirs, with the environment acting only as a conduit for infection.</ce:para></ce:section></ce:section><ce:section id="s0315"><ce:section-title id="st0300">Transmission of infection</ce:section-title><ce:para id="p0795">Communicable diseases may be transmitted by one or more of the following routes:<ce:list id="ulist0170"><ce:list-item id="u0395"><ce:label>•</ce:label><ce:para id="p0800"><ce:italic>Respiratory route</ce:italic>: inhalation.</ce:para></ce:list-item><ce:list-item id="u0400"><ce:label>•</ce:label><ce:para id="p0805"><ce:italic>Faecal–oral route</ce:italic>: ingestion of material originating from faeces.</ce:para></ce:list-item><ce:list-item id="u0405"><ce:label>•</ce:label><ce:para id="p0810"><ce:italic>Sexually transmitted infections</ce:italic>: direct contact between mucous membranes.</ce:para></ce:list-item><ce:list-item id="u0410"><ce:label>•</ce:label><ce:para id="p0815"><ce:italic>Blood-borne infections</ce:italic>: direct inoculation of blood or body fluids.</ce:para></ce:list-item><ce:list-item id="u0415"><ce:label>•</ce:label><ce:para id="p0820"><ce:italic>Direct contact</ce:italic>: very few organisms are capable of causing infection by direct contact with intact skin. Most infection by this route requires contact with damaged skin (e.g. surgical wound).</ce:para></ce:list-item><ce:list-item id="u0420"><ce:label>•</ce:label><ce:para id="p0825"><ce:italic>Via a vector or fomite</ce:italic>: the vector/fomite bridges the gap between the infected host or reservoir and the uninfected host. Vectors are animate, and include mosquitoes in malaria, dengue and Zika virus infection, fleas in plague and humans in MRSA. Fomites are inanimate objects such as door handles, water taps and ultrasound probes, which are particularly associated with health care-associated infection (HCAI).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0830">The likelihood of infection following transmission of a pathogen depends on organism factors (virulence, <ce:cross-ref id="crf9010" refid="s0100">p. 104</ce:cross-ref>) and host susceptibility. The incubation period is the time between exposure and development of symptoms, and the period of infectivity is the period after exposure during which the patient is infectious to others. Knowledge of incubation periods and of periods of infectivity is important in controlling the spread of disease, although for many diseases these estimates are imprecise (<ce:cross-ref id="crf0225" refid="b0040">Boxes 6.6</ce:cross-ref><ce:float-anchor refid="b0040"/> and <ce:cross-ref id="crf0290" refid="b0035">6.7</ce:cross-ref><ce:float-anchor refid="b0035"/>).</ce:para></ce:section><ce:section id="s0320"><ce:section-title id="st0305">Deliberate release</ce:section-title><ce:para id="p0845">Deliberate release of pathogens with the intention of causing disease is known as biological warfare or bioterrorism, depending on the scale and context. Deliberate release incidents have included a 750-person outbreak of <ce:italic>Salmonella typhimurium</ce:italic> caused by contamination of salads in 1984 (Oregon, USA) and 22 cases of anthrax (five fatal) from the mailing of finely powdered (weaponised) anthrax spores in 2001 (New Jersey, USA). Diseases with high potential for deliberate release include anthrax, plague, tularaemia, smallpox and botulism (through toxin release).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0325"><ce:section-title id="st0310">Infection prevention and control</ce:section-title><ce:para id="p0850">Infection prevention and control (IPC) describes the measures applied to populations with the aim of breaking the chain of infection (see <ce:cross-ref id="crf0475" refid="f0010">Fig. 6.1</ce:cross-ref>, <ce:cross-ref id="crf9015" refid="p0120">p. 100</ce:cross-ref>).</ce:para><ce:section id="s0330"><ce:section-title id="st0315">Health care-associated infection</ce:section-title><ce:para id="p0855">The risk of developing infection following admission to a health-care facility (health care-associated infection, HCAI) in the developed world is about 10%. Many nosocomial bacterial infections are caused by organisms that are resistant to numerous antibiotics (multi-resistant bacteria), including MRSA, extended-spectrum β-lactamases (ESBLs) and carbapenemase-producing Enterobacteriaceae (CPE), and glycopeptide-resistant enterococci (GRE). Other infections of particular concern in hospitals include <ce:italic>C. difficile</ce:italic> (<ce:intra-ref id="ii0200" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1565">p. 264</ce:intra-ref>) and norovirus (<ce:intra-ref id="ii0205" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0985">p. 249</ce:intra-ref>). Some examples are shown in <ce:cross-ref id="crf0480" refid="f0065">Figure 6.12</ce:cross-ref><ce:float-anchor refid="f0065"/>.</ce:para><ce:para id="p0860">IPC measures are described in <ce:cross-ref id="crf0485" refid="b0045">Box 6.8</ce:cross-ref><ce:float-anchor refid="b0045"/>. The most important is maintenance of good hand hygiene (<ce:cross-ref id="crf0505" refid="f0070">Fig. 6.13</ce:cross-ref><ce:float-anchor refid="f0070"/>). Hand decontamination (e.g. using alcohol gel or washing) is mandatory before and after every patient contact. Decontamination with alcohol gel is usually adequate but hand-washing (with hot water, liquid soap and complete drying) is required after any procedure that involves more than casual physical contact, or if hands are visibly soiled. In situations where the prevalence of<ce:italic>C. difficile</ce:italic> is high (e.g. a local outbreak), alcohol gel decontamination between patient contacts is inadequate as it does not kill<ce:italic>C. difficile</ce:italic> spores, and hands must be washed.</ce:para><ce:para id="p1000">Some infections necessitate additional measures to prevent cross-infection (<ce:cross-ref id="crf0510" refid="b0050">Box 6.9</ce:cross-ref><ce:float-anchor refid="b0050"/>). To minimise risk of infection, invasive procedures must be performed using strict aseptic technique.</ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0340">Outbreaks of infection</ce:section-title><ce:para id="p1010">Descriptive terms are defined in <ce:cross-ref id="crf0535" refid="b0055">Box 6.10</ce:cross-ref><ce:float-anchor refid="b0055"/>. Confirmation of an infectious disease outbreak usually requires evidence from ‘typing’ that the causal organisms have identical phenotypic and/or genotypic characteristics. If this is found not to be the case, the term pseudo-outbreak is used. When an outbreak of infection is suspected, a case definition is agreed. The number of cases that meet the case definition is then assessed by case-finding, using methods ranging from administration of questionnaires to national reporting systems. Case-finding usually includes microbiological testing, at least in the early stages of an outbreak. Temporal changes in cases are noted in order to plot an outbreak curve, and demographic details are collected to identify possible sources of infection. A case–control study, in which recent activities (potential exposures) of affected ‘cases’ are compared to those of unaffected ‘controls’, may be undertaken to establish the outbreak source, and measures are taken to manage the outbreak and control its spread. Good communication between relevant personnel during and after the outbreak is important to inform practice in future outbreaks.</ce:para><ce:para id="p1020">Surveillance ensures that disease outbreaks are either prevented or identified early. In hospitals, staff are made aware of the isolation of alert organisms, which have the propensity to cause outbreaks, and alert conditions, which are likely to be caused by such organisms. Analogous systems are used nationally; many countries publish lists of organisms and diseases, which, if detected (or suspected), must be reported to public health authorities (reportable or notifiable diseases). Reasons for a disease to be classified as reportable are shown in <ce:cross-ref id="crf0545" refid="b0060">Box 6.11</ce:cross-ref><ce:float-anchor refid="b0060"/>.</ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0345">Immunisation</ce:section-title><ce:para id="p1030">Immunisation may be passive or active. Passive immunisation is achieved by administering antibodies targeting a specific pathogen. Antibodies are obtained from blood, so confer some of the risks associated with blood products (<ce:intra-ref id="ii0210" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0470">p. 933</ce:intra-ref>). The protection afforded by passive immunisation is immediate but of short duration (a few weeks or months); it is used to prevent or attenuate infection before or after exposure (<ce:cross-ref id="crf0555" refid="b0065">Box 6.12</ce:cross-ref><ce:float-anchor refid="b0065"/>).</ce:para><ce:section id="s0375"><ce:section-title id="st0360">Vaccination</ce:section-title><ce:para id="p1075">Active immunisation is achieved by vaccination with whole organisms or organism components (<ce:cross-ref id="crf0565" refid="b0070">Box 6.13</ce:cross-ref><ce:float-anchor refid="b0070"/>).</ce:para><ce:section id="s0395"><ce:section-title id="st0380">Types of vaccine</ce:section-title><ce:para id="p1210">Whole-cell vaccines consist of live or inactivated (killed) microorganisms. Component vaccines contain only extracted or synthesised components of microorganisms (e.g. polysaccharides or proteins). Live vaccines contain organisms with attenuated (reduced) virulence, which cause only mild symptoms but induce T-lymphocyte and humoral responses (<ce:intra-ref id="ii0215" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0125">p. 68</ce:intra-ref>) and are therefore more immunogenic than inactivated whole-cell vaccines. The use of live vaccines in immunocompromised individuals is not generally recommended, but they may be used by specialists following a risk/benefit assessment.</ce:para><ce:para id="p1215">Component vaccines consisting only of polysaccharides, such as the pneumococcal polysaccharide vaccine (PPV), are poor activators of T lymphocytes and produce a short-lived antibody response without long-lasting memory. Conjugation of polysaccharide to a protein, as in the <ce:italic>Haemophilus influenzae</ce:italic> type B (Hib) vaccine and the protein conjugate pneumococcal vaccine (PCV), activates T lymphocytes, which results in a sustained response and immunological memory. Toxoids are bacterial toxins that have been modified to reduce toxicity but maintain antigenicity. Vaccine response can be improved by co-administration with mildly pro-inflammatory adjuvants, such as aluminium hydroxide.</ce:para></ce:section><ce:section id="s0400"><ce:section-title id="st0385">Use of vaccines</ce:section-title><ce:para id="p1220">Vaccination may be applied to entire populations or to subpopulations at specific risk through travel, occupation or other activities. In ring vaccination, the population immediately surrounding a case or outbreak of infectious disease is vaccinated to curtail further spread. Vaccination is aimed mainly at preventing infectious disease. However, vaccination against human papillomavirus (HPV) was introduced to prevent cervical and other cancers that complicate HPV infection. Vaccination guidelines for individuals are shown in <ce:cross-ref id="crf0570" refid="b0075">Box 6.14</ce:cross-ref><ce:float-anchor refid="b0075"/>.</ce:para><ce:para id="p1260">Vaccination becomes successful once the number of susceptible hosts in a population falls below the level required to sustain continued transmission of the target organism (herd immunity). Naturally acquired smallpox was declared to have been eradicated worldwide in 1980 through mass vaccination. In 1988, the WHO resolved to eradicate poliomyelitis by vaccination; the number of cases worldwide has since fallen from approximately 350 000 per annum to 74 in 2015. Recommended vaccination schedules vary between countries. In addition to standard vaccination schedules, catch-up schedules are specified for individuals who join vaccination programmes later than the recommended age.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0405"><ce:section-title id="st0390">Antimicrobial stewardship</ce:section-title><ce:para id="p1265">Antimicrobial stewardship (AMS) refers to the systems and processes applied to a population to optimise the use of antimicrobial agents. The populations referred to here may be a nation, region, hospital, or a unit within a health-care organisation (e.g. ward or clinic). AMS aims to improve patient outcomes and reduce antimicrobial resistance (AMR). IPC and AMS complement each other (<ce:cross-ref id="crf0575" refid="f0080">Fig. 6.14</ce:cross-ref><ce:float-anchor refid="f0080"/>). Elements of AMS include treatment guidelines, antimicrobial formularies and ward rounds by infection specialists.</ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0395">Treatment of infectious diseases</ce:section-title><ce:para id="p1270">Key components of treating infection are:<ce:list id="ulist0225"><ce:list-item id="u0710"><ce:label>•</ce:label><ce:para id="p1275">optimising antimicrobial therapy while minimising selection for antimicrobial resistance and the impact on commensal flora</ce:para></ce:list-item><ce:list-item id="u0715"><ce:label>•</ce:label><ce:para id="p1280">addressing predisposing factors, e.g. glycaemic control in diabetes mellitus; viral load control in HIV-1-associated opportunistic infection</ce:para></ce:list-item><ce:list-item id="u0720"><ce:label>•</ce:label><ce:para id="p1285">considering source control, e.g. removal of an infected medical device or necrotic tissue</ce:para></ce:list-item><ce:list-item id="u0725"><ce:label>•</ce:label><ce:para id="p1290">managing complications, e.g. severe sepsis (systemic inflammatory response syndrome, or SIRS, <ce:intra-ref id="ii0220" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0475">p. 196</ce:intra-ref>) and acute kidney injury (<ce:intra-ref id="ii0225" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0660">p. 411</ce:intra-ref>).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1295">For communicable disease, treatment must also take into account contacts of the infected patient, and may include IPC interventions such as isolation, antimicrobial prophylaxis, vaccination and contact tracing.</ce:para><ce:section id="s0415"><ce:section-title id="st0400">Principles of antimicrobial therapy</ce:section-title><ce:para id="p1300">In some situations (e.g. pneumonia) it is important to start appropriate antimicrobial therapy promptly, whereas in others prior confirmation of the diagnosis and pathogen is preferred. The principles underlying the choice of antimicrobial agent(s) are discussed below. The WHO ‘World Antibiotic Awareness Week’ campaign is a yearly event aimed at highlighting the importance of prudent antimicrobial prescribing (see ‘<ce:cross-ref id="crf0580" refid="st1065">Further information</ce:cross-ref>’).</ce:para><ce:section id="s0420"><ce:section-title id="st0405">Antimicrobial action and spectrum</ce:section-title><ce:para id="p1305">Antimicrobial agents may kill or inhibit microorganisms by targeting essential and non-essential cellular processes, respectively. The range, or spectrum, of microorganisms that is killed or inhibited by a particular antimicrobial agent needs consideration when selecting therapy. Mechanisms of action of the major classes of antibacterial agent are listed in <ce:cross-ref id="crf0585" refid="b0080">Box 6.15</ce:cross-ref><ce:float-anchor refid="b0080"/> and appropriate agents for some common infecting organisms are shown in <ce:cross-ref id="crf0590" refid="b0085">Box 6.16</ce:cross-ref><ce:float-anchor refid="b0085"/>. In severe infections and/or immunocompromised patients, it is customary to use bactericidal agents in preference to bacteriostatic agents.</ce:para><ce:section id="s0470"><ce:section-title id="st0455">Empiric versus targeted therapy</ce:section-title><ce:para id="p1405">Empiric antimicrobial therapy is selected to treat a suspected infection (e.g. meningitis) before the microbiological cause is known. Targeted or ‘directed’ therapy can be prescribed when the pathogen(s) is known. Empirical antimicrobial regimens need to have activity against the range of pathogens that could be causing the infection in question; because broad-spectrum agents affect many more bacteria than needed, they select for antimicrobial resistance. ‘Start Smart – Then Focus’ (<ce:cross-ref id="crf0600" refid="f0085">Fig. 6.15</ce:cross-ref><ce:float-anchor refid="f0085"/>) describes the principle of converting from empiric therapy to narrow-spectrum targeted therapy. Optimum empiric therapy depends on the site of infection, patient characteristics and local antimicrobial resistance patterns. National or local guidelines are often used to inform antimicrobial prescribing decisions.</ce:para></ce:section><ce:section id="s0475"><ce:section-title id="st0460">Combination therapy</ce:section-title><ce:para id="p1410">It is sometimes appropriate to combine antimicrobial agents:<ce:list id="ulist0275"><ce:list-item id="u0775"><ce:label>•</ce:label><ce:para id="p1415">when there is a need to increase clinical effectiveness (e.g. biofilm infections)</ce:para></ce:list-item><ce:list-item id="u0780"><ce:label>•</ce:label><ce:para id="p1420">when no single agent's spectrum covers all potential pathogens (e.g. polymicrobial infection)</ce:para></ce:list-item><ce:list-item id="u0785"><ce:label>•</ce:label><ce:para id="p1425">when there is a need to reduce development of antimicrobial resistance in the target pathogen, as the organism would need to develop resistance to multiple agents simultaneously (e.g. antituberculous chemotherapy, <ce:intra-ref id="ii0230" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1140">p. 592</ce:intra-ref>; antiretroviral therapy (ART), <ce:intra-ref id="ii0235" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0435">p. 324</ce:intra-ref>).</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0480"><ce:section-title id="st0465">Antimicrobial resistance</ce:section-title><ce:para id="p1430">Microorganisms have evolved in the presence of naturally occurring antibiotics and have therefore developed resistance mechanisms (categorised in <ce:cross-ref id="crf0605" refid="f0090">Fig. 6.16</ce:cross-ref><ce:float-anchor refid="f0090"/>) to all classes of antimicrobial agent (antibiotics and their derivatives). Intrinsic resistance is an innate property of a microorganism, whereas acquired resistance arises by spontaneous mutation or horizontal transfer of genetic material from another organism (e.g. via a plasmid, <ce:cross-ref id="crf9020" refid="p0120">p. 100</ce:cross-ref>). Plasmids often encode resistance to multiple antibiotics.</ce:para><ce:para id="p1435">The <ce:italic>mecA</ce:italic> gene encodes a penicillin-binding protein, which has a low affinity for penicillins and therefore confers resistance to β-lactam antibiotics in staphylococci. Extended-spectrum β-lactamases (ESBLs) are frequently encoded on plasmids, which are transferred relatively easily between bacteria, including Enterobacteriaceae. Plasmid-encoded carbapenemases have been detected in strains of <ce:italic>Klebsiella pneumoniae</ce:italic> (e.g. New Delhi metallo-β-lactamase 1, NDM-1)<ce:italic>.</ce:italic> Strains of MRSA have been described that also have reduced susceptibility to glycopeptides through the development of a relatively impermeable cell wall.</ce:para><ce:para id="p1440">Factors promoting antimicrobial resistance include the inappropriate use of antibiotics (e.g. to treat viral infections), inadequate dosage or unnecessarily prolonged treatment, and use of antimicrobials as growth promoters in agriculture. However, <ce:italic>any</ce:italic> antimicrobial use exerts a selection pressure that favours the development of resistance. Combination antimicrobial therapy may reduce the emergence of resistance in the target pathogen but not in the normal flora that it also affects. Despite use of combination therapy for <ce:italic>M. tuberculosis</ce:italic>, multidrug-resistant tuberculosis (MDR-TB, resistant to isoniazid and rifampicin) and extremely drug-resistant tuberculosis (XDR-TB, resistant to isoniazid and rifampicin, any fluoroquinolone and at least one injectable antimicrobial antituberculous agent) have been reported worldwide and are increasing in incidence.</ce:para><ce:para id="p1445">The term ‘post-antibiotic era’ has been coined to describe a future in which the acquisition of resistance by bacteria will have been so extensive that antibiotic therapy is rendered useless. A more realistic scenario, which is currently being experienced, is a gradual but inexorable progression of resistance, necessitating the use of ever more toxic and expensive antimicrobials.</ce:para></ce:section><ce:section id="s0485"><ce:section-title id="st0470">Duration of therapy</ce:section-title><ce:para id="p1450">Treatment duration reflects the severity of infection and accessibility of the infected site to antimicrobial agents. For most infections, there is limited evidence available to support a specific duration of treatment (<ce:cross-ref id="crf0610" refid="b0090">Box 6.17</ce:cross-ref><ce:float-anchor refid="b0090"/>). Depending on the indication, initial intravenous therapy can often be switched to oral as soon as the patient is apyrexial and improving. In the absence of specific guidance, antimicrobial therapy should be stopped when there is no longer any clinical evidence of infection.</ce:para></ce:section><ce:section id="s0490"><ce:section-title id="st0475">Pharmacokinetics and pharmacodynamics</ce:section-title><ce:para id="p1460">Pharmacokinetics of antimicrobial agents determine whether adequate concentrations are obtained at the sites of infection. Septic patients often have poor gastrointestinal absorption, so the preferred initial route of therapy is intravenous. Knowledge of anticipated antimicrobial drug concentrations at sites of infection is critical. For example, achieving a ‘therapeutic’ blood level of gentamicin is of little practical use in treating meningitis, as CSF penetration of the drug is poor. Knowledge of routes of antimicrobial elimination is also critical; for instance, urinary tract infection is ideally treated with a drug that is excreted unchanged in the urine.</ce:para><ce:para id="p1465">Pharmacodynamics describes the relationship between antimicrobial concentration and microbial killing. For many agents, antimicrobial effect can be categorised as ‘concentration-dependent’ or ‘time-dependent’. The concentration of antimicrobial achieved after a single dose is illustrated in <ce:cross-ref id="crf0620" refid="f0095">Figure 6.17</ce:cross-ref><ce:float-anchor refid="f0095"/>. The maximum concentration achieved is C<ce:inf loc="post">max</ce:inf> and the measure of overall exposure is the area under the curve (AUC). The efficacy of antimicrobial agents whose killing is concentration-dependent (e.g. aminoglycosides) increases with the amount by which C<ce:inf loc="post">max</ce:inf> exceeds the minimum inhibitory concentration (C<ce:inf loc="post">max</ce:inf> : MIC ratio). For this reason, it has become customary to administer aminoglycosides (e.g. gentamicin) infrequently at high doses (e.g. 7 mg/kg) rather than frequently at low doses. This has the added advantage of minimising toxicity by reducing the likelihood of drug accumulation. Conversely, the β-lactam antibiotics and vancomycin exhibit time-dependent killing, and their efficacy depends on C<ce:inf loc="post">max</ce:inf> exceeding the MIC for a certain time (which is different for each class of agent). This is reflected in the dosing interval of benzylpenicillin, which is usually given every 4 hours in severe infection (e.g. meningococcal meningitis), and may be administered by continuous infusion. For other antimicrobial agents, the pharmacodynamic relationships are more complex and often less well understood. With some agents, bacterial inhibition persists after antimicrobial exposure (post-antibiotic and post-antibiotic sub-MIC effects).</ce:para><ce:section id="s0495"><ce:section-title id="st0480">Therapeutic drug monitoring</ce:section-title><ce:para id="p1470">Therapeutic drug monitoring is used to confirm that levels of antimicrobial agents with a low therapeutic index (e.g. aminoglycosides) are not excessive, and that levels of agents with marked pharmacokinetic variability (e.g. vancomycin) are adequate. Specific recommendations for monitoring depend on individual clinical circumstances; for instance, different pre- and post-dose levels of gentamicin are recommended, depending on whether it is being used in traditional divided doses, once daily or for synergy in endocarditis (<ce:intra-ref id="ii0245" xlink:href="pii:B978-0-7020-7028-0.00016-0#p6795">p. 530</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0500"><ce:section-title id="st0485">Antimicrobial prophylaxis</ce:section-title><ce:para id="p1475">Antimicrobial prophylaxis is the use of antimicrobial agents to prevent infection. Primary prophylaxis is used to reduce the risk of infection following certain medical procedures (e.g. colonic resection or prosthetic hip insertion), following exposure to a specific pathogen (e.g. <ce:italic>Bordetella pertussis</ce:italic>) or in specific situations such as post-splenectomy (<ce:cross-ref id="crf0625" refid="b0095">Box 6.18</ce:cross-ref><ce:float-anchor refid="b0095"/>). It should be associated with minimal adverse effects. In the case of exposure, it may be combined with passive immunisation (see <ce:cross-ref id="crf0635" refid="b0065">Box 6.12</ce:cross-ref>). Secondary prophylaxis is used in patients who have been treated successfully for an infection but remain predisposed to it. It is used in haemato-oncology patients in the context of fungal infection and in HIV-positive individuals with an opportunistic infection until a defined level of immune reconstitution is achieved.</ce:para></ce:section></ce:section><ce:section id="s0505"><ce:section-title id="st0490">Antibacterial agents</ce:section-title><ce:para id="p1485">For details of antibacterial usage in pregnancy and old age, see <ce:cross-ref id="crf0640" refid="b0100">Boxes 6.19</ce:cross-ref><ce:float-anchor refid="b0100"/> and <ce:cross-ref id="crf0655" refid="b0105">6.20</ce:cross-ref><ce:float-anchor refid="b0105"/>.</ce:para><ce:section id="s0525"><ce:section-title id="st0510">Beta-lactam antibiotics</ce:section-title><ce:para id="p1635">These antibiotics have a β-lactam ring structure and exert a bactericidal action by inhibiting enzymes involved in cell wall synthesis (penicillin-binding proteins, PBPs). They are classified in <ce:cross-ref id="crf0660" refid="b0110">Box 6.21</ce:cross-ref><ce:float-anchor refid="b0110"/>.</ce:para><ce:section id="s0550"><ce:section id="s0555"><ce:section-title id="st0535">Pharmacokinetics</ce:section-title><ce:para id="p1695"><ce:list id="ulist0320"><ce:list-item id="u0950"><ce:label>•</ce:label><ce:para id="p1700">Good drug levels are achieved in lung, kidney, bone, muscle and liver, and in pleural, synovial, pericardial and peritoneal fluids.</ce:para></ce:list-item><ce:list-item id="u0955"><ce:label>•</ce:label><ce:para id="p1705">CSF levels are low, except when meninges are inflamed.</ce:para></ce:list-item><ce:list-item id="u0960"><ce:label>•</ce:label><ce:para id="p1710">Activity is not inhibited in abscess (e.g. by low pH and <ce:italic>P</ce:italic>O<ce:inf loc="post">2</ce:inf>, high protein or neutrophils).</ce:para></ce:list-item><ce:list-item id="u0965"><ce:label>•</ce:label><ce:para id="p1715">Beta-lactams are subject to an ‘inoculum effect’ – activity is reduced in the presence of a high organism burden (PBP expression is down-regulated by high organism density).</ce:para></ce:list-item><ce:list-item id="u0970"><ce:label>•</ce:label><ce:para id="p1720">Generally safe in pregnancy (except imipenem/cilastatin).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0560"><ce:section-title id="st0540">Adverse effects</ce:section-title><ce:para id="p1725">Immediate (IgE-mediated) allergic reactions are rare but life-threatening. Approximately 90% of patients who report a penicillin allergy do not have a true IgE-mediated allergy. Other reactions, such as rashes, fever and haematological effects (e.g. low white cell count), usually follow more prolonged therapy (more than 2 weeks). A large proportion of patients with infectious mononucleosis develop a rash if given aminopenicillins; this does not imply lasting allergy. The relationship between allergy to penicillin and allergy to cephalosporins depends on the specific cephalosporin used; there is significant cross-reactivity with first-generation cephalosporins but cross-reactivity to second-/third-generation cephalosporins is less common. Avoidance of cephalosporins, however, is recommended in patients who have IgE-mediated penicillin allergy (<ce:intra-ref id="ii9010" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0565">p. 84</ce:intra-ref>). Cross-reactivity between penicillin and carbapenems is rare (approximately 1% by skin testing) and carbapenems may be administered if there are no suitable alternatives and appropriate resuscitation facilities are available. The monobactam aztreonam (<ce:cross-ref id="crf9025" refid="s0565">p. 121</ce:cross-ref>) is the β-lactam least likely to cross-react in patients with penicillin allergy.</ce:para><ce:para id="p1730">Gastrointestinal upset and diarrhoea are common, and a mild reversible hepatitis is recognised with many β-lactams. More severe forms of hepatitis can be observed with flucloxacillin and co-amoxiclav. Leucopenia, thrombocytopenia, coagulation deficiencies, interstitial nephritis and potentiation of aminoglycoside-mediated kidney damage are also recognised (<ce:cross-ref id="crf9030" refid="s0610">p. 122</ce:cross-ref>). Seizures and encephalopathy have been reported, particularly with high doses in the presence of renal insufficiency. Thrombophlebitis occurs in up to 5% of patients receiving parenteral β-lactams.</ce:para></ce:section><ce:section id="s0565"><ce:section-title id="st0545">Drug interactions</ce:section-title><ce:para id="p1735">Synergism occurs in combination with aminoglycosides in vitro. Ampicillin decreases the biological effect of oral contraceptives and the whole class is significantly affected by concurrent administration of probenecid, producing a 2–4-fold increase in the peak serum concentration.</ce:para></ce:section></ce:section><ce:section id="s0570"><ce:section-title id="st0550">Penicillins</ce:section-title><ce:para id="p1740">Natural penicillins are primarily effective against Gram-positive organisms (except staphylococci, most of which produce a penicillinase) and anaerobic organisms. <ce:italic>Strep. pyogenes</ce:italic> has remained sensitive to natural penicillins worldwide. According to the European Antimicrobial Resistance Surveillance Network (EARS-Net), the prevalence of non-susceptibility to penicillin in <ce:italic>Strep. pneumoniae</ce:italic> in Europe in 2014 varied widely from 0% (Cyprus) to 46.7% (Romania).</ce:para><ce:para id="p1745">Penicillinase-resistant penicillins are the mainstay of treatment for infections with <ce:italic>Staph. aureus</ce:italic>, other than MRSA. However, EARS-Net data from 2014 indicate that MRSA rates in Europe vary widely from 0.9% (Netherlands) to 56% (Romania).</ce:para><ce:para id="p1750">Aminopenicillins have the same spectrum of activity as the natural penicillins, with additional Gram-negative cover against Enterobacteriaceae. Amoxicillin has better oral absorption than ampicillin. Unfortunately, resistance to these agents is widespread (57.1% of <ce:italic>E. coli</ce:italic> Europe-wide in 2014, range 34.7–73%), so they are no longer appropriate for empirical use in Gram-negative infections. In many organisms, resistance is due to β-lactamase production, which can be overcome by the addition of β-lactamase inhibitors (clavulanic acid or sulbactam).</ce:para><ce:para id="p1755">Carboxypenicillins (e.g. ticarcillin) and ureidopenicillins (e.g. piperacillin) are particularly active against Gram-negative organisms, especially <ce:italic>Pseudomonas</ce:italic> spp., which are resistant to the aminopenicillins. Beta-lactamase inhibitors may be added to extend their spectrum of activity (e.g. piperacillin–tazobactam). Temocillin is derived from ticarcillin; it has good activity against Enterobacteriaceae, including those that produce ESBL enzymes, but poor activity against <ce:italic>Pseudomonas aeruginosa</ce:italic> and Gram-positive bacteria.</ce:para></ce:section><ce:section id="s0575"><ce:section-title id="st0555">Cephalosporins and cephamycins</ce:section-title><ce:para id="p1760">Cephalosporins are broad-spectrum agents. Unfortunately, their use is associated with CDI (<ce:intra-ref id="ii0270" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1565">p. 264</ce:intra-ref>). With the exception of ceftobiprole, the group has no activity against enterococci. Only the cephamycins have anti-anaerobic activity. All cephalosporins are inactivated by ESBL. Cephalosporins are arranged in ‘generations’ (<ce:cross-ref id="crf0670" refid="b0115">Box 6.22</ce:cross-ref><ce:float-anchor refid="b0115"/>).<ce:list id="ulist0370"><ce:list-item id="u1035"><ce:label>•</ce:label><ce:para id="p1830"><ce:italic>First-generation compounds</ce:italic> have excellent activity against Gram-positive organisms and some activity against Gram-negatives.</ce:para></ce:list-item><ce:list-item id="u1040"><ce:label>•</ce:label><ce:para id="p1835"><ce:italic>Second-generation drugs</ce:italic> retain Gram-positive activity but have extended Gram-negative activity. Cephamycins (e.g. cefoxitin), included in this group, are active against anaerobic Gram-negative bacilli.</ce:para></ce:list-item><ce:list-item id="u1045"><ce:label>•</ce:label><ce:para id="p1840"><ce:italic>Third-generation agents</ce:italic> further improve anti-Gram-negative cover. For some (e.g. ceftazidime), this is extended to include <ce:italic>Pseudomonas</ce:italic> spp. Cefotaxime and ceftriaxone have excellent Gram-negative activity and retain good activity against <ce:italic>Strep. pneumoniae</ce:italic> and β-haemolytic streptococci. Ceftriaxone is administered once daily and is therefore a suitable agent for outpatient intravenous (parenteral) antimicrobial therapy (OPAT).</ce:para></ce:list-item><ce:list-item id="u1050"><ce:label>•</ce:label><ce:para id="p1845"><ce:italic>Fourth-generation agents</ce:italic>, e.g. cefipime, have a broad spectrum of activity, including streptococci and some Gram-negatives, including <ce:italic>P. aeruginosa.</ce:italic></ce:para></ce:list-item><ce:list-item id="u1055"><ce:label>•</ce:label><ce:para id="p1850"><ce:italic>Fifth-generation agents</ce:italic>, such as ceftobiprole and ceftaroline, have an enhanced spectrum of Gram-positive activity that includes MRSA, and also have activity against Gram-negative bacteria; some, such as ceftobiprole, are active against <ce:italic>P. aeruginosa</ce:italic>.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1855">The spectrum of cephalosporins has also been enhanced by adding β-lactamase inhibitors.</ce:para></ce:section><ce:section id="s0580"><ce:section-title id="st0560">Monobactams</ce:section-title><ce:para id="p1860">Aztreonam is the only available monobactam. It is active against Gram-negative bacteria, except ESBL-producing organisms, but inactive against Gram-positive organisms or anaerobes. It is a parenteral-only agent and may be used safely in most penicillin-allergic patients other than those with an allergy to ceftazidime, which shares a common side chain with aztreonam.</ce:para></ce:section><ce:section id="s0585"><ce:section-title id="st0565">Carbapenems</ce:section-title><ce:para id="p1865">These intravenous agents have the broadest antibiotic activity of the β-lactam antibiotics, covering most clinically significant bacteria, including anaerobes (e.g. imipenem, meropenem, ertapenem).</ce:para></ce:section></ce:section><ce:section id="s0590"><ce:section-title id="st0570">Macrolide and lincosamide antibiotics</ce:section-title><ce:para id="p1870">Macrolides (e.g. erythromycin, clarithromycin and azithromycin) and lincosamides (e.g. clindamycin) are bacteriostatic agents. Both classes bind to the same component of the ribosome, so they are not administered together. Macrolides are used for <ce:italic>Legionella</ce:italic>, <ce:italic>Mycoplasma</ce:italic>, <ce:italic>Chlamydia</ce:italic> and <ce:italic>Bordetella</ce:italic> infections. Azithromycin is employed for single-dose/short-course therapy for genitourinary <ce:italic>Chlamydia/Mycoplasma</ce:italic> spp. infections. Clindamycin is used primarily for skin, soft tissue, bone and joint infections.</ce:para><ce:section id="s0595"><ce:section id="s0600"><ce:section-title id="st0575">Pharmacokinetics</ce:section-title><ce:section id="s0605"><ce:section-title id="st0580">Macrolides</ce:section-title><ce:para id="p1875"><ce:list id="ulist0375"><ce:list-item id="u1060"><ce:label>•</ce:label><ce:para id="p1880">Variable bioavailability (intravenous and oral preparations available).</ce:para></ce:list-item><ce:list-item id="u1065"><ce:label>•</ce:label><ce:para id="p1885">Frequency of administration: erythromycin is administered 4 times daily, clarithromycin twice daily, azithromycin once daily.</ce:para></ce:list-item><ce:list-item id="u1070"><ce:label>•</ce:label><ce:para id="p1890">High protein binding.</ce:para></ce:list-item><ce:list-item id="u1075"><ce:label>•</ce:label><ce:para id="p1895">Excellent intracellular accumulation.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0610"><ce:section-title id="st0585">Lincosamides (e.g. clindamycin)</ce:section-title><ce:para id="p1900"><ce:list id="ulist0380"><ce:list-item id="u1080"><ce:label>•</ce:label><ce:para id="p1905">Good oral bioavailability.</ce:para></ce:list-item><ce:list-item id="u1085"><ce:label>•</ce:label><ce:para id="p1910">Food has no effect on absorption.</ce:para></ce:list-item><ce:list-item id="u1090"><ce:label>•</ce:label><ce:para id="p1915">Good bone/joint penetration; limited CSF penetration.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0615"><ce:section-title id="st0590">Adverse effects</ce:section-title><ce:para id="p1920"><ce:list id="ulist0385"><ce:list-item id="u1095"><ce:label>•</ce:label><ce:para id="p1925">Gastrointestinal upset, especially in young adults (erythromycin 30%).</ce:para></ce:list-item><ce:list-item id="u1100"><ce:label>•</ce:label><ce:para id="p1930">Cholestatic jaundice with erythromycin estolate.</ce:para></ce:list-item><ce:list-item id="u1105"><ce:label>•</ce:label><ce:para id="p1935">Prolongation of QT interval can cause torsades de pointes (<ce:intra-ref id="ii0275" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0830">p. 476</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u1110"><ce:label>•</ce:label><ce:para id="p1940">Clindamycin predisposes to CDI.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:section><ce:section id="s0620"><ce:section-title id="st0595">Aminoglycosides and spectinomycin</ce:section-title><ce:para id="p1945">Aminoglycosides are effective mainly in Gram-negative infections and are therefore commonly used in regimens for intra-abdominal infection. Some aminoglycosides, e.g. amikacin, are important components of therapy for MDR-TB. Because they act synergistically with β-lactam antibiotics they are used in combinations to treat biofilm infections, including infective endocarditis and orthopaedic implant infections. They cause very little local irritation at injection sites and negligible allergic responses. Oto- and nephrotoxicity must be avoided by monitoring of renal function and drug levels and by use of short treatment regimens. Aminoglycosides are not subject to an inoculum effect (<ce:cross-ref id="crf9035" refid="s0505">p. 120</ce:cross-ref>) and they all exhibit a post-antibiotic effect (<ce:cross-ref id="crf9040" refid="s0495">p. 119</ce:cross-ref>).</ce:para><ce:section id="s0625"><ce:section id="s0630"><ce:section-title id="st0600">Pharmacokinetics</ce:section-title><ce:para id="p1950"><ce:list id="ulist0390"><ce:list-item id="u1115"><ce:label>•</ce:label><ce:para id="p1955">Negligible oral absorption.</ce:para></ce:list-item><ce:list-item id="u1120"><ce:label>•</ce:label><ce:para id="p1960">Hydrophilic, so excellent penetration to extracellular fluid in body cavities and serosal fluids.</ce:para></ce:list-item><ce:list-item id="u1125"><ce:label>•</ce:label><ce:para id="p1965">Very poor intracellular penetration (except hair cells in cochlea and renal cortical cells).</ce:para></ce:list-item><ce:list-item id="u1130"><ce:label>•</ce:label><ce:para id="p1970">Negligible CSF and corneal penetration and may require intrathecal administration during neurosurgical infections.</ce:para></ce:list-item><ce:list-item id="u1135"><ce:label>•</ce:label><ce:para id="p1975">Peak plasma levels 30 minutes after infusion.</ce:para></ce:list-item><ce:list-item id="u1140"><ce:label>•</ce:label><ce:para id="p1980">Monitoring of therapeutic levels required.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0635"><ce:section-title id="st0605">Gentamicin dosing</ce:section-title><ce:para id="p1985"><ce:list id="ulist0395"><ce:list-item id="u1145"><ce:label>•</ce:label><ce:para id="p1990">Except in certain forms of endocarditis, pregnancy, severe burns, end-stage renal disease and paediatric patients, gentamicin is administered at 7 mg/kg body weight. The appropriate dose interval depends on drug clearance and is determined by reference to the Hartford nomogram (<ce:cross-ref id="crf0675" refid="f0100">Fig. 6.18</ce:cross-ref><ce:float-anchor refid="f0100"/>).</ce:para></ce:list-item><ce:list-item id="u1150"><ce:label>•</ce:label><ce:para id="p1995">In streptococcal and enterococcal endocarditis, gentamicin is used with a cell wall active agent (usually a β-lactam), to provide synergy. Commonly used doses are 1 mg/kg 2–3 times daily for enterococcal endocarditis and 3 mg/kg once daily for most strains of oral streptococci. Target pre- and post-dose levels are &#x003C; 1 mg/L and 3–5 mg/L, respectively, when gentamicin is dosed 3 times daily.</ce:para></ce:list-item><ce:list-item id="u1155"><ce:label>•</ce:label><ce:para id="p2000">When not used according to the Hartford regimen or for endocarditis, gentamicin is administered twice or 3 times daily at 3–5 mg/kg/day. Target pre- and post-dose levels are &#x003C; 1 mg/L and 5–10 mg/L (7–10 mg/L with less sensitive organisms, e.g. <ce:italic>P. aeruginosa</ce:italic>), respectively.</ce:para></ce:list-item><ce:list-item id="u1160"><ce:label>•</ce:label><ce:para id="p2005">For other aminoglycosides, consult local guidance.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0640"><ce:section-title id="st0610">Adverse effects</ce:section-title><ce:para id="p2010"><ce:list id="ulist0400"><ce:list-item id="u1165"><ce:label>•</ce:label><ce:para id="p2015">Renal toxicity (usually reversible) accentuated by other nephrotoxic agents.</ce:para></ce:list-item><ce:list-item id="u1170"><ce:label>•</ce:label><ce:para id="p2020">Cochlear toxicity (permanent) more likely in older people and those with a predisposing mitochondrial gene mutation.</ce:para></ce:list-item><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p2025">Neuromuscular blockade after rapid intravenous infusion (potentiated by calcium channel blockers, myasthenia gravis and hypomagnesaemia).</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0645"><ce:section-title id="st0615">Spectinomycin</ce:section-title><ce:para id="p2030">Chemically similar to the aminoglycosides and given intramuscularly, spectinomycin was developed to treat strains of <ce:italic>Neisseria gonorrhoeae</ce:italic> resistant to β-lactam antibiotics. Unfortunately, resistance to spectinomycin is very common. Its only indication is the treatment of gonococcal urethritis in pregnancy or in patients allergic to β-lactam antibiotics.</ce:para></ce:section></ce:section><ce:section id="s0650"><ce:section-title id="st0620">Quinolones and fluoroquinolones</ce:section-title><ce:para id="p2035">These are effective and generally well-tolerated bactericidal agents. The quinolones have purely anti-Gram-negative activity, whereas the fluoroquinolones are broad-spectrum agents (<ce:cross-ref id="crf0680" refid="b0120">Box 6.23</ce:cross-ref><ce:float-anchor refid="b0120"/>). Ciprofloxacin has anti-pseudomonal activity but resistance emerges rapidly. In 2014, European surveillance showed that resistance to fluoroquinolones in <ce:italic>E. coli</ce:italic> ranged between 7.8% (Iceland) and 46.4% (Cyprus). Quinolones and fluoroquinolones are used for a variety of common infections, including urinary tract infection and pneumonia, and less common problems like MDR-TB.</ce:para><ce:section id="s0655"><ce:section id="s0660"><ce:section-title id="st0625">Pharmacokinetics</ce:section-title><ce:para id="p2045"><ce:list id="ulist0405"><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p2050">Well absorbed after oral administration but delayed by food, antacids, ferrous sulphate and multivitamins.</ce:para></ce:list-item><ce:list-item id="u1185"><ce:label>•</ce:label><ce:para id="p2055">Wide volume of distribution; tissue concentrations twice those in serum.</ce:para></ce:list-item><ce:list-item id="u1190"><ce:label>•</ce:label><ce:para id="p2060">Good intracellular penetration, concentrating in phagocytes.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0665"><ce:section-title id="st0630">Adverse effects</ce:section-title><ce:para id="p2065"><ce:list id="ulist0410"><ce:list-item id="u1195"><ce:label>•</ce:label><ce:para id="p2070">Gastrointestinal side-effects in 1–5%.</ce:para></ce:list-item><ce:list-item id="u1200"><ce:label>•</ce:label><ce:para id="p2075">Rare skin reactions (phototoxicity).</ce:para></ce:list-item><ce:list-item id="u1205"><ce:label>•</ce:label><ce:para id="p2080">Tendinitis and Achilles tendon rupture, especially in older people.</ce:para></ce:list-item><ce:list-item id="u1210"><ce:label>•</ce:label><ce:para id="p2085">Central nervous system effects (delirium, tremor, dizziness and occasional seizures in 5–12%), especially in older people.</ce:para></ce:list-item><ce:list-item id="u1215"><ce:label>•</ce:label><ce:para id="p2090">Reduces clearance of xanthines and theophyllines, potentially inducing insomnia and increased seizure potential.</ce:para></ce:list-item><ce:list-item id="u1220"><ce:label>•</ce:label><ce:para id="p2095">Prolongation of QT interval on ECG, cardiac arrhythmias.</ce:para></ce:list-item><ce:list-item id="u1225"><ce:label>•</ce:label><ce:para id="p2100">Ciprofloxacin use is associated with the acquisition of MRSA and emergence of <ce:italic>C. difficile</ce:italic> ribotype 027 (<ce:intra-ref id="ii0290" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1565">p. 264</ce:intra-ref>).</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:section><ce:section id="s0670"><ce:section-title id="st0635">Glycopeptides</ce:section-title><ce:para id="p2105">Glycopeptides (vancomycin and teicoplanin) are effective against Gram-positive organisms only, and are used against MRSA and ampicillin-resistant enterococci. Some staphylococci and enterococci demonstrate intermediate sensitivity or resistance. Vancomycin use should be restricted to limit emergence of resistant strains. Teicoplanin is not available in all countries. Neither drug is absorbed after oral administration but vancomycin is used orally to treat CDI.</ce:para><ce:section id="s0675"><ce:section id="s0680"><ce:section-title id="st0640">Pharmacokinetics</ce:section-title><ce:section id="s0685"><ce:section-title id="st0645">Vancomycin</ce:section-title><ce:para id="p2110"><ce:list id="ulist0415"><ce:list-item id="u1230"><ce:label>•</ce:label><ce:para id="p2115">Administered by slow intravenous infusion, good tissue distribution and short half-life.</ce:para></ce:list-item><ce:list-item id="u1235"><ce:label>•</ce:label><ce:para id="p2120">Enters the CSF only in the presence of inflammation and may require intrathecal administration during neurosurgical infections.</ce:para></ce:list-item><ce:list-item id="u1240"><ce:label>•</ce:label><ce:para id="p2125">Therapeutic monitoring of intravenous vancomycin is recommended, to maintain pre-dose levels of &#x003E; 10 mg/L (15–20 mg/L in serious staphylococcal infections).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0690"><ce:section-title id="st0650">Teicoplanin</ce:section-title><ce:para id="p2130"><ce:list id="ulist0420"><ce:list-item id="u1245"><ce:label>•</ce:label><ce:para id="p2135">Long half-life allows once-daily dosing.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0695"><ce:section-title id="st0655">Adverse effects</ce:section-title><ce:para id="p2140"><ce:list id="ulist0425"><ce:list-item id="u1250"><ce:label>•</ce:label><ce:para id="p2145">Histamine release due to rapid vancomycin infusion produces a ‘red man’ reaction (rare with modern preparations).</ce:para></ce:list-item><ce:list-item id="u1255"><ce:label>•</ce:label><ce:para id="p2150">Nephrotoxicity is rare but may occur with concomitant aminoglycoside use, as may ototoxicity.</ce:para></ce:list-item><ce:list-item id="u1260"><ce:label>•</ce:label><ce:para id="p2155">Teicoplanin can cause rash, bronchospasm, eosinophilia and anaphylaxis.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:section><ce:section id="s0700"><ce:section-title id="st0660">Lipopeptides</ce:section-title><ce:para id="p2160">Daptomycin is a cyclic lipopeptide with bactericidal activity against Gram-positive organisms (including MRSA and GRE) but not Gram-negatives. It is not absorbed orally, and is used intravenously to treat Gram-positive infections, such as soft tissue infections and <ce:italic>Staph. aureus</ce:italic> infective endocarditis. Daptomycin is not effective for community-acquired pneumonia. Treatment can be associated with increased levels of creatine kinase and eosinophilic pneumonitis.</ce:para></ce:section><ce:section id="s0705"><ce:section-title id="st0665">Polymyxins</ce:section-title><ce:para id="p2165">Colistin is a polymyxin antibiotic that binds and disrupts the outer cell membrane of Gram-negative bacteria, including <ce:italic>P. aeruginosa</ce:italic> and <ce:italic>Acinetobacter baumannii</ce:italic>. Its use has increased with the emergence and spread of multi-resistant Gram-negative bacteria, including CPEs. It can be administered by oral, intravenous and nebulised routes. Significant adverse effects include neurotoxicity, including encephalopathy, and nephrotoxicity.</ce:para></ce:section><ce:section id="s0710"><ce:section-title id="st0670">Folate antagonists</ce:section-title><ce:para id="p2170">These are bacteriostatic antibacterials (<ce:cross-ref id="crf9045" refid="s0260">p. 109</ce:cross-ref>). A combination of a sulphonamide and either trimethoprim or pyrimethamine is most commonly used, which interferes with two consecutive steps in the metabolic pathway. Available combinations include trimethoprim/sulfamethoxazole (co-trimoxazole) and pyrimethamine with either sulfadoxine (used to treat malaria) or sulfadiazine (used in toxoplasmosis). Co-trimoxazole is the first-line drug for <ce:italic>Pneumocystis jirovecii</ce:italic> infection, the second-line drug for treatment and prevention of <ce:italic>B. pertussis</ce:italic> (whooping cough) infection, and is also used for a variety of other infections, including <ce:italic>Staph. aureus</ce:italic>. Dapsone is used to treat leprosy (Hansen's disease) and to prevent toxoplasmosis and pneumocystis when patients are intolerant of other medications. Folinic acid should be given to prevent myelosuppression if these drugs are used long-term or unavoidably in early pregnancy.</ce:para><ce:section id="s0715"><ce:section id="s0720"><ce:section-title id="st0675">Pharmacokinetics</ce:section-title><ce:para id="p2175"><ce:list id="ulist0430"><ce:list-item id="u1265"><ce:label>•</ce:label><ce:para id="p2180">Well absorbed orally.</ce:para></ce:list-item><ce:list-item id="u1270"><ce:label>•</ce:label><ce:para id="p2185">Sulphonamides are hydrophilic, distributing well to the extracellular fluid.</ce:para></ce:list-item><ce:list-item id="u1275"><ce:label>•</ce:label><ce:para id="p2190">Trimethoprim is lipophilic with high tissue concentrations.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0725"><ce:section-title id="st0680">Adverse effects</ce:section-title><ce:para id="p2195"><ce:list id="ulist0435"><ce:list-item id="u1280"><ce:label>•</ce:label><ce:para id="p2200">Trimethoprim is generally well tolerated, with few adverse effects.</ce:para></ce:list-item><ce:list-item id="u1285"><ce:label>•</ce:label><ce:para id="p2205">Sulphonamides and dapsone may cause haemolysis in glucose-6-phosphate dehydrogenase deficiency (<ce:intra-ref id="ii0300" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0860">p. 948</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u1290"><ce:label>•</ce:label><ce:para id="p2210">Sulphonamides and dapsone cause skin and mucocutaneous reactions, including Stevens–Johnson syndrome and ‘dapsone syndrome’ (rash, fever and lymphadenopathy).</ce:para></ce:list-item><ce:list-item id="u1295"><ce:label>•</ce:label><ce:para id="p2215">Dapsone causes methaemoglobinaemia (<ce:intra-ref id="ii0305" xlink:href="pii:B978-0-7020-7028-0.00007-X#s0040">p. 135</ce:intra-ref>) and peripheral neuropathy.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:section><ce:section id="s0730"><ce:section-title id="st0685">Tetracyclines and glycylcyclines</ce:section-title><ce:section id="s0735"><ce:section-title id="st0690">Tetracyclines</ce:section-title><ce:para id="p2220">Of this mainly bacteriostatic class, the newer drugs doxycycline and minocycline show better absorption and distribution than older ones. Many streptococci and Gram-negative bacteria are now resistant, in part due to their use in animals (which is banned in Europe). Tetracyclines are indicated for <ce:italic>Mycoplasma</ce:italic> spp., <ce:italic>Chlamydia</ce:italic> spp., <ce:italic>Rickettsia</ce:italic> spp., <ce:italic>Coxiella</ce:italic> spp., <ce:italic>Bartonella</ce:italic> spp., <ce:italic>Borrelia</ce:italic> spp., <ce:italic>Helicobacter pylori</ce:italic>, <ce:italic>Treponema pallidum</ce:italic> and atypical mycobacterial infections. Tetracyclines can also be used for malaria prevention.</ce:para><ce:section id="s0740"><ce:section-title id="st0695">Pharmacokinetics</ce:section-title><ce:para id="p2225"><ce:list id="ulist0440"><ce:list-item id="u1300"><ce:label>•</ce:label><ce:para id="p2230">Best oral absorption is in the fasting state (doxycycline is 100% absorbed unless gastric pH rises) and absorption is inhibited by cations, e.g. calcium or iron, which should not be administered at the same time.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0745"><ce:section-title id="st0700">Adverse effects</ce:section-title><ce:para id="p2235"><ce:list id="ulist0445"><ce:list-item id="u1305"><ce:label>•</ce:label><ce:para id="p2240">All tetracyclines except doxycycline are contraindicated in renal failure.</ce:para></ce:list-item><ce:list-item id="u1310"><ce:label>•</ce:label><ce:para id="p2245">Dizziness with minocycline.</ce:para></ce:list-item><ce:list-item id="u1315"><ce:label>•</ce:label><ce:para id="p2250">Binding to metallic ions in bones and teeth causes discoloration (avoid in children and pregnancy) and enamel hypoplasia.</ce:para></ce:list-item><ce:list-item id="u1320"><ce:label>•</ce:label><ce:para id="p2255">Oesophagitis/oesophageal ulcers with doxycycline.</ce:para></ce:list-item><ce:list-item id="u1325"><ce:label>•</ce:label><ce:para id="p2260">Phototoxic skin reactions.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0750"><ce:section-title id="st0705">Glycylcyclines (tigecycline)</ce:section-title><ce:para id="p2265">Chemical modification of tetracycline has produced tigecycline, a broad-spectrum, parenteral-only antibiotic with activity against resistant Gram-positive and Gram-negative pathogens, such as MRSA and ESBL (but excluding <ce:italic>Pseudomonas</ce:italic> spp.). Re-analysis of trial data has shown that there was excess mortality following tigecycline treatment as opposed to comparator antibiotics, so tigecycline should be used only when there has been adequate assessment of risk versus benefit.</ce:para></ce:section></ce:section><ce:section id="s0755"><ce:section-title id="st0710">Nitroimidazoles</ce:section-title><ce:para id="p2270">Nitroimidazoles are highly active against strictly anaerobic bacteria, especially <ce:italic>Bacteroides fragilis</ce:italic>, <ce:italic>C. difficile</ce:italic> and other <ce:italic>Clostridium</ce:italic> spp. They also have significant antiprotozoal activity against amoebae and <ce:italic>Giardia lamblia</ce:italic>.</ce:para><ce:section id="s0760"><ce:section id="s0765"><ce:section-title id="st0715">Pharmacokinetics</ce:section-title><ce:para id="p2275"><ce:list id="ulist0450"><ce:list-item id="u1330"><ce:label>•</ce:label><ce:para id="p2280">Almost completely absorbed after oral administration (60% after rectal administration).</ce:para></ce:list-item><ce:list-item id="u1335"><ce:label>•</ce:label><ce:para id="p2285">Well distributed, especially to brain and CSF.</ce:para></ce:list-item><ce:list-item id="u1340"><ce:label>•</ce:label><ce:para id="p2290">Safe in pregnancy.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0770"><ce:section-title id="st0720">Adverse effects</ce:section-title><ce:para id="p2295"><ce:list id="ulist0455"><ce:list-item id="u1345"><ce:label>•</ce:label><ce:para id="p2300">Metallic taste (dose-dependent).</ce:para></ce:list-item><ce:list-item id="u1350"><ce:label>•</ce:label><ce:para id="p2305">Severe vomiting if taken with alcohol – ‘Antabuse effect’.</ce:para></ce:list-item><ce:list-item id="u1355"><ce:label>•</ce:label><ce:para id="p2310">Peripheral neuropathy with prolonged use.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:section><ce:section id="s0775"><ce:section-title id="st0725">Phenicols</ce:section-title><ce:para id="p2315">Chloramphenicol is the only example in clinical use. In developed countries its use tends to be reserved for severe and life-threatening infections when other antibiotics are either unavailable or impractical, largely because of concerns about toxicity. It is bacteriostatic to most organisms but apparently bactericidal to <ce:italic>H. influenzae</ce:italic>, <ce:italic>Strep. pneumoniae</ce:italic> and <ce:italic>N. meningitidis</ce:italic>. It has a very broad spectrum of activity against aerobic and anaerobic organisms, spirochaetes, <ce:italic>Rickettsia</ce:italic>, <ce:italic>Chlamydia</ce:italic> and <ce:italic>Mycoplasma</ce:italic> spp. It competes with macrolides and lincosamides for ribosomal binding sites, so should not be used in combination with these agents. Significant adverse effects are ‘grey baby’ syndrome in infants (cyanosis and circulatory collapse due to inability to conjugate drug and excrete the active form in urine); reversible dose-dependent bone marrow depression in adults receiving high cumulative doses; and severe aplastic anaemia in 1 in 25 000–40 000 exposures (unrelated to dose, duration of therapy or route of administration).</ce:para></ce:section><ce:section id="s0780"><ce:section-title id="st0730">Oxazolidinones</ce:section-title><ce:para id="p2320">Linezolid and tedizolid are examples and their good activity against Gram-positive organisms means they are often used to treat skin and soft tissue infections. They may also be used in infection caused by resistant Gram-positive bacteria, including MRSA and GRE. Administration can be intravenous or oral. Common linezolid adverse effects include mild gastrointestinal upset and tongue discoloration. Myelodysplasia and peripheral and optic neuropathy can occur with prolonged use. Linezolid has monoamine oxidase inhibitor (MAOI) activity, and co-administration with other MAOIs or serotonin re-uptake inhibitors should be avoided, as this may precipitate a ‘serotonin syndrome’ (<ce:intra-ref id="ii0315" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0820">p. 1199</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0785"><ce:section-title id="st0735">Other antibacterial agents</ce:section-title><ce:section id="s0790"><ce:section-title id="st0740">Fusidic acid</ce:section-title><ce:para id="p2325">This antibiotic, active against Gram-positive bacteria, is available in intravenous, oral or topical formulations. It is lipid-soluble and distributes well to tissues. Its antibacterial activity is, however, unpredictable. Fusidic acid is used in combination, typically with antistaphylococcal penicillins, or for MRSA with clindamycin or rifampicin. It interacts with coumarin derivatives and oral contraceptives.</ce:para></ce:section><ce:section id="s0795"><ce:section-title id="st0745">Nitrofurantoin</ce:section-title><ce:para id="p2330">This drug has very rapid renal elimination and is active against aerobic Gram-negative and Gram-positive bacteria, including enterococci. It is used only for treatment of urinary tract infection, being generally safe in pregnancy and childhood. With prolonged treatment, however, it can cause eosinophilic lung infiltrates, fever, pulmonary fibrosis, peripheral neuropathy, hepatitis and haemolytic anaemia so its use must be carefully balanced against risks.</ce:para></ce:section><ce:section id="s0800"><ce:section-title id="st0750">Fidaxomicin</ce:section-title><ce:para id="p2335">Fidaxomicin is an inhibitor of RNA synthesis, and was introduced for the treatment of CDI in 2012. In non-severe CDI it is non-inferior to oral vancomycin and is associated with a lower recurrence rate. Its effectiveness has not been assessed in severe CDI.</ce:para></ce:section><ce:section id="s0805"><ce:section-title id="st0755">Fosfomycin</ce:section-title><ce:para id="p2340">Fosfomycin acts by inhibiting cell wall synthesis. It has activity against Gram-negative but also Gram-positive bacteria and can demonstrate in vitro synergy against MRSA when combined with other antimicrobials. It is used for treatment of urinary tract infections but can be employed in other situations against multi-resistant bacteria.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0810"><ce:section-title id="st0760">Antimycobacterial agents</ce:section-title><ce:section id="s0815"><ce:section id="s0820"><ce:section-title id="st0765">Isoniazid</ce:section-title><ce:para id="p2345">Isoniazid is bactericidal for replicating bacteria and bacteriostatic for non-replicating bacteria. It is activated by mycobacterial catalase-peroxidase (KatG) and inhibits the <ce:italic>InhA</ce:italic> gene product, a reductase involved in mycolic acid synthesis. Mutations in <ce:italic>KatG</ce:italic> or <ce:italic>InhA</ce:italic> result in isoniazid resistance, which was reported in 15% of cases of <ce:italic>M. tuberculosis</ce:italic> infection globally in 2013. Isoniazid is well absorbed orally and metabolised by acetylation in the liver. The major side-effects are hepatitis, neuropathy (ameliorated by co-administration of pyridoxine) and hypersensitivity reactions.</ce:para></ce:section><ce:section id="s0825"><ce:section-title id="st0770">Rifampicin</ce:section-title><ce:para id="p2350">Rifampicin inhibits DNA-dependent RNA polymerase and is bactericidal against replicating bacteria. It is also active in necrotic foci, where mycobacteria have low levels of replication, and is therefore important in sterilisation and sputum conversion. Resistance most often involves the β-subunit of RNA polymerase and most often occurs with isoniazid-resistant MDR-TB. Rifampicin is well absorbed orally. It is metabolised by the liver via the microsomal cytochrome P450 system and is one the most potent inducers of multiple P450 isoenzymes, so is subject to extensive drug–drug interactions. Common side-effects include hepatitis, influenza-like symptoms and hypersensitivity reactions. Orange discoloration of urine and body secretions is expected.</ce:para></ce:section><ce:section id="s0830"><ce:section-title id="st0775">Pyrazinamide</ce:section-title><ce:para id="p2355">The mechanism of action of pyrazinamide is incompletely defined but includes inhibition of fatty acid synthase and ribosomal trans-translation. Pyrazinamide is often bacteriostatic but can be bactericidal and is active against semidormant bacteria in a low-pH environment. Primary resistance is rare but MDR-TB strains are frequently pyrazinamide-resistant and intrinsic resistance is a feature of <ce:italic>Mycobacterium bovis</ce:italic> strains. Pyrazinamide is well absorbed orally and metabolised by the liver. Side-effects include nausea, hepatitis, asymptomatic elevation of uric acid and myalgia.</ce:para></ce:section><ce:section id="s0835"><ce:section-title id="st0780">Ethambutol</ce:section-title><ce:para id="p2360">Ethambutol is a bacteriostatic agent. It inhibits arabinosyl transferase, which is involved in the synthesis of arabinogalactan, a component of the mycobacterial cell wall. Resistance is usually seen when resistance to other antimycobacterial agents is also present, e.g. in MDR-TB strains. It is orally absorbed but, in contrast to the first-line agents described above, it achieves poor CSF penetration and is renally excreted. The major side-effect is optic neuritis with loss of red–green colour discrimination and impaired visual acuity. It can also cause hepatitis.</ce:para></ce:section><ce:section id="s0840"><ce:section-title id="st0785">Streptomycin</ce:section-title><ce:para id="p2365">Streptomycin is an aminoglycoside whose mechanism of action and side-effects are similar to those of other aminoglycosides. It is administered intramuscularly.</ce:para></ce:section><ce:section id="s0845"><ce:section-title id="st0790">Other antituberculous agents</ce:section-title><ce:para id="p2370">Second-line agents used in MDR or XDR strains (<ce:cross-ref id="crf9050" refid="s0410">p. 116</ce:cross-ref>) include aminoglycosides (amikacin, capreomycin or kanamycin) and fluoroquinolones (moxifloxacin or levofloxacin), discussed above. Other established second-line agents administered orally are cycloserine (which causes neurological side-effects); ethionamide or prothionamide (which are not active with <ce:italic>InhA</ce:italic>-gene-mediated resistance but have reasonable CSF penetration; their side-effect profile includes gastrointestinal disturbance, hepatotoxicity and neurotoxicity); and paraminosalicylic acid (which causes rashes and gastrointestinal upset). Linezolid may also be used and has good CSF penetration, while meropenem with co-amoxiclav is occasionally chosen. New drugs developed for XDR-TB include delamanid and bedaquiline; their adverse effects include QT prolongation and cardiac arrhythmias. Their co-administration with other agents with a similar side-effect profile (e.g. fluoroquinolones) therefore requires careful risk assessment.</ce:para></ce:section><ce:section id="s0850"><ce:section-title id="st0795">Clofazimine</ce:section-title><ce:para id="p2375">Clofazimine is used against <ce:italic>M. leprae</ce:italic> and resistant strains of <ce:italic>M. tuberculosis</ce:italic>. Its mode of action may involve induction of oxidative stress and it is weakly bactericidal. Oral absorption is variable and it is excreted in the bile. Side-effects include gastrointestinal upset, dry eyes and skin, and skin pigmentation, especially in those with pigmented skin.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0855"><ce:section-title id="st0800">Antifungal agents</ce:section-title><ce:para id="p2380">See <ce:cross-ref id="crf0690" refid="b0125">Box 6.24</ce:cross-ref><ce:float-anchor refid="b0125"/>.</ce:para><ce:section id="s0860"><ce:section-title id="st0805">Azole antifungals</ce:section-title><ce:para id="p2390">The azoles (imidazoles and triazoles) inhibit synthesis of ergosterol, a constituent of the fungal cell membrane. Side-effects vary but include gastrointestinal upset, hepatitis and rash. Azoles are inhibitors of cytochrome P450 enzymes, so tend to increase exposure to cytochrome P450-metabolised drugs (<ce:intra-ref id="ii0325" xlink:href="pii:B978-0-7020-7028-0.00002-0#u0520">p. 24</ce:intra-ref>).</ce:para><ce:section id="s0865"><ce:section-title id="st0810">Imidazoles</ce:section-title><ce:para id="p2395">Miconazole, econazole, clotrimazole and ketoconazole are relatively toxic and therefore administered topically. Clotrimazole is used extensively to treat superficial fungal infections. Triazoles are used for systemic treatment because they are less toxic.</ce:para></ce:section><ce:section id="s0870"><ce:section-title id="st0815">Triazoles</ce:section-title><ce:para id="p2400">Fluconazole is effective against yeasts (<ce:italic>Candida</ce:italic> and <ce:italic>Cryptococcus</ce:italic> spp.) and has a long half-life (approximately 30 hours) and an excellent safety profile. The drug is highly water-soluble and distributes widely to all body sites and tissues, including CSF. Itraconazole is lipophilic and distributes extensively, including to toenails and fingernails. CSF penetration is poor. Because oral absorption is erratic, therapeutic drug monitoring is required. Voriconazole is well absorbed orally but variability in levels requires therapeutic drug monitoring. It is used mainly in aspergillosis (<ce:intra-ref id="ii0330" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1195">p. 596</ce:intra-ref>). Side-effects include photosensitivity, hepatitis and transient retinal toxicity. Posaconazole and isavuconazole are broad-spectrum azoles, with activity against <ce:italic>Candida</ce:italic> spp., <ce:italic>Aspergillus</ce:italic> spp. and some mucoraceous moulds<ce:italic>.</ce:italic> Isavuconazole is non-inferior to voriconazole in the management of invasive aspergillosis and may be considered as an alternative when voriconazole is not tolerated.</ce:para></ce:section></ce:section><ce:section id="s0875"><ce:section-title id="st0820">Echinocandins</ce:section-title><ce:para id="p2405">The echinocandins inhibit β-1,3-glucan synthesis in the fungal cell wall. They have few significant adverse effects. Caspofungin, anidulafungin and micafungin are used to treat systemic candidosis, and caspofungin is also used in aspergillosis.</ce:para></ce:section><ce:section id="s0880"><ce:section-title id="st0825">Polyenes</ce:section-title><ce:para id="p2410">Amphotericin B (AmB) deoxycholate causes cell death by binding to ergosterol and damaging the fungal cytoplasmic membrane. Its use in resource-rich countries has been largely supplanted by less toxic agents. Its long half-life enables once-daily administration. CSF penetration is poor.</ce:para><ce:para id="p2415">Adverse effects include immediate anaphylaxis, other infusion-related reactions and nephrotoxicity. Nephrotoxicity may be sufficient to require dialysis and occurs in most patients who are adequately dosed. It may be ameliorated by concomitant infusion of normal saline. Irreversible nephrotoxicity occurs with large cumulative doses of AmB.</ce:para><ce:para id="p2420">Nystatin has a similar spectrum of antifungal activity to AmB. Its toxicity limits it to topical use, e.g. in oral and vaginal candidiasis.</ce:para><ce:section id="s0885"><ce:section id="s0890"><ce:section-title id="st0830">Lipid formulations of amphotericin B</ce:section-title><ce:para id="p2425">Lipid formulations of AmB have been developed to reduce AmB toxicity and have replaced AmB deoxycholate in many regions. They consist of AmB encapsulated in liposomes (liposomal AmB, L-AmB) or complexed with phospholipids (AmB lipid complex, ABLC). The drug becomes active on dissociating from its lipid component. Adverse effects are similar to, but considerably less frequent than, those with AmB deoxycholate, and efficacy is similar. Lipid formulations of AmB are used in invasive fungal disease, as empirical therapy in patients with neutropenic fever (<ce:intra-ref id="ii0335" xlink:href="pii:B978-0-7020-7028-0.00033-0#p0960">p. 1327</ce:intra-ref>), and also in visceral leishmaniasis (<ce:intra-ref id="ii0340" xlink:href="pii:B978-0-7020-7028-0.00011-1#p6860">p. 282</ce:intra-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0895"><ce:section-title id="st0835">Other antifungal agents</ce:section-title><ce:section id="s0900"><ce:section-title id="st0840">Flucytosine</ce:section-title><ce:para id="p2430">Flucytosine (5-fluorocytosine) has particular activity against yeasts. When it is used as monotherapy, acquired resistance develops rapidly, so it should be given in combination with another antifungal agent. Adverse effects include myelosuppression, gastrointestinal upset and hepatitis.</ce:para></ce:section><ce:section id="s0905"><ce:section-title id="st0845">Griseofulvin</ce:section-title><ce:para id="p2435">Griseofulvin has been largely superseded by terbinafine and itraconazole for treatment of dermatophyte infections, except in children, for whom these agents remain largely unlicensed. It is deposited in keratin precursor cells, which become resistant to fungal invasion.</ce:para></ce:section><ce:section id="s0910"><ce:section-title id="st0850">Terbinafine</ce:section-title><ce:para id="p2440">Terbinafine distributes with high concentration to sebum and skin, with a half-life of more than 1 week. It is used topically for dermatophyte skin infections and orally for onychomycosis. The major adverse reaction is hepatic toxicity (approximately 1: 50 000 cases). Terbinafine is not recommended for breastfeeding mothers.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0915"><ce:section-title id="st0855">Antiviral agents</ce:section-title><ce:para id="p2445">Most viral infections in immunocompetent individuals resolve without intervention. Antiviral therapy is available for a limited number of infections only (<ce:cross-ref id="crf0695" refid="b0130">Box 6.25</ce:cross-ref><ce:float-anchor refid="b0130"/>).</ce:para><ce:section id="s0920"><ce:section-title id="st0860">Antiretroviral agents</ce:section-title><ce:para id="p2455">These agents, used predominantly against HIV, are discussed on <ce:intra-ref id="ii0350" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0435">page 324</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0925"><ce:section-title id="st0865">Anti-herpesvirus agents</ce:section-title><ce:section id="s0930"><ce:section-title id="st0870">Aciclovir, valaciclovir, penciclovir and famciclovir</ce:section-title><ce:para id="p2460">These antivirals are acyclic analogues of guanosine, which inhibit viral DNA polymerase after being phosphorylated by virus-derived thymidine kinase (TK). Aciclovir is poorly absorbed after oral dosing; better levels are achieved intravenously or by use of the prodrug valaciclovir. Famciclovir is the prodrug of penciclovir. Resistance is mediated by viral TK or polymerase mutations.</ce:para></ce:section><ce:section id="s0935"><ce:section-title id="st0875">Ganciclovir</ce:section-title><ce:para id="p2465">Chemical modification of the aciclovir molecule allows preferential phosphorylation by protein kinases of cytomegalovirus (CMV) and other β-herpesviruses (e.g. human herpesvirus (HHV) 6/7) and hence greater inhibition of the DNA polymerase, but at the expense of increased toxicity. Ganciclovir is administered intravenously or as a prodrug (valganciclovir) orally.</ce:para></ce:section><ce:section id="s0940"><ce:section-title id="st0880">Cidofovir</ce:section-title><ce:para id="p2470">Cidofovir inhibits viral DNA polymerases with potent activity against CMV, including most ganciclovir-resistant CMV. It also has activity against aciclovir-resistant herpes simplex virus (HSV) and varicella zoster virus (VZV), HHV6 and occasionally adenovirus, poxvirus, papillomavirus or polyoma virus, and may be used to treat these infections in immunocompromised hosts.</ce:para></ce:section><ce:section id="s0945"><ce:section-title id="st0885">Foscarnet</ce:section-title><ce:para id="p2475">This analogue of inorganic pyrophosphate acts as a non-competitive inhibitor of HSV, VZV, HHV6/7 or CMV DNA polymerase. It does not require significant intracellular phosphorylation and so may be effective when HSV or CMV resistance is due to altered drug phosphorylation. It has variable CSF penetration.</ce:para></ce:section></ce:section><ce:section id="s0950"><ce:section-title id="st0890">Anti-influenza agents</ce:section-title><ce:section id="s0955"><ce:section-title id="st0895">Zanamivir and oseltamivir</ce:section-title><ce:para id="p2480">These agents inhibit influenza A and B neuraminidase, which is required for release of virus from infected cells (see <ce:cross-ref id="crf0705" refid="f0015">Fig. 6.2</ce:cross-ref>, <ce:cross-ref id="crf9055" refid="s0085">p. 101</ce:cross-ref>). They are used in the treatment and prophylaxis of influenza. Administration within 48 hours of disease onset reduces the duration of symptoms by approximately 1–<ce:inline-figure baseline="0.0"><ce:link id="ln0245" locator="if006-001-9780702070280" xlink:href="pii:B9780702070280000068/if006-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0430" role="short">Image 26</ce:alt-text></ce:inline-figure> days. In the UK, their use is limited mainly to adults with chronic respiratory or renal disease, significant cardiovascular disease, immunosuppression or diabetes mellitus, during known outbreaks. Peramivir has been developed as a distinct chemical structure, which means that it retains activity against some oseltamivir- and zanamivir-resistant strains. It has poor oral bioavailability and has been developed as an intravenous or intramuscular formulation for treatment of severe cases of influenza, e.g. in intensive care units. It is now approved for use in adults in a number of countries. An intravenous formulation of zanamivir is also in development for critically ill patients. Laninamivir is approved as an intranasal formulation in Japan.</ce:para></ce:section><ce:section id="s0960"><ce:section-title id="st0900">Amantadine and rimantadine</ce:section-title><ce:para id="p2485">These drugs reduce replication of influenza A by inhibition of viral M2 protein ion channel function, which is required for uncoating (see <ce:cross-ref id="crf0710" refid="f0015">Fig. 6.2</ce:cross-ref>). Resistance develops rapidly and is widespread, and amantadine and rimantadine should be used only if the prevalence of resistance locally is known to be low. They are no longer recommended for treatment or prophylaxis in the UK or USA, having been superseded by zanamivir and oseltamivir. However, they may still be indicated to treat oseltamivir-resistant influenza A in patients unable to take zanamivir (e.g. ventilated patients).</ce:para></ce:section></ce:section><ce:section id="s0965"><ce:section-title id="st0905">Other agents used to treat viruses</ce:section-title><ce:para id="p2490">Antiviral agents used to treat hepatitis B and C virus are discussed on <ce:intra-ref id="ii0365" xlink:href="pii:B978-0-7020-7028-0.00022-6#p2860">pages 875</ce:intra-ref> and <ce:intra-ref id="ii9015" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0745">878</ce:intra-ref>, and those used against HIV-1 are described on <ce:intra-ref id="ii0370" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0435">page 324</ce:intra-ref>.</ce:para><ce:section id="s0970"><ce:section-title id="st0910">Ribavirin</ce:section-title><ce:para id="p2495">Ribavirin is a guanosine analogue that inhibits nucleic acid synthesis in a variety of viruses. It is used in particular in the treatment of hepatitis C virus but also against certain viral haemorrhagic fevers, e.g. Lassa fever, although it has not been useful against Ebola virus.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0975"><ce:section-title id="st0915">Antiparasitic agents</ce:section-title><ce:section id="s0980"><ce:section-title id="st0920">Antimalarial agents</ce:section-title><ce:section id="s0985"><ce:section-title id="st0925">Artemisinin (qinghaosu) derivatives</ce:section-title><ce:para id="p2500">Artemisinin originates from a herb (sweet wormwood, <ce:italic>Artemisia annua</ce:italic>), which was used in Chinese medicine to treat fever. Its derivatives, artemether and artesunate, were developed for use in malaria in the 1970s. Their mechanism of action is unknown. They are used in the treatment, but not prophylaxis, of malaria, usually in combination with other antimalarials, and are effective against strains of <ce:italic>Plasmodium</ce:italic> spp. that are resistant to other antimalarials. Artemether is lipid-soluble and may be administered via the intramuscular and oral routes. Artesunate is water-soluble and is administered intravenously or orally. Serious adverse effects are uncommon. Current advice for malaria in pregnancy is that the artemisinin derivatives should be used to treat uncomplicated <ce:italic>falciparum</ce:italic> malaria in the second and third trimesters, but should not be prescribed in the first trimester until more information becomes available.</ce:para></ce:section><ce:section id="s0990"><ce:section-title id="st0930">Atovaquone</ce:section-title><ce:para id="p2505">Atovaquone inhibits mitochondrial function. It is an oral agent, used for treatment and prophylaxis of malaria, in combination with proguanil (see below), without which it is ineffective. It is also employed in the treatment of mild cases of <ce:italic>Pneumocystis jirovecii</ce:italic> pneumonia, where there is intolerance to co-trimoxazole. Significant adverse effects are uncommon.</ce:para></ce:section><ce:section id="s0995"><ce:section-title id="st0935">Folate synthesis inhibitors (proguanil, pyrimethamine–sulfadoxine)</ce:section-title><ce:para id="p2510">Proguanil inhibits dihydrofolate reductase and is used for malaria prophylaxis. Pyrimethamine–sulfadoxine may be used in the treatment of malaria.</ce:para></ce:section><ce:section id="s1000"><ce:section-title id="st0940">Quinoline-containing compounds</ce:section-title><ce:para id="p2515">Chloroquine and quinine are believed to act by intraparasitic inhibition of haem polymerisation, resulting in toxic build-up of intracellular haem. The mechanisms of action of other agents in this group (quinidine, amodiaquine, mefloquine, primaquine, etc.) may differ. They are employed in the treatment and prophylaxis of malaria. Primaquine is used for radical cure of malaria due to <ce:italic>Plasmodium vivax</ce:italic> and <ce:italic>P. ovale</ce:italic> (destruction of liver hypnozoites). Chloroquine may also be given for extra-intestinal amoebiasis.</ce:para><ce:para id="p2520">Chloroquine can cause a pruritus sufficient to compromise adherence to therapy. If used in long-term, high-dose regimens, it causes an irreversible retinopathy. Overdosage leads to life-threatening cardiotoxicity. The side-effect profile of mefloquine includes neuropsychiatric effects ranging from mood change, nightmares and agitation to hallucinations and psychosis. Quinine may cause hypoglycaemia and cardiotoxicity, especially when administered parenterally. Primaquine causes haemolysis in people with glucose-6-phosphate dehydrogenase deficiency (<ce:intra-ref id="ii0375" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0860">p. 948</ce:intra-ref>), which should be excluded before therapy. Chloroquine is considered safe in pregnancy but mefloquine should be avoided in the first trimester.</ce:para></ce:section><ce:section id="s1005"><ce:section-title id="st0945">Lumefantrine</ce:section-title><ce:para id="p2525">Lumefantrine is used in combination with artemether to treat uncomplicated <ce:italic>falciparum</ce:italic> malaria, including chloroquine-resistant strains. Its mechanism of action is unknown. Significant adverse effects are uncommon.</ce:para></ce:section></ce:section><ce:section id="s1010"><ce:section-title id="st0950">Drugs used in trypanosomiasis</ce:section-title><ce:section id="s1015"><ce:section-title id="st0955">Benznidazole</ce:section-title><ce:para id="p2530">Benznidazole is an oral agent used to treat South American trypanosomiasis (Chagas' disease, <ce:intra-ref id="ii0380" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2110">p. 279</ce:intra-ref>). Significant and common adverse effects include dose-related peripheral neuropathy, purpuric rash and granulocytopenia.</ce:para></ce:section><ce:section id="s1020"><ce:section-title id="st0960">Eflornithine</ce:section-title><ce:para id="p2535">Eflornithine inhibits biosynthesis of polyamines by ornithine decarboxylase inhibition, and is used in West African trypanosomiasis (<ce:italic>T. brucei gambiense</ce:italic> infection) of the central nervous system. It is administered as an intravenous infusion 4 times daily, which may be logistically difficult in the geographical areas affected by this disease. Significant adverse effects are common and include convulsions, gastrointestinal upset and bone marrow depression.</ce:para></ce:section><ce:section id="s1025"><ce:section-title id="st0965">Melarsoprol</ce:section-title><ce:para id="p2540">This is an arsenical agent, used to treat central nervous system infections in East and West African trypanosomiasis (<ce:italic>T. brucei rhodesiense</ce:italic> and <ce:italic>gambiense</ce:italic>). It is administered intravenously. Melarsoprol treatment is associated with peripheral neuropathy and reactive arsenical encephalopathy (RAE), which carries a significant mortality.</ce:para></ce:section><ce:section id="s1030"><ce:section-title id="st0970">Nifurtimox</ce:section-title><ce:para id="p2545">Nifurtimox is administered orally to treat South American trypanosomiasis (Chagas' disease). Gastrointestinal and neurological adverse effects are common.</ce:para></ce:section><ce:section id="s1035"><ce:section-title id="st0975">Pentamidine isetionate</ce:section-title><ce:para id="p2550">Pentamidine is an inhibitor of DNA replication used in West African trypanosomiasis (<ce:italic>T. brucei gambiense</ce:italic>) and, to a lesser extent, in visceral and cutaneous leishmaniasis. It is also prescribed in <ce:italic>Pneumocystis jirovecii</ce:italic> pneumonia. It is administered via intravenous or intramuscular routes. It is a relatively toxic drug, commonly causing rash, renal impairment, profound hypotension (especially on rapid infusion), electrolyte disturbances, blood dyscrasias and hypoglycaemia.</ce:para></ce:section><ce:section id="s1040"><ce:section-title id="st0980">Suramin</ce:section-title><ce:para id="p2555">Suramin is a naphthaline dye derivative, used to treat East African trypanosomiasis (<ce:italic>T. brucei rhodesiense</ce:italic>). It is administered intravenously. Adverse effects are common and include rash, gastrointestinal disturbance, blood dyscrasias, peripheral neuropathies and renal impairment.</ce:para></ce:section></ce:section><ce:section id="s1045"><ce:section-title id="st0985">Other antiprotozoal agents</ce:section-title><ce:section id="s1050"><ce:section-title id="st0990">Pentavalent antimonials</ce:section-title><ce:para id="p2560">Sodium stibogluconate and meglumine antimoniate inhibit protozoal glycolysis by phosphofructokinase inhibition. They are used parenterally (intravenous or intramuscular) to treat leishmaniasis. Adverse effects include arthralgia, myalgias, raised hepatic transaminases, pancreatitis and electrocardiogram changes. Severe cardiotoxicity leading to death is not uncommon.</ce:para></ce:section><ce:section id="s1055"><ce:section-title id="st0995">Diloxanide furoate</ce:section-title><ce:para id="p2565">This oral agent is used to eliminate luminal cysts following treatment of intestinal amoebiasis, or in asymptomatic cyst excreters. The drug is absorbed slowly (enabling luminal persistence) and has no effect in hepatic amoebiasis. It is a relatively non-toxic drug, the most significant adverse effect being flatulence.</ce:para></ce:section><ce:section id="s1060"><ce:section-title id="st1000">Iodoquinol (di-iodohydroxyquinoline)</ce:section-title><ce:para id="p2570">Iodoquinol is a quinoline derivative (<ce:cross-ref id="crf9060" refid="s0970">p. 128</ce:cross-ref>) with activity against <ce:italic>Entamoeba histolytica</ce:italic> cysts and trophozoites. It is used orally to treat asymptomatic cyst excreters or, in association with another amoebicide (e.g. metronidazole), to treat extra-intestinal amoebiasis. Long-term use of this drug is not recommended, as neurological adverse effects include optic neuritis and peripheral neuropathy.</ce:para></ce:section><ce:section id="s1065"><ce:section-title id="st1005">Nitazoxanide</ce:section-title><ce:para id="p2575">Nitazoxanide is an inhibitor of pyruvate–ferredoxin oxidoreductase-dependent anaerobic energy metabolism in protozoa. It is a broad-spectrum agent, active against various nematodes, tapeworms, flukes and intestinal protozoa. Nitazoxanide also has activity against some anaerobic bacteria and viruses. It is administered orally in giardiasis and cryptosporidiosis. Adverse effects are usually mild and involve the gastrointestinal tract (e.g. nausea, diarrhoea and abdominal pain).</ce:para></ce:section><ce:section id="s1070"><ce:section-title id="st1010">Paromomycin</ce:section-title><ce:para id="p2580">Paromomycin is an aminoglycoside (<ce:cross-ref id="crf9065" refid="s0610">p. 122</ce:cross-ref>) that is used to treat visceral leishmaniasis and intestinal amoebiasis. It is not significantly absorbed when administered orally, and is therefore given orally for intestinal amoebiasis and by intramuscular injection for leishmaniasis. It showed early promise in the treatment of HIV-associated cryptosporidiosis but subsequent trials have demonstrated that this effect is marginal at best.</ce:para></ce:section></ce:section><ce:section id="s1075"><ce:section-title id="st1015">Drugs used against helminths</ce:section-title><ce:section id="s1080"><ce:section-title id="st1020">Benzimidazoles (albendazole, mebendazole)</ce:section-title><ce:para id="p2585">These agents act by inhibiting both helminth glucose uptake, causing depletion of glycogen stores, and fumarate reductase. Albendazole is used for hookworm, ascariasis, threadworm, <ce:italic>Strongyloides</ce:italic> infection, trichinellosis, <ce:italic>Taenia solium</ce:italic> (cysticercosis) and hydatid disease. Mebendazole is used for hookworm, ascariasis, threadworm and whipworm. The drugs are administered orally. Absorption is relatively poor but is increased by a fatty meal. Significant adverse effects are uncommon.</ce:para></ce:section><ce:section id="s1085"><ce:section-title id="st1025">Bithionol</ce:section-title><ce:para id="p2590">Bithionol is used to treat fluke infections with <ce:italic>Fasciola hepatica</ce:italic>. It is well absorbed orally. Adverse effects are mild (e.g. nausea, vomiting, diarrhoea, rashes) but relatively common (approximately 30%).</ce:para></ce:section><ce:section id="s1090"><ce:section-title id="st1030">Diethylcarbamazine</ce:section-title><ce:para id="p2595">Diethylcarbamazine (DEC) is an oral agent used to treat filariasis and loiasis. Treatment of filariasis is often followed by fever, headache, nausea, vomiting, arthralgia and prostration. This is caused by the host response to dying microfilariae, rather than the drug, and may be reduced by pre-treatment with glucocorticoids.</ce:para></ce:section><ce:section id="s1095"><ce:section-title id="st1035">Ivermectin</ce:section-title><ce:para id="p2600">Ivermectin binds to helminth nerve and muscle cell ion channels, causing increased membrane permeability. It is an oral agent, used in <ce:italic>Strongyloides</ce:italic> infection, filariasis and onchocerciasis. Significant side-effects are uncommon.</ce:para></ce:section><ce:section id="s1100"><ce:section-title id="st1040">Niclosamide</ce:section-title><ce:para id="p2605">Niclosamide inhibits oxidative phosphorylation, causing paralysis of helminths. It is an oral agent, used in <ce:italic>Taenia saginata</ce:italic> and intestinal <ce:italic>T. solium</ce:italic> infection. Systemic absorption is minimal and it has few significant side-effects.</ce:para></ce:section><ce:section id="s1105"><ce:section-title id="st1045">Piperazine</ce:section-title><ce:para id="p2610">Piperazine inhibits neurotransmitter function, causing helminth muscle paralysis. It is an oral agent, used in ascariasis and threadworm (<ce:italic>Enterobius vermicularis</ce:italic>) infection. Significant adverse effects are uncommon but include neuropsychological reactions such as vertigo, delirium and convulsions.</ce:para></ce:section><ce:section id="s1110"><ce:section-title id="st1050">Praziquantel</ce:section-title><ce:para id="p2615">Praziquantel increases membrane permeability to Ca<ce:sup loc="post">2+</ce:sup>, causing violent contraction of worm muscle. It is the drug of choice for schistosomiasis and is also used in <ce:italic>T. saginata</ce:italic>, <ce:italic>T. solium</ce:italic> (cysticercosis) and fluke infections (<ce:italic>Clonorchis</ce:italic>, <ce:italic>Paragonimus</ce:italic>) and in echinococcosis. It is administered orally and is well absorbed. Adverse effects are usually mild and transient, and include nausea and abdominal pain.</ce:para></ce:section><ce:section id="s1115"><ce:section-title id="st1055">Pyrantel pamoate</ce:section-title><ce:para id="p2620">This agent causes spastic paralysis of helminth muscle through a suxamethonium-like action. It is used orally in ascariasis and threadworm infection. Systemic absorption is poor and adverse effects are uncommon.</ce:para></ce:section><ce:section id="s1120"><ce:section-title id="st1060">Thiabendazole</ce:section-title><ce:para id="p2625">Thiabendazole inhibits fumarate reductase, which is required for energy production in helminths. It is used orally in <ce:italic>Strongyloides</ce:italic> infection and topically to treat cutaneous larva migrans. Significant adverse effects are uncommon.</ce:para></ce:section></ce:section></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st1065">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st1070">Websites</ce:section-title><ce:bib-reference id="bib1"><ce:label>,</ce:label><sb:reference id="sr0010"><sb:host><sb:e-host><ce:inter-ref id="iw0030" xlink:href="http://cdc.gov">cdc.gov</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0180"><ce:italic>Centers for Disease Control and Prevention, Atlanta, USA. Provides information on all aspects of communicable disease, including prophylaxis against malaria.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>,</ce:label><sb:reference id="sr0015"><sb:host><sb:e-host><ce:inter-ref id="iw0035" xlink:href="http://dh.gov.uk">dh.gov.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0185"><ce:italic>UK Department of Health. The publications section provides current UK recommendations for immunisation.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0040" xlink:href="http://ecdc.europa.eu">ecdc.europa.eu</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0190"><ce:italic>European Centre for Disease Prevention and Control. Includes data on prevalence of antibiotic resistance in Europe.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>,</ce:label><sb:reference id="sr0025"><sb:host><sb:e-host><ce:inter-ref id="iw0045" xlink:href="http://gov.uk/government/organisations/public-health-england">gov.uk/government/organisations/public-health-england</ce:inter-ref></sb:e-host></sb:host><sb:comment><ce:italic>Public Health England. Provides information on infectious diseases relating mainly to England, including community infection control</ce:italic></sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><sb:reference id="sr0030"><sb:host><sb:e-host><ce:inter-ref id="iw0050" xlink:href="http://idsociety.org">idsociety.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0195"><ce:italic>Infectious Diseases Society of America. Publishes up-to-date, evidence-based guidelines.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><sb:reference id="sr0035"><sb:host><sb:e-host><ce:inter-ref id="iw0055" xlink:href="http://who.int">who.int</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0200"><ce:italic>World Health Organization. Provides up-to-date information on global aspects of infectious disease, including outbreak updates. Also has information on the ‘World Antibiotic Awareness Week’ campaign.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>